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ABSTRACT
,I

S. OBAIDULLAH ASEEM. The Epigenetic Regulation of Cubilin and the Physiological
Role of this Receptor in Maintaining the Homeostasis of Serum Albumin and HDL

Cubilin is an endocytic receptor capable of mediating the endocytosis of multiple
ligands including High Density Lipoprotein apolipoprotein A-I (apoA-I) and albumin. It
is highly expressed on the epithelium of intestinal villi and renal proximal tubules. In the
kidney, endocytosis mediated by cubilin and its co-receptor megalin is the principal
mechanism for proximal tubule reabsorption of filtered proteins, such as albumin and
apoA-I. Yet, the consequences of cubilin deficiency on the blood levels of albumin and

apoA-I have not been studied. Furthennor~:~?~?'is downregulated in chronic diseases
I

such as diabetes. However, little is known about the regulation of cubilin expression.
In this study, we show that cubilin expression is under epigenetic regulation by at

least two processes. The first process involves inactivatioh of expression of one of the
cubilin alleles. This monoallelic expression state could not be\transformed to biallelic by
inhibiting DNA methylation or histone deacetylation. The second process involves
transcriptional regulation of cubilin by peroxisome proliferator-activated receptor
(PPAR) transcription factors that are themselves regulated by DNA methylation and
histone deacetylation. This is supported by findings that inhibitors of DNA methylation
and histone deacetylation, 5Aza and TSA, increase cubilin mRNA and protein in renal
and intestinal cell lines. Not only was the expression ofPPARa and y inducible by 5Aza
and TSA, but also the positive effects ofTSA and 5Aza on cubilin expression were
dependent on both increased PP AR transcription and activation. Additionally, 5Aza and
ix

TSA had similar effects on the expression of the cubilin co-receptor, megalin. Together,
~

these findings reveal that cubilin and megalin expression is under epigenetic control and
thus point to new avenues for overcoming pathological suppression of these genes
through targeting of epigenetic regulatory processes.
We also demonstrate that cubilin is necessary for maintaining the blood levels of
albumin and HDL. In a heterozygous mouse model of targeted cubilin gene deletion
(cubilin HT), cubilin haploinsufficiency led to a significant decrease in blood levels of
albumin and apoA-I as well as HDL and HDL-cholesterol. Cubilin HT mice displayed
reduced renal proximal tubule uptake of albumin and apoA-I, and significantly increased
urinary loss of albumin and apoA-I. Urinary levels of apoA-I inversely correlated with
plasma apoA-I levels. Furthermore, the frac~~iearance of smaller HDL particles
I

(d>1.13 glmL) from the blood was significantly increased in cubilin HT mice, indicating
a decreased half-life for HD L particles that are filtered through the glomerulus. In
contrast, there was no significant change in the fractional 'clearange of larger HD L2
particles, which are not filtered through the glomerulus.

Furt~nnore,

no significant

change was observed in the levels of albumin and apoA-I protein or mRNA extracted
from liver, kidney or intestine of cubilin HT mice as compared to wildtype. Therefore,
cubilin deficiency leads to reduced albumin and apoA-I renal proximal tubule salvage
back to blood, which results in reduced albumin and apoA-IIHDL blood levels. These
findings are consistent with previous studies demonstrating renal proximal tubule
transcytosis of albumin and the necessity of this process in maintaining blood albumin
levels. In addition, clinical data indicate that proteinuria in patients with intact glomerular
function leads to reduced blood levels ofHDL. Therefore, our study is relevant to

x

pathological proteinuria where patients might benefit from increased cubilin expression
.I

to reduce proteinuria and raise albumin and HDL levels.

xi

Chapter 1. An overview of cubilin expression, interactions and function

Introduction
Receptor-mediated endocytosis is a ubiquitous process by which cells in the body
internalize a variety of complex biological material [1]. Endocytosis is initiated with the
specific binding of the ligand to a receptor, followed by intracellular signaling that results

in the fonnation of an endocytic vesicle [2~:,~~,i;1jti is a receptor that mediates the
!

endocytosis of a variety of protein ligands. It was first identified as a receptor for intrinsic
factor-cobalaminlvitamin-B I2 (IF-BI2) complex, and was initially named intrinsic factorcobalamin receptor [3]. Now the name cubilin is more colnmonly used and accepted.
Cubilin is co-expressed with two other membrane proteins, amnionless and
\

megalinlLRP2, and is dependent on these partners for its cell membrane localization and
endocytic function[ 4, 5]. Cubilin-mediated endocytosis is responsible for important
functions such as the absorption of nutrients in intestine and the reabsorption of proteins
in kidney[ 6, 7]. Loss of cubilin function, either by deletions of or mutations in the cubilin
gene (CVBN) or its partners, leads to vitamin BI2 deficiency due to its malabsorption in
the small intestine and proteinuria due to the inability of the renal proximal tubules to
absorb filtered proteins [8, 9]. Cubilin and megalin are downregulated in rodent models
of diseases such as diabetes and acute kidney injury [10, 11]. However, relatively little is

1

known about the regulation of cubilin expression in health and disease. Furthennore, key
.I

questions of cubilin function and its importance in maintaining homeostatic levels of its
ligands are unexplored. In this chapter, cubilin expression and regulation in health and
disease, interaction with its partner proteins and function will be reviewed. In addition,
the potential role of cubilin in regulating blood homeostasis of two of its ligands,
apolipoprotein A-I (apoA-I) and albumin, will be discussed, and gaps in the
understanding of processes involving cubilin will be identified.

Cubilin structure
Cubilin is an evolutionarily cons~~;rrtor protein that is expressed in many
organisms, including mammals and flies [6, 7, 12]. It is a 460-kDa peripheral membrane
glycoprotein that lacks a membrane-spanning region. The protein consists of 8 epidennal
growth factor (EGF)-like and 27 CUB (complement Clr/Cls, Ue~;f, and bone
morphogenic protein-I) domains (Fig. l-lA) [6, 7]. Since the,CUB domains constitute
88% of the protein mass, the name cubilin was proposed to replace intrinsic factorcobalamin receptor [13]. At the cubilin amino tenninus ( 113 residues) is an amphipathic
helix that can mediate its interaction with the plasma membrane[6, 7]. Perhaps more
important to cubilin plasma membrane anchorage is the integral membrane protein
amnionless (Amn), a transmembrane protein that interacts with the Ca+2-binding EGF
domains in the amino tenninal region of cubilin[4, 5]. The amino tenninal region is also
the site responsible for the fonnation of cubilin trimers [14]. Cubilin interacts with its
partner receptor, megalin, by the amino tenninus and CUB domains 12-17 and 22-27

2

[15]. Furthennore, the cubilin amino tenninus and CUB domains 5-8 bind IF-B12, and the
.1

amino terminus, possibly the EGF repeats and CUB domains 7-8 bind albumin [16, 17].
The endocytic receptor chaperone, receptor-associated protein (RAP), binds cubilin on
CUB domains 13-14 [16]. Cubilin is known to bind numerous other ligands, which are
listed in Table 1. However, the precise binding sites of these ligands have not been
worked out yet.

Cubilin expression

In adults, cubilin expression has been detected in various tissues including the
kidney [18], intestine [19], gallbladder [201~Jria [21], inner ear [22], male
reproductive tract [23], lung [24] and brain [25]. However, the highest level of cubilin
expression is likely at the absorptive epithelia of renal proximal tubules followed by the
small intestine. Rat and human renal podocytes have also'been s~own to express cubilin,
but mouse podocytes do not express cubilin [26]. Following its synthesis, cubilin is
transported to the apical membrane where it is expressed with amnionless and megalin
[4-7]. Amnionless is a 35-50 kDa protein, which is required for amnion and primitive
streak development in mice [27]. It is thought that cubilin and amnionless might interact
early in their synthesis fonning a complex, tenned Cubam [4,28]. Cubilin and
amnionless interaction is required for the apical trafficking and expression of either
protein in the kidney [4]. Mutations in the amnionless gene in dogs and genetic ablation
of amnionless in mice have both been shown to cause cubilin retention in cytoplasmic
compartments in renal proximal tubule cells [28, 29]. Likewise, cubilin deficiency in
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humans and genetic knockdown of cubilin in mice both resulted in the cytoplasmic
.l

accumulation of amnionless in renal proximal tubule cells [30, 31]. Furthennore, all these
mutants also lack cubilin function in the proximal tubules [28-31]. Thus, the interaction
of cubilin and amnionless is indispensible for the apical expression of both proteins and
for cubilin function in the kidney. Whether this interaction has similar consequences on
the expression of cubilin and amnionless in the intestine has not been elucidated.

Cubilin interactions with amnionless and megalin
Since cubilin does not have a cytoplasmic domain, it must rely on its partners,
amnionless and megalin, for the CytOPlasm!~.~iflillg required for endocytosis. Initially,
it was proposed that megalin was solely responsible for the intracellular signaling of
cubilin-mediated endocytosis [13]. Indeed, cubilin directly interacts with megalin (see
above), and megalin deficiency, by genetic ablation in mibe and 4ue to mutation in
humans, leads to a failure of absorption of cubilin ligands in t~e kidney [1, 32]. Megalin
is a member of the low-density lipoprotein (LDL) receptor family that functions as an
endocytic receptor for numerous ligands [6, 7]. It has a cytoplasmic domain with binding
sites for various sorting and signaling proteins [6, 7]. Among these are two endocytic
(NPXY) motifs, believed to mediate the clustering of ligand bound megalin and cubilin
receptors into clathrin coated pits [6, 7]. Disabled-2 (Dab2) and autosomal recessive
hypercholesterolemia (ARH) are components of the clathrin coat that directly bind the
megalin endocytic motifs, and are involved in megalin-mediated endocytosis [2].
However, megalin deficient patients do not develop megaloblastic anemia[32]. This

4

observation prompted the hypothesis that cubilin-mediated endocytosis ofIF-B 12 in the
.I

intestine must be facilitated by amnionless. Indeed, amnionless also contains two
FXNPXF signals both of which are able to mediate the endocytosis of cubilin-amnionless
complex through interaction with Dab2 and ARH [33]. Therefore, cubilin-mediated
endocytosis can be facilitated by intracellular signaling from either megalin or
amnionless.

Once internalized, the endocytic vesicles fonn early endosomes where
acidification allows the dissociation of cubilin from its ligands (Fig. I-IB) [2]. At this
step, cubilin is either recycled back to the apical membrane or routed for lysosomal
degradation (Fig. I-IB)[34]. Likewise, cubilin ligands can be routed either into the
t .

/ Ii

.#.

~

transcytotic or lysosomal degradation pathw~Yrig. I-lB)[2]. Endosomal acidification
and fusion with lysosomes involves multiple proteins including Na+/H+ exchanger
isofonn 3 (NHE3), H+/Cr exchange transporter 5 (CIC5ICLCN5) and V-type H+ATPases, and Limp2/SCARB2 [35-37]. NHE3, CIC5 andV-type.H+-ATPases are
responsible for the acidification of endosomes, and Limp2/SGARB2 mediates endosome
fusion with lysosomes[35-37]. Mutations in these genes have also been shown to result in
proteinuria of cubilin and megalin ligands [35-37]. For example, mutations in SCARB2
and CLCN5 cause Action Myoclonus-Renal Failure Syndrome and Dent's disease
respectively [36, 37].

Cubilin function
Cubilin-mediated endocytosis allows for the absorption of numerous ligands in
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the intestine and renal proximal tubules (Table 1). Mutations in the CUBN or amnionless
.I

gene that result in deficient cubilin expression or function are described as the cause of
Imerslund-Grasbeck syndrome (IGS) [37]. Endocytosis mediated by the cubam complex
in the intestine is responsible for the absorption ofIF-BI2 [8]. Mutations in CUBN in
humans result in megaloblastic anemia-I, a component oflGS, which stems from
decreased intestinal IF-B12 endocytosis [38]. Similarly, mutations in AMN also result in
deficient vitamin B12 absorption in humans and dogs [28].

Intriguingly, cubilin has also been proposed to have a role in the absorption and
processing of lipids in the intestine [39]. Lipid absorption in the intestine is accompanied
by the localization of an intestinal alkaline phosphatase (IAP)-containing membrane
t .

,I,

'.'~

,

surrounding the lipid droplets in the cytosolf~'Cl,'.::A;o].
7f '" Cubilin has been shown to coI

localize with lAP around these lipid droplets [39]. This study, therefore, proposed a
possible role for cubilin in facilitating the intracellular trafficking of the lipid droplet and
binding to the basolateral membrane for exocytosis [39].l-Iowev~, this hypothesis has
not been confirmed in cubilin animal models yet. Since cubilin is a multi-ligand receptor
capable of binding diverse proteins, it is likely to be involved in the intestinal absorption
of nutrients in addition to vitamin B 12.

In the kidney, cubilin expressed by the proximal tubule mediates the endocytosis
of multiple proteins [6, 7]. The combined action of cubilin and megalin in the proximal
tubules is responsible for the absorption of the majority of proteins that are filtered across
the glomerulus [6, 7]. Presently, this is the only established mechanism by which filtered
proteins are reabsorbed by the proximal tubules. The list of protein ligands for cubilinmediated endocytosis by the proximal tubules includes vitamin carriers, such as vitamin

6

D binding protein [41]; lipoproteins, such as apoA -I [42, 43]; albumin [44] and others
.I

(Table 1). Some of these ligands, such as albumin, are shared with megalin, whereas
others, such as apoA-I, bind solely to cubilin (Table 1) [42-44]. Defective cubilin
expression in the proximal tubule of dogs leads to urinary loss of large amounts of
albumin, apoA-I, vitamin D binding protein and transferrin [7, 41, 42, 44]. Likewise,
proteinuric lOS patients have been reported to have significant urinary loss of cubilin
ligands such as vitamin D binding protein [41], apoA-1 [42] and transferrin [7]. A mouse
model of full-length cubilin deletion by CUBN truncation is also reported to have
increased albuminuria but surprisingly no significant loss of other cubilin ligands in the
urine [31]. One possible explanation is that in this mouse model cubilin may not be fully
deleted, and a truncated fragment of cubilin capal;>le of binding some cubilin ligands
might still be expressed[31]. Additionally,

;~~~cmodels are known to have different

glomerular sieving coefficients depending on the rodent strain [45, 46]. Thus, proteinuria
and the amount and type of proteins filtered through the ~omerulus will probably vary
with rodent strain. Nevertheless, cubilin expression and function is certainly required for
\

the renal proximal tubule absorption of numerous ligands and its absence leads to urinary
loss of these ligands.

7

Table 1. Cubilin ligands and partner proteins
Ligand name

Binding site

Carrier proteins
N-tenninus, CUB 5-8

Intrinsic-factor cobalamin/vitamin B 12 [47]
Vitamin D-binding protein# [41]
ApoA-I/HDL [42, 43]
ApoA-II [48]
Albumin# [44]

N-tenninus, CUB 7-8

Hemoglobin# [49]
Myoglobin# [50]
Transferrin [7]
Immune related proteins
Immunoglobulin light chains# [51]
Clara cell secretory protein [52]
Alphal-microglobulin# [30]

t '

: Ii

.~.

•

'>'~'r

Receptors
Megalin [13]

N-tenninus, CUB 12-17 and 22-27

Amnionless [5]

EOF-like modules

Cubilin [14]

N-tenninus
\

Others
Receptor-associated protein# [53]

CUB 13-14

Factor Vila (Recombinant activated)# [54]
Aminoglycosides# [22]
Doxorubicin (Adriamycin) [55]
Fibroblast growth factor 8 (FOF8) [56]
#Indicates ligands that are shared with megalin

8

The regulation of cubilin expression in health and disease
Relatively little is known about the regulation of cubilin expression. Decreased
expression of cubilin in the intestine has been reported in aged mice, which might be in
part responsible for aging-induced vitamin B12 deficiency [57]. In the kidney, the fulllength cubilin expression does not change with age in rats even though megalin
expression is decreased [58]. However, aging results in lesser cubilin localization at the
apical brush border and more diffuse cytoplasmic localization in the proximal tubule cells
[58]. These observations warrant further investigation into the mechanisms of aginginduced changes in cubilin expression.
One possible mechanism for the decli~~ ~~tc:ubilin expression with aging might be
due to reduced retinoic acid signaling

[59]."2~i.~ has been shown to be robustly

upregulated by retinoic acid treatment in vitro [21]. However, the precise mechanism for
this effect remains to be established. Retinoic acid signaling is mediated by retinoic acid
~

receptors (RARs) and retinoid X receptors (RXRs), which form heterodimers upon
\

retinoic acid binding [60]. The heterodimers bind the retinoic acid response elements
(RAREs) or retinoid X response elements (RXREs) within the promoters of retinoic acidresponsive genes, and thereby, modifying transcriptional activity of these genes [60]. It is
not yet known whether the cubilin promoter region has any RAREs or RXREs or that the
effect of retinoic acid on cubilin expression is exerted via these receptors. Alternatively,
RXR, being a promiscuous receptor, can heterodimerize with other receptors such as
vitamin D3 receptor, liver X receptors, peroxisome proliferator-activated receptors
(PPARs) and others [61]. Intriguingly, cubilin co-receptor, megalin, has been recently
shown to be regulated by PPARa and'Y [62]. Since cubilin expression goes in conjunction

9

with megalin expression, it is possible that PPARs also regulate cubilin expression in
,I

collaboration or independent of retinoic acid signaling.

Cubilin expression has been reported to be downregulated in several pathological
conditions, in which proteinuria is pathognomonic. Both cubilin and megalin are
downregulated in the kidney in streptozotocin-induced diabetes in mice[ 10]. This
downregulation is accompanied by cubilin and megalin loss of function, i.e. significant
albuminuria [10]. Although cubilin levels have not been directly analyzed in diabetic
patients yet, a study of type 1 diabetic patients reported urinary shedding of cubilin and
megalin accompanied by urinary loss of their ligands including albumin, apoA-I, vitamin
D-binding protein and others [63]. Diabetes also results in the downregulation of PP AR
levels in the kidney [64]. Thus, reduced PPAR l,tivity in diabetes might lead to
I.

decreased expression ofmegalin[62]. This association lends further support to the
hypothesis that PP ARs might also regulate cubilin expression and explain how it is
decreased in diabetes.
\

Cubilin and megalin expression in the kidney is also reduced in mouse models of
acute kidney injury (AKI), including lipopolysaccharide-induced endotoxemia and
ischemia-reperfusion kidney injury, which are accompanied by significant albuminuria
[11]. Furthermore, cubilin expression in both the intestine and kidney is downregulated in
a mouse model of cystic fibrosis [58, 65]. This decrease in the renal expression of cubilin
was accompanied by increased urinary loss of cubilin ligands [58]. The mechanism by
which cubilin and megalin are downregulated in these diseases is not known. AKI, cystic
fibrosis and diabetes each have a strong inflammatory component, which might reduce
PP AR levels [66, 67]. In contrast, PP AR stimulation attenuates the degree of renal
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dysfunction, injury, and inflammation caused by ischemia-reperfusion injury [68]. PP AR
,I

stimulation is also widely utilized in the treatment of diabetic patients [69]. Thus, reduced
PP AR activity in these conditions might lead to the decreased expression of both cubilin
and megalin. Further studies are required to delineate this link.

Another aspect of kidney disease is proximal tubule protein overload resulting
from damage to the glomerular filtration barrier. Although the effect of protein overload
on cubilin expression has not been studied, both in vivo and in vitro studies have
demonstrated that protein overload lead to decreased megalin expression [62, 70]. Protein
overload also activates the intrarenal renin-angiotensin system (RAS) [71], which has
been implicated in decreased cubilin expression in another pathological condition [72].
RAS is also implicated in inflammation

[73J{.~ch

in tum would affect PPAR activity.

Thus, it is likely that protein overload would also lead to decreased cubilin expression.

Cubilin has not been extensively studied in chronic kidney disease. Cubilin
l

dysfunction along with a paradoxical increase in cubilin expression has been reported in
\

the remnant kidney model of chronic kidney disease [74]. Furthermore, analysis of
genome-wide association studies revealed a correlation between a single-nucleotide
polymorphism (SNP) in the cubilin gene with levels of albuminuria in both the general
population and in diabetic patients [75]. Another study reported a different SNP in cubilin
gene associated with end-stage renal disease and graft failure in transplanted kidneys.
Although a causal link has not been established yet, these studies indicate a role for
cubilin in chronic kidney disease.
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Tubulointerstitial fibrosis is the principal process leading the progression from
chronic kidney disease to end-stage renal disease[76]. Renal fibrosis is brought on by
interplay of multiple factors, including the RAS, matrix metalloproteinases and tumor
growth factor (TGF)-beta [76]. TGF-beta is also demonstrated to downregulate cubilin
and megalin expression and function in vitro [77]. Since TGF -beta has been associated
with retinoic acid signaling in development, immunity and tissue repair [78], it is likely
that the effect ofTGF-beta on decreased cubilin expression is mediated by decreased
retinoic acid signaling. Therefore, cubilin dysregulation might be another component of
chronic kidney disease and progression to end-stage renal disease.

In summary, decreased cubilin expression and function has been observed in
multiple pathological conditions with strong . in~mmatory components. The regulation of
'"

cubilin expression in these diseases and in health probably involves the retinoic acid and
PPAR signaling pathways.

\

The potential role of cubilin in the homeostasis of serum apoA-I/HDL and albumin
In the intestine, cubilin mediates the absorption of vitamin B 12 bound to intrinsic
factor, IF-B12 [34]. Vitamin B12 then dissociates from both cubilin and intrinsic factor,
and is transferred to transcobalamin for secretion into blood [34]. Clearly, cubilin is
required to maintain homeostatic levels of vitamin B12 in the blood, and lack of cubilin
function leads to vitamin B12 deficiency [8]. In the kidney, however, the potential role of
cubilin in maintaining homeostatic levels of its ligands is not as clear. One view is that
cubilin and megalin-mediated endocytosis leads to the transcytosis of non-protein

12

nutrients such as vitamin D, whereas the protein ligands undergo lysosomal degradation
[34]. However, there is evidence from multiple studies suggesting that cubilin protein
ligands may also undergo transcytosis. If this were indeed the case, then lack of cubilin
function would also result in decreased levels of these ligands in the blood. However, the
effect of renal cubilin deficiency on the plasma levels of its ligands has not been directly
studied. In this section, the metabolism of two cubilin ligands, apoA-I1HDL and albumin,
both of which are important components of this dissertation, will be reviewed. In
addition, a potential role for cubilin in maintaining blood levels of both ligands will be
postulated.

High Density Lipoprotein (HDL)

High density lipoprotein is a heterogeneous group of lipoproteins responsible for
the transport of cholesterol and lipids from the peripheraHtissue to the liver, termed
'reverse cholesterol transport' [79]. HDL also serves as an anti-inflammatory mediator
and a carrier for signaling lipids such as sphingosine-I-phosphate (S 1P) [79].

There is ample epidemiological evidence indicating that HDL-cholesterol (HDLC) blood levels are inversely correlated with risk of coronary heart disease (CHD)[8083]. In fact, data suggest that a 1% decrease in HDL-C is associated with a 2-3% increase
in CHD risk[84]. Furthermore, HDL-C levels are shown to be an independent risk and its
correlation with CHD is maintained when corrected for other risk variables, such as
triglyceride levels, obesity, and diabetes[80]. Recent studies suggest that signaling by
SIP carried on HD L might be a mechanistic basis of the cardiovascular effects of HD L
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[85-87]. Therefore, understanding HD L homeostasis is a critical component of future
,/

prevention and treatment ofCHD.

HDL biosynthesis

HDL biosynthesis can be separated into two phases: the synthesis and secretion of
HDL apolipoproteins, and the apolipoprotein lipidation [88]. The major HDL
apolipoproteins are apoA-I and apoA-II. ApoA-I constitutes approximately 70% ofHDL
protein and is virtually present in all HDL particles [89, 90]. Thus, it is not surprising that
apoA-I deficient mice have severely low levels ofHDL and develop significantly
increased atherosclerosis [89, 90]. Similarly, plasma apoA-I absence in humans leads to
significantly reduced HDL levels and early 0~set,90ronary artery disease [91].
,~ -~, ~/'

Overexpression of apoA-I, on the other hand~ has been shown to increase HD Lcholesterol (HDL-C) levels [92]. Therefore, apoA-I plasma levels correlate closely with
plasma HDL-C concentration. ApoA-I is synthesized both in the intestine and the liver,
l

and its expression has been shown to be increased by PP AR-a agonists in both humans
\

and mice [93]. In addition, the orphan nuclear receptor liver receptor homolog-1 (LRH -1)
has been reported to upregulate apoA-I transcription by directly binding the apoA-I
promoter [94]. However, studies ofHDL metabolism have that revealed apoA-I
fractional catabolic rate is a better determinant of human HDL-C levels than the rate of
apoA-I synthesis [95, 96].

ApoA-II constitutes about 20% ofHDL protein and is present in about two-thirds
ofHDL particles [88]. ApoA-II is synthesized only in the liver and its overexpression has
been shown to lead to increased HDL concentration in mice [97]. Unlike apoA-I, plasma
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apoA-11 concentration is determined primarily by the rate of its production [96].
.1

PPARa/y and alcohol have been shown to increase apoA-II production and plasma HDL
levels [88].

Newly synthesized apolipoproteins must acquire lipids in order to form HDL
particles. Evidence suggests that HD L apolipoprotein lipidation occurs primarily after
their secretion[88]. Newly secreted apoA-1 particles acquire lipids by the action of ATPbinding cassette, subfamily A, member 1 (ABCAl)[98]. ABCAI mediates the rate
limiting step in HDL particle formation, which is the cell surface assembly of apoA-1
particle with cholesterol and phospholipids[99]. This process leads to the formation of
nascent, discoidal HDL particles[99]. ABCAlioss of function mutations in the human
gene cause Tangiers disease, characterized,by, ~ low HDL levels and rapid HDL
degradation [100]. The liver X receptors a and

~ (LXRa/~)

are the major regulators of

ABCA 1 gene expression[96]. LXRs form heterodimers with their partner the retinoid X
receptor and are activated by oxysterols[96]. Although wIdely expressed, ABCA 1
expressed in the intestine and liver is responsible for the generation of virtually all of
plasma HDL [98, 101]. Liver-specific and intestine-specific Abcal knockout mice were
shown to have an approximately 80% and 30% decrease in plasma HDL respectively[98,
101]. Additionally, since scantily lipidated apoA-1 is rapidly degraded, it is thought that
this proportion may reflect the contribution of each organ to the plasma pool of apoA -I as
well [96]. Although, studies have shown that cubilin acts as a receptor for both apoA-1
and apoA-II, it is not clear whether cubilin plays a role in the biosynthesis of HDL[ 42,
44, 48, 102, 103].
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HDL maturation and remodeling
.1

Nascent HD L particles, fonned in the liver and intestine, undergo intravascular
maturation by acquiring more lipids[88]. Since extrahepatic tissues cannot metabolize
cholesterol and have to efflux cholesterol to HDL, most of the lipids on HDL particles
originate from extrahepatic sites[96]. This process is thought to happen by various
mechanisms, including aqueous diffusion and SR-BI and ABCG1-mediated transfer[96].
Lipids from these extrahepatic sites are delivered to the liver for excretion in bile or
metabolism by various pathways, a process tenned "reverse cholesterol transport". Free
cholesterol effluxed by peripheral tissue associates with HDL in plasma and is converted
to cholesterol esters by lecithin-cholesterol acyltransferase (LCAT) [88]. Cholesterol
esters are more hydrophobic and move to

the..C~pter

ofHDL particles, resulting in the

fonnation of mature, spherical HDL particles[88]. HDL particles also acquire
phospholipids fonn other lipoproteins such as VLD Land chylomicrons via the action of
phospholipid transfer protein (PLTP) and lipoprotein lipa~e (LPL), which results in the
fonnation of larger HDL2 particles[96]. HDL cholesterol esters (HDL-CE) are transferred
to apoB lipoproteins, such as chylomicrons, VLDL and LDL, in exchange for
triglycerides by the action of cholesteryl ester transfer protein (CETP) [96]. Cholesterol
esters carried by these particles can be transferred to liver via LDL-receptor. HDL-C can
be directly delivered to liver via the scavenger receptor class BI (SR-BI) [104]. HDL
phospholipids and triglycerides are also transferred to liver by hepatic lipase (HL) and to
other tissues and lipoprotein particles by endothelial lipase (EL) and secretory
phospholipase A2 (sPLA2) [96].
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HDL catabolism
.1

Kinetic studies in humans have indicated that the rate of apoA -I turnover is a
more important determinant of plasma apoA-I and HDL-C concentration than its
production[95]. Animal studies using apoA-I labeled with covalently linked

[125 1]-labeled

tyramine cellobiose, which accumulates in the cells degrading the apolipoprotein, showed
that about a third of apoA -I is catabolized by the kidney and the rest is catabolized by the
liver[I05]. Relatively little is known about the hepatic uptake and degradation ofHDL.
ApoE-rich HDL is taken up by the liver via the LDLR and other apoE receptors[88].
However, the mechanism by which apoE-poor HDL is taken up by the liver is unknown.
Further research is required to elucidate the mechanisms of hepatic HDL catabolism.
>

'~I ~~l

In the kidney, apoA-I, presumably in lipId-poor form, is filtered at the glomerulus,
which then undergoes endocytosis via cubilin expressed on the proximal tubule epithelial
cells[ 42, 44]. One view is that ApoA-1 undergoes catabolism at the proximal tubules
1

following cubilin-mediated endocytosis [88]. Furthermore, the rate-limiting step is
\

thought to be glomerular filtration and that mature HD L is too large to be filtered and
escape renal catabolism[96]. In Tangier disease, in which ABCA 1 mutation leads to the
inability to lipidate newly synthesized apoA-I, apoA-1 is rapidly catabolized, primarily by
the kidneys[l 06]. This condition leads to drastically low plasma HDL levels. Therefore,
poor lipidation of apoA-1 prevents the formation of mature, larger HDL particles and
allows apoA -I filtration at the glomerulus and subsequent catabolism. This hypothesis is
supported by studies of LCAT deficiency, which results in accelerated apoA-1
catabolism[96]. The accelerated catabolism is presumed to happen because HDL particles
cannot acquire the cholesterol ester core to form larger, mature particles [96]. Mature
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HDL particles can be also remodeled into smaller particles that can be then subjected to
,I

glomerular filtration. The most important remodeling processes involve the HDL-CE
transfer to other lipoproteins via CETP, and HDL-CE and free cholesterol uptake by the
liver via SR-BI[88]. Both processes can affect the turnover of apoA-1. CETP deficiency
in humans is associated with reduced apoA-1 turnover, whereas overexpression ofCETP
and SR-BI in mice accelerates apoA-1 turnover[88, 107]. Another study investigating the
overexpression of endothelial lipase reported increased apoA -I catabolism[ 108].
However, apoA-I degradation was proportionally increased in both the liver and the
kidney[ 108]. In light of these observations, the lipidation status of HDL particles is
theorized to be an important factor in HDL/apoA-1 catabolism[88]. Yet critical gaps
remain in understanding the role of kidney in the ,catabolism ofHDL. Genetic and

,,:., t/"
functional cubilinlmegalin deficiency studies need to be undertaken to determine the
mechanism of renal HDL catabolism. Furthermore, whether renal catabolism of

,

HDL/apoA-1 has a regulatory effect on plasma HDL levels also remains unknown.

Based on more recent evidence, an alternative pathway of renal handling of apoAI, which avoids lysosomal degradation and delivers apoA-1 back into circulation, is also
plausible. Other cubilin and megalin ligands, such as albumin and retinol binding protein,
have been shown to undergo transcytosis across renal proximal tubule cells following
uptake [45, 109-113]. In fact, several studies have indicated that this process is critical for
maintaining homeostatic levels of albumin (see next section) [45, 113]. Additional
support for this concept comes from epidemiological studies of type 1 diabetic patients.
Diabetic patients generally suffer from dyslipidemia and lower levels of blood HDL
[114]. Furthermore, a study of normoalbuminuric type 1 diabetic patients with normal
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glomerular function reported a correlation between lower levels of total HDL-C and
I

smaller sized HDL3-C with albuminuria, but not larger HDL2-C [115]. Similarly, another
study reported a shift of HDL size distribution toward large particles in patients with
proteinuria [116]. Diabetes in a mouse model has been shown to lead to cubilin
downregulation, and in humans has been associated with increased shedding in the urine
along with its ligands apoA-I, albumin and others [10, 63]. Taken together, these lines of
evidence indicate that cubilin-mediated endocytosis might salvage renal filtered apoA-I
back to circulation, which is otherwise lost in the urine leading to decreased blood HDL
levels. Therefore, the kidney, in addition to catabolism, may also be involved in a
recycling pathway of apoA-I required for maintaining plasma homeostatic levels of
apoA-I/HDL.

Albumin

Albumin is the most abundant protein in plasma. It is also
a major constituent of
\
interstitial fluid, lymph and cerebrospinal fluid, and found in all bodily secretions [117].
Albumin has multiple functions in the plasma, including maintaining colloid oncotic
pressure of plasma, transport of hormones, fatty acids and metabolites, regulation of
microvascular permeability and others[118]. It is also associated with anti-oxidant, antithrombotic and anti-inflammatory properties[118]. Thus, albumin homeostasis in the
blood is critical and reduced levels of albumin in plasma, hypoalbuminemia, is observed
in numerous diseases. The most obvious symptom of hypoalbuminemia is edema caused
by reduced colloid osmotic pressure to counterbalance hydrostatic pressure [ 118].
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Hypoalbuminemia is most commonly caused by inflammatory responses, but is also
caused by other diseases including nephrotic syndrome, hepatic cirrhosis, heart failure,
and malnutrition [118]. Serum albumin levels are also associated with an independent
risk for cardiovascular disease [119]. Therefore, understanding the regulation of blood
albumin homeostasis might be important in treating and preventing many common
diseases. The processes responsible for maintaining homeostatic levels of albumin
include the absolute rate of albumin synthesis, degradation and exogenous loss, and
distribution between intravascular and extravascular compartments [118].

Albumin synthesis

The majority of serum albumin is

synt~es~~ed
.

--;:.

in the liver and secreted directly

" --, rl

',-

into hepatic plasma [11 7]. Although albumin expression has been reported in other
organs, including cubilin-expressing organs such as intestine and kidney, the contribution

,

of these organs to the serum pool of albumin is not clear [120]. Albumin synthesis in the
liver is regulated at the level of transcription and ---15g of albumin are produced to
\

maintain steady state levels (r--4g/dL) in humans [121]. The most important factors
regulating albumin synthesis are nutrition and inflammation [11 7]. Evidence suggests
that TNF -alpha in concert with other cytokines playa key role in inflammatory regulation
of albumin synthesis in cachexia of numerous chronic diseases, including cancers,
cirrhosis, AIDS and inflammatory disorders [11 7, 121]. Albumin synthesis is also
regulated by hormones including thyroid hormones and cortisone [117]. In addition,
albumin synthesis has been observed to change with osmotic pressure, for example
raising the colloidal content of plasma by exogenous administration of proteins resulted
in reduced albumin synthesis [117]. Albumin synthesis may also be decreased in
20

gastrointestinal diseases [117]. However, this is postulated to be due to poor hepatic
supply of amino acids [117].

Although cubilin is associated with intestinal absorption of nutrients, loss of
cubilin function dos not result in the severe malnutrition associated with reduced albumin
synthesis and hypoalbuminemia [8]. Therefore, cubilin is unlikely to playa direct role in
serum albumin synthesis.

Albumin catabolism
Serum albumin catabolism is not as well understood as its synthesis. No one
organ has been indicated as the major site of albumin degradation. According to early
kinetic studies in animals, albumin degradaJi,9~~§c'curs in the intravascular fluid
I"

compartment [122, 123]. Since blood cells alone are too few to account for albumin
degradation, the major degradation site is most likely the endothelium, and perhaps,
organs with fenestrated endothelium, all of which might take up

~lbumin

by pinocytosis

[123]. In addition, small fractions of albumin are degraded or Jost in stool, excreted or
degraded in the kidney, and metabolized by the liver [117]. The overall albumin
degradation equals the net hepatic albumin synthesis resulting in steady state levels [124].
Furthermore, albumin does not appear to undergo any specific processes that would label
it for degradation [117]. The endogenous half-life of albumin in humans and rodents is
approximately 19 and <1.5-2.5 days respectively [125].

More recently, it was demonstrated that the neonatal Fc receptor, also known as
the major histocompatibility complex-related Fc receptor (FcRn), plays a critical role in
protecting albumin from degradation [124]. FcRn is expressed in virtually all nucleated
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cells, and is located in acidic endosomes. It binds albumin only in acidic conditions
"I

following albumin endocytosis, and mediates the albumin recycling back into circulation,
thereby rescuing albumin from lysosomal degradation [123, 124]. In FcRn global
knockout mice, albumin degradation is twice as fast as in wildtype, indicating that FcRn
protects as much albumin from degradation as is produced [124]. Serum albumin
concentration in these mice was significantly reduced with a modest compensatory
increase in albumin synthesis to stabilize serum albumin steady state levels at about half
of normal [124].

In the kidney, where a small fraction of albumin is degraded, cubilin mediates the
reabsorption of albumin filtered through the glomerulus. One view is that cubilinmediated endocytosis of albumin results

in,t~ WSosomal

degradation of albumin[34].

However, evidence also suggests an alternative pathway of albumin recycling back to the
blood pool. In fact, FcRn is also expressed by the renal proximal tubules where it is
implicated in the transcytosis of albumin from the glomerblar filtrate, across the proximal
tubule epithelium and back into circulation [113, 126]. Mice with FcRn deficient kidneys
had reduced serum albumin levels, reduced albumin half-life in blood and increased
albuminuria [113]. These observations are consistent with another recent study
demonstrating albumin transcytosis in renal proximal tubules using fluorescent live
imaging [113]. However, FcRn deficient kidneys retain the capacity to bind albumin by
their brush borders [113]. This is consistent with numerous other studies demonstrating
that cubilin mediates the binding and endocytosis of albumin in the renal proximal tubule
cells, and that FcRn binds albumin in acidic endosomes after albumin endocytosis [126129]. Similarly, BSA overload of mice led to increased albuminuria due to overwhelming
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of the endosomal processing [36]. This albuminuria was accompanied with decreased
serum albumin levels [46]. Therefore, cubilin-mediated endocytosis of albumin might be
followed by albumin transcytosis across the renal proximal tubule epithelium and back
into circulation. If this were indeed the case, then cubilin deficiency in the renal proximal
tubules would lead to albuminuria and reduced serum albumin levels.

In summary, cubilin-mediated endocytosis of apoA-I and albumin filtered in the
kidney might lead to lysosomal catabolism or transcytosis and salvage back to the
circulating blood pool. In the latter case, cubilin deficiency would lead to reduced blood
levels of apoA-I1HDL and albumin.

\
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Figure 1-1. Schematic diagrams depicting the structure of cubilin (A) and cubilinmediated endocytosis (B). (A) Cubilin is composed of27 CUB domains, 8 EGF-like
modules and a 113 residue amino tenninus. (B) Cubilin-mediated endocytosis is
clathrin-dependent and initiated by intracellular signaling from either megalin or
amnionless cytosolic domains. Once internalized the receptors are sorted in
endosomes either for lysosomal degradation or recycling back to the apical plasma
membrane. Similarly, cubilin ligands are either sorted for lysosomal degradation or
undergo transcytosis.
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Chapter 2. Cubilin expression is mono allelic and epigenetically augmented via
PPARs

Abstract
Cubilin is an endocytic receptor that is necessary for renal and intestinal
absorption of a range of ligands. Endocytosis mediated by cubilin and its co-receptor
megalin is the principal mechanism for proxim§:l.tubule reabsorption of proteins from the
,

.~ I

'~/"

glomerular filtrate. Cubilin is also required for intestinal endocytosis of intrinsic factorvitamin B12 complex. Despite its importance, little is known about the regulation of
cubilin expression.

Here we show that cubilin expression is under epigenetic regulation by at least
two processes. The first process involves inactivation of expression of one of the cubilin
alleles. This monoallelic expression state could not be transformed to biallelic by
inhibiting DNA methylation or histone deacetylation. The second process involves
transcriptional regulation of cubilin by peroxisome proliferator-activated receptor
(PP AR) transcription factors that are themselves regulated by DNA methylation and
histone deacetylation. This is supported by findings that inhibitors of DNA methylation
and histone deacetylation, 5Aza and TSA, increase cubilin mRNA and protein in renal
and intestinal cell lines. Not only was the expression of PP ARa and y inducible by 5Aza
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and TSA, but the positive effects ofTSA and 5Aza on cubilin expression were also
dependent on both increased PP AR transcription and activation. Additionally, 5Aza and
TSA had similar effects on the expression of the cubilin co-receptor, megalin. Together,
these findings reveal that cubilin and megalin mRNA expression is under epigenetic
control and thus point to new avenues for overcoming pathological suppression of these
genes through targeting of epigenetic regulatory processes.

26

Introduction
I

Cubilin is a 460-kDa peripheral membrane glycoprotein, anchored to the plasma
membrane via an amino terminal amphipathic helix [6, 7] and through interactions with
the transmembrane protein, amnionless, forming the so-called cubam complex [4, 5].
Cubilin is expressed by the absorptive epithelia of tissues such as renal proximal
convoluted tubules [130], ileum [131], and yolk sac [132], where it mediates the
endocytosis of numerous ligands [6], in some cases acting in concert with another
endocytic receptor, LRP-2/megalin [102].

Cubilin was first described as the intrinsic factor-cobalamin/vitamin B12 receptor
important for intestinal absorption of vitamin ~121133]. Mutations of the cubilin gene are
,' .. ~,

~j

the cause of Imerslund-Grasbeck syndrome, also known as selective vitamin B12
malabsorption with proteinuria [134]. Proteinuria in these individuals results from the
inability of the cubilin-deficient kidney to reabsorb ligands that filter across the
l

glomerulus, including albumin and apolipoprotein A-I, the major apolipoprotein of HDL
\

[42, 44].

In vitro studies have shown that cubilin mRNA expression is stimulated by
retinoic acid and that it is not sterol-regulated [102]. Cubilin is co-expressed with megalin
in numerous tissues [20, 23, 102, 132], suggesting the possibility that the genes share
common transcriptional regulatory mechanisms. Peroxisome proliferator-activated
receptors (PPARs), transcription factors belonging to the nuclear receptor superfamily,
upregulate megalin expression [62], but it is not yet known whether these factors
influence cubilin expression. Furthermore, expression of megalin is regulated by histone
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acetylation and methylation and DNA methylation [135], but it is not yet known whether
.1

cubilin is regulated epigenetically in a similar manner.

The availability of a mouse carrying a knockin of an EGFP cassette into the
cubilin gene [136] has enabled precise histological analysis of cubilin expression. While
evaluating cubilin-EGFP expression in renal tissue of mice heterozygous for the knockin
allele, we observed a striking difference in the distribution of EGFP immunoreactivity
versus cubilin immunoreactivity. Although both were detected at sites that matched
cubilin distribution in wildtype animals, the cellular distributions in heterozygous mice
were largely exclusive such that cells appeared to express predominantly either EGFP or
cubilin. This led us to postulate that cubilin might undergo an allelic inactivation that
silenced or strongly diminished

expressiono£.e~er

the maternal or paternal allele. This

phenomenon, called monoallelic expression [137], can occur through chromosomal
inactivation (e.g., X inactivation), autosomal gene imprinting or random gene inactivation
[138]. Monoallelic expression of a variety of autosomal gbnes have been described [138,
139], including p120 catenin [140], certain cytokines [141], olfactory receptors and
antigen receptors [142, 143]. Here we explored the possibility that cubilin (Cubn), an
autosomal gene [144], is regulated through epigenetic mechanisms and whether such
processes might have consequences on cubilin function and on the expression of its
partners, amnionless and megalin.
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Materials and Methods

Animals

All studies involved the use of 1-6 month old male mice heterozygous for cubilin
exon 1-6 deletion with an EGFP cassette insertion (Cubn +/del exon 1-6;EGFP) [136] or age/sex
matched wildtype (WT) littermates. Mouse experimentation was conducted with approval
from the IACUC. Cubn +/del exon 1-6,EGFP (Cubilin HT) and WT mice were administered
Trichostatin A (TSA) (Sigma-Aldrich, St. Louis, MO) at 2 Jlg/g of mouse body weight or
equal volume of vehicle DMSO intraperitoneally for 7 consecutive days. TSA was
dissolved in DMSO to yield a solution of 6.048 mg/ml. This TSA solution or an equal
volume ofDMSO only was further diluted in

~alipe to

a final TSA concentration of --599

Jlg/ml, which was administered to mice.

Antibodies

Goat anti-cubilin IgG (A20) was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA), rabbit anti-EGFP IgG was from Abeam (Cambridge, MA), goat antialbumin was obtained from Bethyl Laboratories, Inc. (Montgomery, TX), mouse antihuman a-tubulin was purchased from Sigma-Aldrich (St. Louis, MO) and rabbit antiactin was from Abeam. Rabbit anti-human intrinsic factor serum was generously
provided by Dr. David H. Alpers (Washington University School of Medicine, St. Louis,
MO). Rabbit anti-porcine megalin (rb6286) was described previously [145]. Antiserum
to amnionless (rb4156/57) was prepared by immunizing rabbits with synthetic multiple
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antigenic peptide containing amino acid residues 165-178 (accession number
NM_001108061.1). The resulting antiserum reacted with a single ",45 kDa polypeptide in
mouse kidney extracts and ---35 kDa and 30 kDa bands in intestinal extracts and an ---30
kDa band in extracts ofE8.5 mouse embryo extracts and rat BN cells (Fig. 3D and data
not shown). Donkey anti-goat and donkey anti-rabbit-Alexa Fluor (488 or 568)
conjugates were purchased from Invitrogen (Carlsbad, CA).

Tissue procurement and immunofluorescence
Following euthanization, animals were perfused first with phosphate-buffered
saline (PBS) and then with 4% paraformald~h~~l,'PBS. Tissues were dissected and
further fixed by immersion in 4% paraformaldehyde PBS for 12 h. For kidney
immunohistochemical analysis, ---0.25 cm thick strips of cortex tissue were isolated. For

°

small intestine immunohistochemical analysis, '" 1 cm long se~ents of duodenum
(extending distally from the fundus of the stomach), jejunum (beginning ",5 cm from the
end of duodenum) and ileum (ending ",2 cm superior of the cecum) were isolated.
Isolated tissues were embedded in paraffin and sectioned at 6 flm thickness. Tissue
sections were incubated with primary antibodies diluted in PBS containing 3% BSA,
washed with PBS and incubated with Alexa Fluor conjugated secondary antibodies.
Nuclei were stained using Draq5 (Cell Signaling Technology, Danvers, MA). Labeled
sections were analyzed using a Leica SP5 confocal microscope (Leica Microsystems Inc.,
Exton, P A) using the 63x objective or a Zeiss Axio M2 microscope using the 40x
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objective. Whole mount images of unlabeled intestine EGFP-fluorescence were taken by
a Leica MZ FLIII microscope at ",5x magnification.
"1 VI·11·I fr om Cu
b +/de/
exon 1-6EGFP"1
"d"Issected under
Intesttna
n
'
mouse I eum were mlcroGFP light at lOx magnification using Leica MZ FLIII microscope. Villi that appeared
predominantly EGFP-positive or EGFP-negative as well as a random sampling of both
were separately isolated using dissection scissors in Hank's buffered salt solution (HBSS)
(Thermo Scientific) containing 4% FBS. Villi were then briefly span down, the
supernatant removed and RNA extracted from the samples using the RNeasy Plus Mini
Kit (QIAGEN, Valencia, CA). qPCR was performed as described below.

Immunoblot analysis

Unfixed segments of small intestine were homogenized in 1% Triton X-I00, 0.5%
l

Tween20, 0.5 M NaCl, 50 mM Hepes, pH 7.5 containing a protease inhibitor cocktail
(Complete-mini, EDTA-free, Roche, Germany) using a Polyt~on-aggregate (Brinkmann
Instruments, Switzerland). Extracts were subjected to centrifugation at lOOK x g for 30
min at 4aC. Protein concentration in extracts was quantified using Pierce BCA Protein
Assay Kit (Rockford, IL). Equal amounts of protein from the extracts were loaded onto
NuP AGE 4-12% polyacrylamide gradient, Bis-Tris gels in the presence of SDS (no
reducing agent). Following electrophoresis, the proteins were transferred onto PVDF
membranes, which were blocked with 5% non-fat milk in TBS and probed with primary
and secondary antibodies diluted in TBS containing 0.50/0 Tween 20 and 5% non-fat
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milk. Chemiluminescent detection of bound antibodies was achieved using the Pierce
EeL Western Blotting Substrate.

C ell culture

NRK-52E (NRK) (ATCC no. CRL-1571) and Caco-2 (ATCC no. HTB-37) cells
were cultured in DMEM (high glucose) with 10% fetal bovine serum, Glutamax (Life
Technologies, Grand Island, NY), non-essential amino acids, 100 units/ml penicillin, and
100 units/ml streptomycin (Thermo Scientific, Rockford, IL), and maintained at 37°C
and 5% CO2 • For trichostatin A (TSA) treatments, cells were plated at 1.0 x 104 cells/cm2
for 6 h, and subsequently treated for 24 h ~j1h ~9~-50 or 100 nM TSA (Sigma,

st. Louis,

MO) (281.6 pM final DMSO concentration in medium). For 5-Azacytidine (5Aza)
treatments, NRK cells were plated at 5 x 103 cells/cm2 for 6 h and subsequently treated
with 1, 5 or 10 J..lM 5Aza (Sigma) (281.6 pM final DMSO concentration in medium) for
60 h with three media changes at 0, 12 and 36 h. For Caco-2 cells, 5Aza treatments were
\

for 84 h with four media changes at 0, 12, 36 and 60 h. To evaluate the effects ofPPAR
transcription factor antagonists on TSA treated cells, TSA treated NRK cells were
incubated with PPARu antagonist (GW6471), PPARy antagonist, (GW9662) (Sigma), or

°

both, each at 1 JlM for 24 h. To evaluate the effects of PP AR transcription factor
antagonists on 5Aza treated cells, NRK cells were treated for 36 h with 5Aza and
incubated with 5Aza-free medium containing PPAR antagonists, each at 10 JlM for 24 h.
In studies evaluating the effects of transgenic PP ARu, NRK cells were transiently
transfected with pSG5 PP AR alpha plasmid [146] (plasmid 22751; Addgene, Cambridge,

32

MA) using Lipofectamine LTX & PLUS Reagent (Invitrogen) according to
manufacturer's instructions. Nearly confluent NRK cells, grown in six-well plates, were
transfected with 1Jlg pSG5 PP AR alpha plasmid or a control plasmid using
Lipofectamine LTX at a 1:3 mass: volume ratio for'" 18 h. The cells were then allowed
to grow for 24 h in complete medium and treated with TSA or vehicle as described
above.

Primary renal tubule cells (PRTCs) were isolated and cultured as described
previously [147, 148]. Briefly, mouse renal cortices were dissected and minced in icecold dissection solution ofHBSS (Thermo Scientific) supplemented with 10mM glucose,
5mM glycine, ImM alanine and 15mM HEPES pH 7.4. The minced fragments were
transferred to a dissection solution containing ~. 0 glml soybean trypsin inhibitor, 1
mglml type 1 collagenase and 0.05% type 2 collagenase, and digested for 30 min at 37°C.
After digestion, the mixture was passed through a 250 Jlm pore size nylon sieve and the
flow-through material passed through an 80 Jlm pore

siz~ nylon sieve. Proximal tubules

(PT) retained on the 80 Jlm sieve were resuspended with 37°(,) HBSS solution containing
1% BSA and then subjected to centrifugation for 5 min at 170xg. The PT pellet was
resuspended in 1:1 mixture ofDMEM:FI2 culture medium containing 15mM HEPES
and 2mM L-glutamine (Thermo Scientific) supplemented with 9% FBS, 50nM
hydrocortisone, ITS (BD Biosciences, San Jose, CA), sodium pyruvate, non-essential
amino acids, 100 units/ml penicillin, and 100 units/ml streptomycin (Thermo Scientific),
and then plated and maintained at 37°C and 5% CO2 . PRTCs were cultured for 4 days
before treatment with a medium change every other day. PRTCs were then treated with
5Aza or TSA or DMSO (vehicle)-containing medium for additional 7 days. On day 7,
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PRTCs were used for protein or RNA extraction using the RNeasy Plus Mini Kit
(QIAGEN, Valencia, CA) or fixed in 4% paraformaldehyde PBS with 1% Triton-XI 00
for 20 min for immunofluorescent microscopy.

For PPAR agonist and antagonist studies, semi-confluent PRTC cultures were
treated with PP AR alpha agonist, WyI4643 (Cayman Chemical Company, Ann Arbor,
MI), PPAR alpha antagonist, GW647I (Sigma) or vehicle DMSO only at the indicated
concentrations for 22hrs in complete media containing 3%FBS. Protein or RNA was
, extracted from independent experiments as already described.

qPCR

RNA from cells or tissue was isolated using the RNeasy Plus Mini Kit (QIAGEN,
Valencia, CA) and quality assessed on an Agilent Bioanalyzer. cDNA was prepared from
~

0.25-1 J,tg total RNA using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA)
according to manufacturer instructions. qPCR was perf~rmed using iQ SYBR Green
Supermix (Quanta BioSciences, Inc., Gaithersburg, MD) reagents and a CIOOO Thermal
Cycler (Bio-Rad). The relative values for each gene were determined using the cycle
thresholds and normalized to reference genes. The following qPCR primers were used:
rat Cubilin forward, 5'-TGGGAGCTGCGTCTATGATT-3' and rat Cubilin reverse, 5'AAGGAAGTTGCCGGAAGAGA-3' (NM_053332.2); rat MegalinlLrp2 forward, 5'ATCTGTGCTCCAGGTCCAAA-3' and rat MegalinlLrp2 reverse, 5'ATTGAGGCAGGTGAACTGGA-3' (NM_030827.l); rat PparD forward, 5'GGCCAAGAGAATCCACGAAG-3' and ratPPARD reverse, 5'-
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ACAAAAGGCGGATTGTTGCT-3' (NM_013196.1); ratPparD forward, 5'GGTGAAACTCTGGGAGATCCT-3' and ratPPARD reverse, 5'CATGGTAATTTCTTGTGAAGTGCT-3' (NM_013124.3); rat Gapdh forward, 5'GTGCCAGCCTCGTCTCATA-3' and rat Gapdh reverse, 5'AGGTCAATGAAGGGGTCGTT-3' (NM_017008.3); rat/mouse Rn18s forward, 5'CGCCGCTAGAGGTGAAATTCT-3' and rat/mouse Rn18s reverse, 5'CGAACCTCCGACTTTCGTTCT-3' (NR 046237.1); human Cubilin forward, 5'CCTGAACTGCGAATGGACTC-3' and human Cubilin reverse, 5'CATCACCCACTCGAAACTCG-3' (NM_OOI081.3); human Lrp2 forward, 5'GATTGGGCTGCTTCACGATT -3' and human Lrp2 reverse, 5'ATGGCAAGTCCAAACGGATG-3' (NM_004525.2); human Gapdh forward, 5'ATGTTCGTCATGGGTGTGAA-3' and human Gapdh reverse, 5'GGTGCTAAGCAGTTGGTGGT-3' (NM_002046.4); mouse Cubilin forward, 5'ATTTTCTCTGGGGTTTTGTTAC-3' and mouse

Cubili~

reverse, 5'-

TAAGTTTCCCTCCTCCGTAG-3' (NM_ 001081084.2); mouse MegalinlLrp2 forward,
\

5' -TGACTGCGGAGACA TGAGTG-3' and mouse MegalinlLrp2 reverse, 5'CACAGACCCAGTGTTGTGGA-3' (NM_OOI081088.1); mouse Gapdh forward, 5'CAGCCTCGTCCCGTAGACA-3' and mouse Gapdh reverse, 5'CAACAATCTCCACTTTGCCACT-3' (NM 008084.2); mousefJaetin forward, 5'AACCGCTCGTTGCCAATA -3' and mouse fJaetin reverse, 5'CGGGACCTGACAGACTACCTC-3' (NM 008084.2); and GFP forward, 5'CAACAGCCACAACGTCTATATCATG-3' and GFP reverse, 5'ATGTTGTGGCGGATCTTGAAG-3' (U50963.1) [149].
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Cubilin promoter luciferase transfection assays

BN cells for luciferase reporter assays were passaged in complete medium (MEM
with 10% fetal bovine serum, Glutamax (Life Technologies, Grand Island, NY), nonessential amino acids, 100 units/ml penicillin, and 100 units/ml streptomycin (Thermo
Scientific) as described previously [102]. Prior to transfection, BN cells were plated at
0.5 xl0 5 cells/cm2 in 24-well culture dishes in complete medium and grown overnight.
Control transfections were performed with PPARa (pSG5 PPAR alpha), PPARy (pcDNA
flag PPAR gamma; Plasmid 8895, Addgene) [150] or pcDNA3.1(+) (Life Technologies,
Grand Island, NY) expression plasmids in combination with a PP AR responsive
luciferase reporter plasmid (PPRE X3-TK-Iuc; Plasmid 1015, Addgene) [151].
Experimental transfections were conducted.wttl}lPARa, PPARy or pcDNA3.1(+)
I,.

expression plasmids in combination with a cubilin promoter luciferase plasmid (pCub 431 Luc) created by insertion of a mouse cubilin promoter fragment (-431 to -5, relative
to the translation start site) into the pGL3-Basic luciferasd report~r plasmid (Prom ega,
Madison, WI). Transfections were performed in triplicate with GenePORTER 2
(Genlantis, San Diego, CA) using 1.5 Jlg of each plasmid (3 Jlg total) and 15 JlI
GenePORTER 2 per transfection. Transfections proceeded for 24h after which cells were
lysed and extracts prepared for luciferase assay with the BD Monolight Enhanced
Luciferase Assay Kit (BD Biosciences, San Jose, CA) according to manufacturer
recommendations. Luciferase activity was measured using a Monolight 2012
Luminometer (BD Biosciences).
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Statistical analysis

Data are presented as mean ± SD of 3 replicates, representative of at least 3
independent experiments. Two-tailed Student's t-tests were used to compare control and
treatment groups.

Results

Monoallelic expression of cubilin in the renal proximal tubules

Kidney sections from wildtype mice and mice heterozygous for Cubn exon 1-6
deletion with an EGFP cassette insertion (Cubn~/del exon 1-6;EGFP) were immunolabeled with
~'.,I /i
C

•

antibodies to cubilin and EGFP. In kidneys from wildtype mice, all proximal tubules
displayed prominent and relatively uniform brush border immunolabeling with anticubilin IgG (Fig. 2-1A). By contrast, the kidneys of Cubnl/del exon 1-6;EGFP mice showed
strong immunolabeling in the brush border regions of only a subset of proximal tubules
\

(Fig. 2-1B). Evaluation ofEGFP immunolabeling in kidney sections from these mice

revealed a similar discontinuous distribution, with some cells showing high levels of antiEGFP immunofluorescence while adjacent cells had only weak fluorescence (Fig. 2-1q.
However, strikingly, the epithelial cells that had strong EGFP immunofluorescence,
displayed little or no cubilin immunolabeling (Fig. 2-1D). Conversely, the proximal
tubules that showed relatively low EGFP immunofluorescence displayed pronounced
cubilin immunolabeling. Similar observations were made in the kidneys of female

Cubn +/del exon 1-6;EGFP mice (data not shown). Thus, in the proximal tubule cells of
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Cubn +/del exon 1-6;EGFP mice, the level of EGFP immunofluorescence was inversely related
to the level of cubilin immunofluorescence. These observations suggest that one of the
two cubilin alleles in these heterozygous mice, either the targeted deletionlEGFP
insertion allele or the wild-type cubilin allele, is suppressed while the remaining allele is
active. Collectively, the findings suggest that cubilin gene is subject to monoallelic
inactivation in the kidney. The allelic inactivation appears to be stochastic in that adjacent
proximal tubule cells could be found in which one cell was expressing high levels of
EGFP and the other not. The fact that most proximal tubule cells in Cubn +/del exon 1-6;EGFP
kidneys were not completely devoid ofEGFP immunofluorescence suggests that the
inactivation process is not absolute.

EGFP expressing, cubilin deficient proximal tubule cells display reduced albumin
localization in Cubn +/de/ exon 1-6;EGFP mice

Cubilin located on the brush border of renal proximal ~ubule cells mediates
binding and endocytosis of albumin from the glomerular filtrate [44]. In kidneys of
wildtype mice, albumin is localized on the apicallbrush border regions of renal proximal
tubules (Fig. 2-1E and F). In Cubn +/del exon 1-6;EGFP mice, pronounced albumin
immunolabeling was apparent in the apicallbrush border regions of a subset of renal
proximal tubules that showed relatively low EGFP immunofluorescence (Fig. 2-1G and
H). By contrast, proximal tubules with strong anti-EGFP immunofluorescence showed

little or no albumin immunolabeling in the brush border region. These findings suggest
that the cubilin-deficient proximal tubules (i.e., those cells with strong anti-EGFP

38

immunofluorescence) are unable to efficiently bind and endocytose albumin, which is
consistent with other studies showing that cubilin deficiency leads to albuminuria [44,
152].

Expression of megalin and amnionless in the kidney of Cubn+/de/ exon 1-6;EGFP mice

We next evaluated the expression of two cubilin-binding membrane proteins,
megalin and amnionless, in proximal tubules of Cubn +/de/ exon 1-6;EGFP mice. As shown in

Figure 2-2A, anti-megalin immunolabeling was relatively uniform in the brush border
regions of all proximal tubules. Furthermore, the relative levels of megalin
immunolabeling were uniform among all pro?\!~j1- tubules, irrespective of the varied
levels of anti -cubilin immunolabeling (Fig. 2-2A and B boxed areas). Based on these
findings, cubilin deficiency resulting from monoallelic inactivation in Cubn +/de/ exon 16;EGFP

mice apparently has no effect on the expression of megalin ~n the renal proximal

tubule brush border. By contrast, immunofluorescence analysi~ of amnionless showed
that in proximal tubules having little or no anti -cubilin labeling, amnionless accumulated
within the proximal tubule cells as compared to proximal tubule cells having high levels
of anti-cubilin labeling (Fig. 2-2D-F). These findings are consistent with previous studies
showing that cubilin prevents intracellular accumulation of amnionless [31].

Expression of cubUin in the intestine

EGFP-fluorescence (hereafter referred to as cubilin-EGFP fluorescence) was
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EGFP fluorescence was detected in all segments of the small intestine, i"e., duodenum,
jejunum and ileum (Fig. 2-3).

Cubilin expression in the duodenum had not been previously reported. To
substantiate this, anti-cubilin immunoblot analysis of intestinal extracts from wild-type
mice was performed (Fig. 2-3D). Similar to what has been observed in rat and canine
ileal extracts [131, 153], mouse ileum and jejunum extracts contained ",460 kDa
monomer, multimer and ",200 kDa forms of cubilin. Cubilin was also detected in extracts
of the duodenum, however the stoichiometry of the various immunoreactive forms in the
duodenum was different from that of ileum and jejunum (i.e., levels of cubilin multimer >
monomer> ---200 kDa forms). The cubilin metn~ane anchor, amnionless, was detected in
all three segments of the small intestine, as was the cubilin ligand intrinsic factor (Fig. 2SD). Megalin expression in the small intestine was also examined and highest levels were

detected in the ileum and jejunum and lowest levels in thelduodenum (Fig. 2-3D).
\

In all three segments of the small intestine, cubilin-EGFP fluorescence was found
in patches of intestinal villi, with regions of relatively strong fluorescence interspersed in
areas of little or no fluorescence. Closer examination revealed that cubilin-EGFP
fluorescence was in discrete segments of each villus (Fig. 2-3E-H).

To test the hypothesis that cubilin is monoallelically expressed in the small
intestine, we performed qPCR analysis on microdissected villi from the ileum of
Cubn +/del exon 1-6;EGFP mice that were predominantly either EGFP positive, EGFP negative
or both. If cubilin expression were biallelic, then the expectation would be that both
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cubilin and EGFP mRNA would only be detected in EGFP-positive cells and no cubilin
or EGFP mRNA would be detected in EGFP-negative enterocytes. However, as shown in

Figure 2-31, cubilin mRNA was not only detected in EGFP-negative enterocytes, it was
also significantly higher as compared to EGFP-positive cells. Conversely, EGFP-negative
enterocytes expressed significantly lower EGFP mRNA levels as compared to EGFPpositive cells (Fig. 2-31). Based on these findings the cubilin gene appears to be largely
expressed from one allele in intestinal cells (i.e., monoallelic expression).
We next examined sections of small intestine from Cubn +/del exon 1-6;EGFP mice after
immunolabeling with antibodies to cubilin and EGFP. Anti -cubilin IgG-reactive material
was apparent as a discrete layer on the apical surfaces of anti-EGFP-positive enterocytes
as well as anti-EGFP-negative enterocytes

(Fig:~)-4A,

arrowheads). In addition, anti-

cubilin immunolabel was also detected within the cytoplasm of ileal enterocytes as
punctate foci located on the apical side of the nuclei (Fig. 2-4A, arrows). This
cytoplasmic staining was present in both anti-EGFP-posidve and anti-EGFP-negative
enterocytes. Thus, despite EGFP-positive enterocytes having significantly lower
expression of cubilin mRNA (Fig. 2-31), they appear to have similar cubilin protein
levels compared to EGFP-negative enterocytes, which have higher expression of cubilin
mRNA. These findings are consistent with the fact that cubilin is known to be secreted
and taken up by enterocytes [39, 154]. As such, enterocytes with the active wild-type
cubilin allele might express and secrete cubilin, which could then bind to EGFP-positive
enterocytes and result in similar levels of cubilin protein in all enterocytes.
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Amnionless in the intestine of Cubn+/de/ exon 1-6,'EGFP mice

We also perfonned anti -amnionless labeling of sections of small intestine from
Cubn +/del exon 1-6,·EGFP mice. Amnionless immunolabeling was present on the cell surface

and in the cytoplasm of EGFP-positive and EGFP-negative enterocytes (Fig. 2-4C and
D). There were no apparent differences in the relative levels or in the subcellular

localization of amnionless between EGFP-positive and EGFP-negative enterocytes. This
is in contrast to what was seen in the kidney, in which amnionless accumulated within
EGFP-positive proximal tubule cells as compared to EGFP-negative proximal tubule
cells (Fig. 2-2F).

Intrinsic factor in the intestine of Cubn+/de/ exon 1-6;EGFP mice

Cubilin expressed by intestinal enterocytes mediates binding and endocytosis of
l

intrinsic factor-cobalamin complex from the intestinal lumen [15S]. Ileal segments from
Cubn +/del exon 1-6;EGFP mice were examined for immunolocalization of intrinsic factor in

cubilin-EGFP-positive and cubilin-EGFP-negative enterocytes. As shown in Figure 2-4E
and F, intrinsic factor immunolabeling was observed on the apical surfaces (Fig. 2-4E,
arrowheads) and within the cytoplasm of both EGFP-positive and EGFP-negative

enterocytes. There was no apparent difference in the relative level of anti-intrinsic factor
immunolabel in EGFP-positive and EGFP-negative enterocytes (Fig. 2-4F). This was
similar to the pattern of intrinsic factor immunolabeling observed in the wildtype
intestine (Fig. 2-4G and H). Based on these observations, the pattern of intrinsic factor

uptake corresponds to anti-cubilin immunolabel found on all enterocytes (Fig. 2-4A),
regardless of the mosaic pattern of cubilin-EGFP or cubilin mRNA expression.

Epigenetic regulation of cubUin

Several lines of evidence suggest that one of the two cubilin alleles may be
inactivated epigenetically in the kidney and intestine: 1) EGFP expressed from the
targeted cubilin allele displays a distinct mosaic pattern in the kidney and intestine, 2)
proximal tubule cells expressing the targeted cubilin allele expressed little or no cubilin
and displayed reduced binding of albumin, suggesting that the wild-type cubilin allele in
these cells was inactive, and 3) EGFP-negatiy~~pterocytes express significantly higher
,

I,

levels of cubilin mRNA as compared to EGFP-positive cells in Cubn +/del exon 1-6;EGFP mice.
Inactivation of the cubilin allele might occur through epigenetic modifications that
control the transition of chromatin from transcriptionally active t~ inactive state. Histone
deacetylation and DNA methylation at CpG sequences are tWQ types of epigenetic
modifications that mediate transcriptional inactivation.

CubUin promoter lacks conserved CpG islands

To determine whether DNA methylation regulates cubilin transcription, we first
analyzed the regions flanking the transcription start site of the mouse cubilin gene for
CpO islands using the CpG island analysis feature of the UCSC Genome Browser and the
EMBOSS CpGPlot algorithm [156,157]. Analysis of5' flanking sequences extending
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from approximately -20,000 to + 3,SOO relative to the transcription start site of the mouse
cubilin gene did not detect any CpG islands (data not shown). A similar analysis of the
human and rat cubilin genes using the CpG island analysis feature of the UCSC Genome
Browser did not detect any CpG islands. These findings did not preclude the possibility
that cubilin expression in these species might be regulated by non-CpG DNA methylation
[IS8]. It is also possible that DNA methylation indirectly regulates cubilin transcriptional

activation.

Effects of 5Aza on cubilin in NRK and Caco-2 cells
We therefore evaluated the effects o.{!?~PNA methylation inhibitor, S.'/

azacytidine (SAza), on cubilin expression in renal NRK cells and intestinal Caco-2 cells.
In NRK cells, SAza treatments augmented cubilin mRNA expression as measured by
qPCR (Fig. 2-5A). In Caco-2 cells, 1 and 5 JlM 5Aza treatments augmented cubilin
expression, but 10 JlM 5Aza decreased cubilin expression (Fi~. 2-5C) as compared to the
vehicle control. These findings suggested that DNA methylation was directly or
indirectly regulating cubilin expression in cultured renal and intestinal epithelial cells.
The effect of SAza treatment on the expression of megalin was also evaluated in these
cells. SAza treatment stimulated megalin expression in NRK cells (Fig. 2-5B), but
inhibited megalin expression in Caco-2 cells (Fig. 2-5D).
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Effects of TSA on cubilin in NRK and Caco-2 cells
We next evaluated the effects of the histone deacetylase (HDAC) inhibitor,
trichostatin A (TSA), on cubilin mRNA expression in NRK and Caco-2 cells. TSA
treatment elicited a concentration dependent increase in cubilin mRNA expression in
both cell lines (Fig. 2-SE and 6). The magnitude of the effect ofTSA on cubilin
expression was generally greater than that achieved using 5Aza. TSA treatment also
augmented megalin expression in both NRK and Caco-2 cells (Fig. 2-SF and H).

Effects of 5Aza and TSA on cubilin monoallelic expression in PRTCs and in vivo
To determine whether allelic inacti\'~tlJlof the cubilin gene might be released by
5Aza or TSA treatment, we employed primary renal tubule cells (PRTCs) isolated from

Cubn +/del exon 1-6;EGFP kidneys. Following isolation of these cells, we consistently observed
l

that <10% of the cultured PRTCs were EGFP-positive which is in contrast to the
\

approximately 1: 1 ratio of EFGP-positive to EGFP-negative cells in proximal tubules as
assessed by immunofluorescence microscopy. The basis for this observation remains to
be defined but it may be an indication that cubilin deficiency in PRTCs might reduce
their migration out of tubules onto the culture plate, inhibit adhesion to the culture plate,
or reduce cell proliferation in vitro.

The mixed population ofPRTCs (i.e., EFGP-positive and EGFP-negative PRTCs)
isolated from Cubn +/del exon 1-6;EGFP kidneys were treated with TSA. TSA treatment
(10nM) resulted in a --2-fold increase in cubilin mRNA levels (Fig. 2-6A), but the effect
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was reduced at higher concentration. TSA treatment also increased megalin mRNA levels

(Fig. 2-6B). Immunoblot analysis of extracts from TSA-treated PRTCs was also
performed and the results showed that both cubilin and megalin protein expression was
augmented by the treatment (Fig. 2-6C). Furthermore, immunoblot analysis of extracts
from 5Aza treated PRTCs was performed and the results showed that both cubilin and
megalin protein expression was augmented by the treatment (Fig. 2-6C).

We next reasoned that if 5Aza or TSA treatment were able to transform cubilin
monoallelic expression to biallelic, then we should observe an increase in the number of
anti-EGFP positive cells. We therefore determined the percent ofEGF-positive cells in
21 imaged fields ofDMSO treated PRTCs and in 34 imaged fields ofTSA treated (10
nM) PRTCs. As shown in Figure 2-6D, TSAilJ!}ltment ofPRTCs did not elicit a
,

I,

significant change in the percentage of anti-EGFP positive PRTCs as compared to vehicle
treated cells (also see Supplementary figure 1). Similarly, PRTCs treated with 5Aza did
not lead to an increase in the number of anti-EGFP positi{re cells ~s compared to vehicle
treated cells (data not shown). In these 5Aza experiments, PRJC proliferation was
inhibited by 5Aza treatment to a much greater extent than was observed for NRK cells.
Since TSA or 5Aza treatment did not increase the number ofEGFP expressing cells, we
concluded that cubilin monoallelic expression was not effected by either treatment.
Evaluating the effects of combined TSA and 5Aza was not possible due to the
detrimental effects that the combined drugs had on PRTC growth. For this reason, we
evaluated the effects of combined TSA and 5Aza treatment using NRK cells. The results
showed that the stimulation of cubilin mRNA expression achieved by combined TSA and
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5Aza treatment was not greater than that observed with TSA, which consistently elicited
the greatest magnitude increase (data not shown).

To determine ifTSA treatment changes cubilin expression in vivo, age-matched
male Cubn +/del exon 1-6;EGFP and WT mice were treated with TSA at 2 Jlgig of mouse body
weight. TSA treatment resulted in significantly increased cubilin mRNA expression in
the ileum of Cubn +/del exon 1-6;EGFP mice (Fig. 2-7A). TSA treatment also increased megalin
mRNA levels in both WT and Cubn +/delexon 1-6;EGFP mice (Fig. 2-7B). We reasoned that if
TSA treatment transforms cubilin monoallelic expression to biallelic, we should observe
significantly increased number of Cubn-EGFP expressing villi. However, TSA treatment
did not appear to increase the number of Cubn-EGFP expressing villi in the intestine of

Cubn +/del exon 1-6;EGFP mice (Fig. 2-7C and D)~~ematively, the Cubn-EGFP fluorescence
intensity appears to be increased with TSA treatment, indicating increased cubilin-EGFP
expression from the active allele. These observations indicate that although intestinal
cubilin expression is increased by TSA treatment, cubilin'monoallelic expression is not
transformed to biallelic.

Epigenetic regulation of cubilin via PPARs
The above findings suggested that TSA and 5Aza treatment increased cubilin
expression by increasing the transcription of the active cubilin allele. HDACs, which are
inhibited by TSA, are known co-repressors of the transcription factors, Peroxisome
Proliferator-Activated Receptor (PP AR) [159-162]. Conversely, PP AR co-activators
increase histone acetylation, resulting in PPAR -mediated transcription [159, 161-163].
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Recent studies show that the expression ofPPAR-y is also regulated by DNA methylation
[164] and histone deacetylation [162]. Furthennore, renal megalin expression is known to
be regulated by PP ARs [62]. We therefore tested whether epigenetic regulation of PP ARs
mediated the effects of 5Aza and TSA on cubilin and megalin expression. Computerized
transcription factor binding site analysis identified three PPAR response elements
conserved in human and mouse cubilin promoters (Fig. 2-8). Analysis of cubilin
promoter activity in cells transfected with a cubilin promoter-Iuciferase reporter found
that cubilin transcription was increased by transfection of cells with PP ARa and y
expression constructs (Fig. 2-8B-D). Furthennore, endogenous cubilin (and megalin)
mRNA expression in NRK cells was blocked by the PPARa and y antagonists, GW6471
and GW9662 (Fig. 2-8E and F). To further evaluate the role of PP ARs in regulating
-~I /1
,"

cubilin expression, we utilized PRTCs. PPARa agonist, Wy14643, treatment ofPRTCs
resulted in a significant increase in cubilin protein levels over a range of agonist
concentrations (Fig. 2-9A). Cubilin mRNA levels were

al~o

significantly increased by

PPARa agonist treatment at 100JlM concentration (Fig. 2-9C). By contrast, PPARa
antagonist, GW6471, significantly decreased endogenous cubilin mRNA expression and
also inhibited the increased cubilin expression achieved by agonist treatment (Fig. 2-9D).
PPARa agonist and antagonist treatments resulted in similar reciprocal changes in the
mRNA levels of A cadI, a known PP ARa-responsive gene [165, 166] (Supplementary

figure 2). Treatment of PRTCs with the PP ARy agonist (Rosiglitazone) also resulted in a
significant increase in cubilin protein levels (Fig. 2-9E). Rosiglitazone at 50nM
concentration also elicited a modest, but significant increase in cubilin mRNA expression
(Fig. 2-9G). Furthennore, the PP ARy antagonist, GW9662, inhibited the increased
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cubilin expression achieved by Rosiglitazone treatment (Fig. 2-9H). Together, these
findings indicate that, similar to megalin [62], cubilin is a gene regulated by both PP ARa
andy.

We next evaluated the effects of 5Aza and TSA on the expression ofPPARa and
yin NRK cells. As shown in Figure 2-l0A, 5Aza treatment elicited a dose dependent
increase in PP ARa mRNA expression. 5Aza also augmented PP ARy expression (Fig. 2lOB) at low concentrations but not at the highest concentration tested (10 JlM). Similarly,

TSA treatment ofNRK cells also produced a concentration dependent increase in PPARa
mRNA levels (Fig. 2-l0C). TSA also increased PPARy expression at the highest
concentration tested (100 nM) (Fig. 2-l0D).

f
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The observations that TSA and 5Aza increased PPARa and y mRNA levels
suggested the possibility that cubilin upregulation by TSA and 5Aza resulted from
increased expression ofPPAR. We therefore evaluated th~ effects ofPPARa and y
antagonists on TSA and 5Aza induction of cubilin expression> As shown in Figure 2lOE, the upregulation of cubilin by 5Aza was inhibited by PPARy antagonist as well as

combined PP ARa and y antagonist treatments. Acadl, a known PP ARa responsive gene
[165, 166], was also increased by 5Aza treatment and the increase was inhibited by
PP ARa antagonist treatment (Supplementary figure 2B). These findings suggested that
the 5Aza-induced expression of cubilin is dependent on 5Aza-induced expression of
PP ARy. Parallel studies showed that 5Aza-mediated induction of megalin expression was
also dependent on 5Aza-induced expression of both PPARa and y (Fig. 2-l0F).
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The effects ofPPARa and y antagonists on TSA-induced cubilin expression were
also evaluated. Results showed that cubilin upregulation by TSA was inhibited by
PP ARa antagonist as well as combined PP ARa and y antagonist treatments (Fig. 2-

lOG). The fact that combined PP ARa and y antagonist treatment produced a greater
magnitude decrease than either antagonist alone suggested that TSA-induced expression
of cubilin is dependent on TSA-induced expression of both PP ARa and y. Parallel studies
showed that TSA-induced expression of megalin was also dependent on TSA-induced
expression of both PPARa and y (Fig. 2-10H). A cadi levels were also increased in
response to TSA treatment and the increase inhibited by PP AR antagonist treatment

(Supplementary figure 2C).
We next tested whether the increase((tr~~scription of PPARs was sufficient to
induce cubilin expression or whether the epigenetic modifiers also influenced the
activation state of PP AR. NRK cells were transfected with a PP ARa expression
l

construct, which greatly increased levels ofPPARa mRNA (Fig. 2-11A). However, the
\

increased PPARa levels alone did not increase cubilin mRNA levels (Fig. 2-11B).
Similarly, the addition of PP ARa agonist alone did not alter cubilin expression (Fig. 2-

lIB). Yet the combination ofPPARa overexpression and PPARa agonist treatment
caused a significant increase in cubilin mRN A expression. These findings indicate that
under normal conditions PP ARs are fully active in NRK cells and the addition of an
agonist alone does not increase cubilin expression. Thus, both PP ARa upregulation and a
PP ARa agonist are required to augment cubilin expression. When control transfected
cells were treated with TSA there was a 4-fold increase in cubilin expression (Fig. 2-
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lIB). The addition of agonist to these cells did not elicit any further increase (Fig. 2lIB). By contrast, PPARa overexpression combined with TSA treatment caused an 8fold increase in cubilin expression. As with controls, the addition of agonist to these cells
did not significantly increase the level of cubilin expression (Fig. 2-IIB). These findings
indicate that the TSA mediated increase in cubilin expression not only involves an
increase in PP AR transcription but also PP AR activation.

Discussion

Here we present evidence that the cubilin gene undergoes allelic inactivation. The
t

evidence includes findings showing that

,j,"

cubilip:~xpression

in the kidneys of mice

I,

heterozygous for targeted cubilin deletionlEGFP insertion is mosaic such that some
proximal tubule cells display active expression of EGFP (i.e., the targeted allele) as well
as suppressed expression of the wild-type cubilin allele, while oth.er proximal tubule cells
display the inverse pattern. Mosaic expression of cubilin was also observed in all three
segments of the small intestine, with cubilin-EGFP fluorescence found in discrete
segments of each villus. Additional support for enterocytes displaying allelic inactivation
of the cubilin gene came from qPCR studies of Cubn +/del exon 1-6;EGFP mice showing that
cubilin mRNA levels were significantly reduced in isolated regions of the small intestine
expressing EGFP as compared to non-EGFP expressing regions. At the protein level,
unlike what was seen in the kidney, enterocytes displayed both expression of the cubilin
allele bearing the targeted deletionlEGFP insertion and contained immunologically
detectable cubilin. Since enterocytes have been shown to release cubilin in association
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with extracellular surfactant-like particles [39], which bind to the apical portion of the
cell [154], it is reasonable to expect that cubilin expressed in some enterocytes from the
wild-type cubilin allele is being released and taken up via cubilin binding receptors (e.g.,
megalin and/or amnionless) expressed by enterocytes in which the wild-type cubilin
allele is suppressed. Furthermore, this form of cubilin appears to be capable of
endocytosis of its ligand, intrinsic-factor cobalamin complex, since intrinsic factor uptake
was similar in enterocytes with suppressed wild-type cubilin allele and those with an
active wild-type cubilin allele.

Unlike what was observed in the kidney where amnionless accumulates
intracellularly in cubilin-deficient cells, the consequences of cubilin deficiency on
amnionless trafficking in intestinal cells was;RO~~lear. Based on our intestinal data, we
speculated that a secreted form of intestinal cubilin might act in a non-cell autonomous
manner to prevent the accumulation of amnionless in enterocytes having lower
endogenous cubilin expression. It is also important to poirlt out that the intestine appears
to express multiple cubilin and amnionless isoforms, which have different stoichiometries
in the kidney (Fig. 2-3D). Therefore, it is possible that in the intestine, cubilin and
amnionless trafficking to the apical cell membrane are not interdependent.

The finding that 5Aza and TSA treatments were unable to release the suppression
of the silenced cubilin allele suggests that DNA methylation and histone deacetylation
may not be the only mechanisms of regulation of cubilin mono allelic expression. Indeed,
diverse mechanisms exist to mediate allelic inactivation including interplay of DNA
modifications by DNA methylation and modifications of the histone proteins by
acetylation, methylation, SUMOylation or phosphorylation [167, 168]. Additionally,
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imprinted monoallelic expression of certain gene clusters is in part mediated by
noncoding RNAs under the control of methylation of imprint control elements [167].
Intriguingly, the cubilin gene is located in the mouse chromosome 2 proximal region,
which is one of several chromosomal regions known to contain genes that undergo
parental imprinting during development [169, 170]. Our observation that groups of
adjacent proximal tubule cells shared the same inactive cubilin allele suggests that the
allelic inactivation is inherited clonally from a progenitor that underwent imprinting
during development. Further research will be required to define the precise mechanisms
regulating cubilin monoallelic expression.

Since cubilin monoallelic expression was unaltered by 5Aza and TSA treatments,
,

we concluded that the increased cubilin mRNA11"els were due to effects of these agents
,

(,

on the transcriptionally active cubilin allele. Both histone deacetylation and DNA
methylation are associated with PP AR repression [162, 164]. In fact, HDAC 1 and 3 are
known PPARy co-repressors [171-173]. Conversely, PPAR co-activators, such as

CBP/p300 and SRC-1, possess histone acetylase activity required for chromatin
remodeling to allow PPAR-mediated transcription [162, 163, 174, 175]. Furthermore,
recent findings show that the cubilin coreceptor, megalin, is a PP AR -responsive gene and
its expression is augmented through inhibition of histone deacetylation [62, 135]. In light
of these studies, we recognized the possibility that the observed effects of TSA and 5Aza
on cubilin might also involve PP AR induction. This led us to discover that the observed
effects of 5Aza and TSA on cubilin expression were dependent on PP ARa and y
induction. Specifically, we showed that cubilin was a PP ARa and y responsive gene, that
the expression ofPPARa and y was inducible by 5Aza and TSA alone, and that the
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effects ofTSA and 5Aza on cubilin expression were dependent on increased expression
of PP ARa and y. Similarly, we showed that TSA and 5Aza-induced megalin expression
was dependent on increased expression ofPPARa and y.

While TSA and 5Aza treatments augmented PP AR and cubilin mRNA levels, no
significant increase in cubilin levels was achieved by overexpressing PP ARa in the
absence ofPPARu agonist. Therefore, the effects ofTSA and 5Aza on cubilin mRNA
levels cannot be attributed to increased PP AR mRNA levels alone. We inferred that, in
addition to increasing PP AR expression, 5Aza and TSA treatments must also lead to
PP AR activation. The underlying mechanism for the apparent agonist-independent effects
of TSA on induction of PP AR-dependent transcription of cubilin remains to be
.',

established. TSA and/or 5Aza might

..t

augmenfl~('els of endogenous PP AR agonists, cause

demethylation of sites on the cubilin gene, or reduce histone occupancy of the cubilin
promoter. Any of these effects might be sufficient for promoting PP AR action in an
l

agonist-independent manner. Since HDACs are known co-repressors and HATs are coactivators ofPPARs [162], it is reasonable to expect that inhiBiting HDAC activity will
shift PP ARs towards a more active state. In fact, HDAC inhibitors have been reported to
act as atypical PP AR agonists [161] and studies have shown that inhibition of HDACs
stimulates transcription ofPPAR responsive genes [171, 176]. Therefore, it is likely that
increased acetylation of histones associated with the cubilin promoter in response to
HDAC inhibitor treatment is sufficient to promote PPAR-driven cubilin expression.

Our findings that cubilin and megalin expression is regulated by DNA
methylation and histone deacetylation raise questions as to whether these genes might be
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predisposed to inactivation by disease-associated increases in DNA methylation and
histone deacetylation. DNA methylation is a major contributing factor to various diseaserelated processes, such as tumorigenesis, atherogenesis and diabetic nephropathy [177179] (including glomerular and interstitial fibrosis [180]). Global DNA
hypennethylation is associated with inflammation and increased mortality in chronic
kidney disease [181] and chronic inflammation has even been implicated as a driving
factor associated with increased DNA methylation in diseases such as chronic gastritis
and gastric cancer [182, 183]. Furthennore, the inflammatory cytokine, IL-6, exerts an
impact on epigenetic changes in cells via regulation of DNA methyltransferase [184].
Histone deacetylation catalyzed by HDACs also contributes to the pathogenesis of
various diseases including gastric and colorectal cancer [185, 186], renal disease such as

. ~~, t,·

polycystic kidney disease [187] and macrophage infiltration and fibrotic changes
associated with tubulointerstitial injury [188].
HDAC inhibitors appear to have significant therap~utic potential in kidney
disease [189]. For example, a number of studies have demonstrated efficacy ofTSA in
ameliorating renal injury in mice following unilateral ureteral obstruction [188],
nephrotoxic serum nephritis [190] and in lupus pathogenesis [191]. In light of findings
presented herein, it is possible that drugs that inhibit HDACs might ameliorate renal
disease by releasing epigenetic suppression of PP ARs, cubilin and megalin. Intriguing
new findings from rodent studies highlight the potential reno-protective benefits of
increased megalin expression on early phase renal injury in responses to protein overload
[62]. Specifically, the studies showed that megalin expression in rats is decreased by
BSA overload and that augmenting megalin expression in rats by PP ARy agonist
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treatment correlated with a reduction in BSA-induced proteinuria. Effects of PP AR
agonist treatments on renal expression of the albumin receptor, cubilin, were not
evaluated in those studies. Thus, it was not clear whether the mechanistic basis for the
observed effects involved PPAR agonist induced changes in cubilin expression. Our
studies demonstrate that cubilin, like megalin, is under PP AR transcriptional regulation
and suggest that the amelioration of protein overload-induced albuminuria by PP AR
agonists observed in other studies is mediated by augmented levels of cubilin.

Future directions

Cubilin mono allelic expression

In this study, we demonstrated that cubilin expression in the kidney and intestine
is predominantly from one allele, i.e. monoallelic expression. This monoallelic
l

expression could not be transformed to biallelic by treating RPTC from adult mice with
TSA or 5Aza, which inhibit HDACs and DNA methylation re~pectively. We postulated
that DNA methylation and histone deacetylation might not be the only mechanisms of
regulation of cubilin monoallelic expression. Cubilin monoallelic expression might be
regulated by interplay of diverse epigenetic processes, including DNA methylation;
modifications of the histone proteins by acetylation, methylation, SUMOylation or
phosphorylation; and noncoding RNAs under the control of methylation of imprint
control elements [ 167, 168]. Alternatively, cubilin monoallelic expression might be
determined in embryonic development. Indeed, the cubilin gene is located in the mouse
chromosome 2 proximal region, which is one of several chromosomal regions known to
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contain genes that undergo parental imprinting during development[ 169, 170].
Furthermore, our observation that groups of adjacent proximal tubules or intestinal villi
shared the same inactive cubilin allele suggests that the allelic inactivation is inherited
clonally from a progenitor that underwent imprinting during development. It is
conceivable that epigenetic mechanisms such as DNA methylation or histone
deacetylation have different roles during development and in adult cells, e.g. determining
allelic inactivation in development and regulating the expression of the active allele in
adults. Therefore, future studies should test the effect of inhibiting DNA methylation or
histone deacetylation during embryonic development on adult cubilin expression.
Preliminary experiments showed that dams treated with 2J.!M 5Aza 14.5 and 16.5 days
post coitus were able to carry pregnancy to teon .. Strikingly, cubilin expression appeared
r~1 };'i
to be decreased in the intestine of 16-day-old pups from one of these pregnancies
.

compared to vehicle treatment. The fact that the effect of 5Aza treatment during
development was passed on to juvenile pups lends furtherlsupport to the hypothesis that
cubilin allelic expression might be determined during development. Further such
\

experiments with different concentrations of 5Aza and other epigenetic modifiers are
required to elucidate the regulation of cubilin expression during development.

Cubilin expression, function and interaction with amnionless in the intestine
Our observation that enterocytes with deficient endogenous cubilin mRNA
expression contained immunologically detectable cubilin is consistent with previous
studies showing that cubilin fragments are secreted and taken up by enterocytes [39,
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154]. This form of cubilin appears to be capable of endocytosis of its ligand, IF-B12, since
intrinsic factor uptake was detected in enterocytes with deficient endogenous cubilin
expression. Future work is required to demonstrate that exogenous administration of
cubilin protein in vitro would result in cubilin-mediated endocytosis of cubilin ligands.

Unlike the renal proximal tubule cells where amnionless accumulates
intracellularly in cubilin-deficient cells, enterocytes lacking endogenous cubilin
expression did not have amnionless intracellular accumulation. It is not clear whether the
secreted form of cubilin prevents amnionless intracellular accumulation or whether the
intestinal cubilin and amnionless isoforms are not interdependent in their trafficking to
the apical membrane. Future work can resolve this by in vitro knock down of cubilin,
,

amnionless or both in intestinal cells, and

anaL~}ng

cubilin and amnionless expression at

the apical membrane. Furthermore, cubilin and amnionless protein within and at the
surface of enterocytes as well as in intestinal lumen content should be isolated and
sequenced. This might identify the secreted form of cubilih and also reveal which
intestinal cubilin isoforms have the amnionless binding site. \

The role of cubilin in the intestinal absorption of nutrients is very important, yet
poorly understood. Presently, IF-B12 complex is the only identified ligand for cubilinmediated endocytosis in the intestine[ 4 7]. Since cubilin is a multi -ligand receptor known
to bind many ligands, it is highly likely that cubilin mediates the absorption of other
nutrients in addition to vitamin-B 12 . Future work should explore the possibility that
cubilin might mediate the absorption of other vitamins in the intestine. One approach that
might be a good starting point would be to purify cubilin and cubilin-bound material from
the intestine, and perform protein sequencing and mass spectrometry analysis to identify
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proteins and other material bound to cubilin. This might reveal numerous candidates for
intestinal cubilin-mediated absorption of nutrients.

PPAR regulation of cubilin expression in kidney diseases
Our studies demonstrated that cubilin expression is upregulated by PP ARs, which
are themselves regulated by epigenetic modifications, i.e. DNA methylation and histone
deacetylation. Evidence suggests that decreased renal cubilin expression in diseases such
as diabetes and acute kidney injury might involve decreased PP AR expression or activity
[10, 11, 64, 66-68]. This link has to be directly established in future studies. Furthermore,
the effect of increased cubilin expression by l~~foent with PP AR agonists on disease
,

I,

outcomes such as proteinuria and overall renal function should be studied.

Epigenetic modifiers, such as treatment with HDAC inhibitors, have been shown
l

to lead to better disease outcomes in models of acute kidney injury in rodents [188-190].
\

There is also evidence that diabetic nephropathy might be ameliorated by treatment with
epigenetic modifying inhibitors [192, 193]. It is not clear whether these effects of
epigenetic modifiers are dependent on increased cubilin or PPAR expression and activity.
Cubilin and PP AR expression and function should be tested in these disease models with
and without treatment with epigenetic modifiers. To tease out the dependence of the
beneficial effects of epigenetic modifiers on PP AR activity, treatment with epigenetic
modifiers could be compared with PP AR agonists alone in these diseases.
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Figure 2-1. Monoallelic expression of cub~~ ". Cubn +/del exon 1-6;EGFP mice leads to
reduced albumin binding to brush borders tlf cubilin-deficient renal proximal
tubules cells.
A shows a confocal micrograph of a section of wildtype mouse kidney labeled with
anti-cubilin IgG (red) and the nuclear stain, Draq5. B shows a confocal image from a
section of a Cubn +/del exon 1-6;EGFP mouse kidney labeled with anti-cubilin and Draq5.
Asterisks indicate proximal tubules displaying relatively 10w levels of anti-cubilin
immunolabeling. C and D are merged images of anti-cubilin immunolabeling (red)
and anti-EGFP immunolabeling (green) and nuclear staining'{blue). D is a digitally
zoomed in view of the boxed area in C. E and G show confocal images of antialbumin labeled sections from wildtype (E) and Cubn +/del exon 1-6;EGFP (F) mouse
kidneys. F and H show images of the sections shown in E and G merged with antiEGFP labeling. G, glomerulus.
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Figure 2-2. Megalin expression is uniform whereas amnionless accumulates in
cubilin-deficient renal proximal tubules of Cubn+/del exon 1-6;EGFP mice.
A-C show confocal images of a section of Cubn +/del exon t 6;EGFP f!1ouse kidney labeled
with anti-megalin IgG (A), anti-cubilin (B). C is a merged image of anti-megalin and
anti-cubilin immunolabeling together with Draq5 nuclear staining (blue). Boxed areas
in A and B highlight an example of a proximal tubule displaying strong anti-megalin
immunolabeling and relatively weak anti-cubilin labeling. D shows a confocal image
from a section of a Cubn +/de/ exon 1-6-EGFP mouse kidnex.labeled with anti-amnionless
(Amn). E is a merged image of the section of Cubn + 'del exon 1-6;EGFP mouse kidney
shown in D labeled with anti-amnionless, anti-cubilin and the nuclear stain, Draq5
(blue). F is a digitally zoomed in view of the boxed areas in D and E showing a
proximal tubule displaying strong anti-cubilin immunolabeling adjacent to two
proximal tubules with little or no anti-cubilin labeling. Arrowheads indicate
intracellular accumulations of Amn immunolabeling. G, glomerulus.

61

Cubilin
o Cubilin
• EGFP

Megalin

Amn

~:=::======:::::::=====::::: -25
IF

. . .~._

- 50
37

·0

_ _ _ _~"""--==.I-

Tubulin

Villi:

EGFP+/- EGFP-

EGFP+

- 50

- 37

Figure 2-3. Cubilin expression in the intestine of Cubn+/de/ exon 1-6;EGFP mice.
A-C show images ofEGFP fluorescence in the luminal surface of whole mount
segments of the duodenum (A), jejunum (B) and ileum (9) from a Cubn +!del exon 1-6;EGFP
mouse. D shows an immunoblot analysis of detergent e~tracts of segments of the
intestine and kidney using antibodies to cubilin, megalin, amnionless (Amn), intrinsic
factor (IF) and tubulin. E is a DIC image of the luminal face\of the small intestine
(ileum) from a Cubn +!del exon 1-6;EGFP mouse. F is an epifluorescence image showing
EGFP fluorescence in the epithelial cells of the intestinal villi shown in E. Note the
mosaic pattern of cubilin-EGFP fluorescence. G is a cross section of the small
intestine from a Cubn +!del exon 1-6;EGFP mouse showing cubilin-EGFP expression in
patches of villi. H is a high magnification view of a cluster of villi showing segmental
cubilin-EGFP expression in epithelial cells within individual villi. I is a qPCR analysis
of cubilin and EGFP mRNA levels in microdissected intestinal villi segments (n=4
mice) that were either predominantly EGFP-positive, negative or both. Asterisks
indicate that mRNA levels measured in EGFP-positive or EGFP-negative villi were
significantly different (p<O.05) from the levels in RNA prepared from villi containing
both EGFP-positive and EGFP-negative cells. Pound signs indicate that mRNA levels
measured in EGFP-positive villi were significantly different (p<O.05) from levels in
EGFP-negative villi.
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Figure 2-4. Subcellular localization of cubilin, amnionless and intrinsic factor in
ileal enterocytes.
A shows a confocal image from a section of a Cubn +/del exon 1-6;EGFP mouse ileum
labeled with anti-cubilin. B is a merged im~e-,,?.fthe section of Cubn +/del exon 1-6EGFP
mouse intestine shown in A labeled with anti-cubilin and anti-EGFP together with
Draq5 nuclear staining (blue). Arrowheads in A and B point to anti-cubilin label on the
apical surfaces of enterocytes. Arrows in A and B point to anti-cubilin label in the
cytoplasm of anti-EGFP-positive enterocytes. Asterisks in B indicate goblet cells
devoid of anti-EGFP labeling and lacking apical anti-cubilin labeling. C shows a
confocal image from a section of a Cubn +/del exon 1-6;EGFP mouse ileum labeled with antiamnionless. D is a merged image of the section of Cubn +/del exon 1-6;EGFP mouse intestine
in C showing cubilin-EGFP expression together with Draq5 puclear labeling.
Arrowheads in C and D point to anti -amnionless label on the apical surfaces of
enterocytes. Arrows in C and D point to anti -amnionless label in the cytoplasm of
EGFP-positive enterocytes. E shows a confocal image from a section of a Cubn +/de/ exon
1-6;EGFP mouse ileum labeled with anti-intrinsic factor (IF). F is a merged image of the
section of Cubn +/del exon 1-6;EGFP mouse intestine in E together with cubilin-EGFP
expression. Arrowheads in E point to anti-intrinsic factor IgG-reactive material present
on the surfaces of both anti-EGFP-positive and anti-EGFP-negative enterocytes. G
shows a confocal image from a section of a wildtype mouse ileum labeled with antiintrinsic factor. H is a merged image of the section of thewildtype mouse intestine
shown in G together with the image from the EGFP channel.
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Figure 2-5. 5Aza and TSA elicit increases in cubilin expression in NRK and Caco2 cells.
A-D, qPCR analysis of cubilin and megalin mRNA expression in RNA isolated from
NRK and Caco-2 cells cultured for 60 h with three medium changes and 84 h with
four medium changes, respectively, each containing the indicated doses of SAza. E-H,
qPCR analysis of cubilin and megalin mRN.~e*piession in RNA isolated from cells
cultured for 24 h with the indicated doses 0'[ 11 A. Cubilin and megalin mRNA
expression data were normalized to GAPDH levels. Asterisks indicate that differences
between mRNA levels in vehicle control and drug treatment groups were significant at
p<O.OS.
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Figure 2-6. TSA or 5Aza treatment does not have an effect on cubilin mono allelic
expression in PRTCs.
A, upstream flanking sequence of the mouse cubilin gene (Cubn). Putative
PP ARlRXR heterodimer binding sites, identified by Genomatix DiAlign, are
indicated. Sequence elements are numbered relative to t\le translation start site (+ 1). B ,
representation of the pCub -431 Luc mouse Cubn promoter construct containing
mouse Cubn proximal flanking sequence (-431 to -5), including the -97 putative
PPARlRXR binding element (shaded box), linked to a luciferase cassette. C, an
established PP AR reporter construct is transactivated by PP ARu and PP ARy in
transfected BN cells. Reporter plasmid (pPPRE X3-TK-Iuc) was cotransfected with
either a PP ARu expression plasmid (pSG5 PP AR alpha), a PP ARy expression plasmid
(pcDNA flag PP AR gamma) or a negative control plasmid (Con). Relative luciferase
activity in lysates from transfected cells is shown. D , PPARu and PP ARy transactivate
the mouse cubilin proximal promoter. Cotransfections were done with the pCub-431
Luc promoter plasmid and either PPARu, PPARy, or a negative control plasmid (Con)
as described for C. Relative luciferase activity in lysates from transfected cells is
shown. E and F, qPCR analysis of cubilin (Cubn) and megalin mRNA in NRK cells
cultured in the presence or absence ofPPARu or PPARy antagonists, GW6471 and
GW9662 (each at 10 J.!M) for 24 h. Asterisks indicate p<0.05.
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Figure 2-7. TSA treatment increases intestinal cubilin mRNA expression but does
not have an effect on intestinal cubilin monoaUelic expression in vivo.
Age-matched, Cubn +/de/ exon 1-6;EGFP (HT) and WT male mice were administered
intraperitoneal injection ofvehicle-DMSO only or TSA at 2 J.lg/g of mouse body
weight for 7 consecutive days. A and B, qPCR analysis of cubilin and megalin mRNA
expression in RNA isolated from the ileum ofDMSO or TSA treated mice. Asterisks
indicate p<O.OS. C and D show EGFP fluorescence in the luminal surface of whole
mount segments of ileum from DMSO (A) or TSA (B) treated Cubn +/de/ exon 1-6;EGFP
mIce.
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Figure 2-8. PPAR regulation of cubUin expression.
A and B , qPCR analysis of cubilin and megalin mRNA expression in RNA isolated
from PRTCs treated for 7 days with DMSO or with the indicated doses ofTSA. C,
shows irnrnunoblot analysis of extracts of PRTCs treated for 7 days with vehicle or
varying concentrations of TSA or SAza using antibodies to cubilin, megalin, and actin.
D shows the number of anti-EGFP positive cells as a fraction of total cells counted in
21 imaged fields ofDMSO-treated and 34 imaged fields of 10nM TSA-treated PRTCs
from three experiments. Asterisks indicate that differences between vehicle control and
drug treatment groups were significant at p<O.OS.
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Figure 2-9. PPARa and '1 regulate cubilin expression in PRTCs.
A anti-cubilin and actin immunoblot analysis of extracts ofPRTCs treated with the PPARa agonist,
Wy14643, at the indicated concentrations for 22 h. B densitometric analysis of anti-cubilin
immunoblot experiments represented in A (n=3). C qPCR analysis of cubilin mRNA in PRTCs
treated with the PP ARa agonist, Wy14643, at the indicated concentrations for 22 h. D qPCR
analysis of cubilin mRNA in PRTCs treated with either PPARa agonist (1 00 J..lM) , PPARa
antagonist, GW6471 (1 OJ..lM) , or both for 22 h. E shows anti-cubilin and actin immunoblot analysis
of extracts ofPRTCs treated daily with the PPARy agonist, Rosiglitazone, at the indicated
concentrations for 3 days. F densitometric analysis of anti-cubilin immunoblot experiments
represented in E (n=3). G qPCR analysis of cubilin mRNA in PRTCs treated daily with the PPARy
agonist, Rosiglitazone, at the indicated concentrations for 3 days. H anti-cubilin and tubulin
immunoblot analysis of extracts ofPRTCs treated twice with PPARy antagonist, GW9662 (lOJ..lM)
PP ARy agonist, Rosiglitazone (2SnM), or both for 36 h. Asterisks indicate that differences between
vehicle control and drug treatment groups were significant at p<O.OS. Pound signs indicate that
differences between agonist treatment alone and combined agonist with antagonist treatment groups
were significant at p<O.OS.
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Figure 2-10. 5Aza and TSA elicit increases in PPARa/y expression, and PPAR
antagonists block 5Aza and TSA-mediated increase in cubilin expression.
A-B, qPCR analysis ofPPARu and y mRNA expression in RNA isolated from NRK
cells cultured for 60 h with 3 medium changes each containing the indicated doses of
SAza. C and D , qPCR analysis of PP ARa and y mRNA expression in RNA isolated
from NRK cells cultured for 24 h with the indicated doses of TSA. E and F , qPCR
analysis of cubilin and megalin was performeg 9D. RNA from NRK cells treated for 36
h with 2 medium changes each containing 5~ ', of SAza and then a 24 h treatment
with SAza-free medium containing PPAR antagonists (each at lOJlM). G andH, qPCR
analysis of cubilin and megalin mRNA in RNA isolated from NRK cells cultured for
24 h with TSA alone (100 nM) or TSA (100 nM) plus PPAR antagonists (each at
10JlM). Cubilin, megalin and PP ARa and y mRNA levels were normalized to
GAPDH. Asterisks indicate that differences between mRtNA levels in vehicle control
and drug treatment groups were significant at p<O.OS. Pound sighs indicate that
differences between mRNA levels in drug treatment groups alone and drug treatment
with PPAR antagonists were significant at p<O.OS.
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Figure 2-11. TSA-mediated increase in cubilin expression involves increases in
both PPAR transcription and activation.
A, qPCR analysis ofPPAR<lmRNA levels in NRK cells transfected with PPARa
expression construct or a control vector. Asterisk in A indicates that differences
between mRNA levels in control and PPARa were significant at p<O.OS. B , qPCR
analysis of cubilin mRNA levels in NRK cells transfected with PP ARa expression
construct or a control vector and treated for. ~4,t ·'· ~·ith either PPARa agonist, Wy14643
(lOOJlM), TSA (100 nM) or TSA (100 nM) plus PPARa agonist (lOOJlM). Asterisks
indicate that differences between mRNA levels in vehicle control and drug treatment
groups were significant at p<O.OS. Pound signs indicate that differences between
mRNA levels in control vector and PP ARa vector transfected cells with the same
treatments were significant at p<O.OS.
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Supplementary figure 2-1. A-C, show confocal images of anti-EGFP and anti-cubilin
labeled renal proximal tubules cells isolated from the cortex of Cubn +/de/ exon 1-6,-EGFP
mouse kidneys and treated for 24 h with DMSO vehicle. D-F, show confocal images
of anti-EGFP and anti-cubilin labeled cells isolated from the renal cortex of Cubn +/de/
exon 1-6;EGFP mouse kidneys and treated for 24 h with TSA (10 nM). Nuclei (blue) were
stained using Draq 5.
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Supplementary figure 2-2. A, qPCR analysis of A cadi mRNA expression in PRTCs
treated with PPARu antagonist, GW6471 (1 OJlM) , PPARu agonist (100JlM), or both
for 22 h. B, qPCR analysis of Acadl was performed on RNA from NRK cells treated
for 36 h with 2 medium changes each containing 5JlM of 5Aza and then a 24 h
treatment with 5Aza-free medium containing PPAR antagonists (each at 10JlM). C,
qPCR analysis of A cadi mRNA in RNA isolated from NRK cells cultured for 24 h
with TSA alone (100 nM) or TSA (100 nM) plus PPAR antagonists (each at 10JlM).
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Chapter 3. Cubilin is essential for maintaining blood levels of high density
lipoprotein and albumin

Abstract
Cubilin is an endocytic receptor capable of mediating the endocytosis of multiple
ligands. It is highly expressed by the renal proximal tubule cells where cubilin and its coreceptor megalin mediate the absorption of filt~r~~~proteins, including albumin and High
" .... , "I
,

'/

Density Lipoprotein apolipoprotein A-I (apoA-I). Cubilin deficiency or mutant cubilin
expression in humans and other animals lead to urinary loss of albumin and apoA-I.
However, the consequences of this urinary loss on the bloop homeostasis of albumin and
apoA-I/HDL had not been studied.

Using a heterozygous mouse model of targeted cubilin gene deletion (Cubilin
HT), we show that cubilin haploinsufficiency led to a significant decrease in blood levels
of albumin and apoA-1 as well as HDL and HDL-cholesterol. Cubilin HT mice displayed
reduced renal proximal tubule uptake of albumin and apoA-I, and significantly increased
urinary loss of albumin and apoA-I. Urinary levels of apoA-1 inversely correlated with
plasma apoA-1 levels. Furthermore, the clearance rate of smaller HDL particles (d>1.13
glmL) from the blood was significantly increased in cubilin HT mice, indicating a
decreased half-life for HDL particles that are filtered through the glomerulus. In contrast,
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there was not a significant change in the clearance rate from blood of HDL2 , larger
particles that are not filtered through the glomerulus. Furthennore, no significant change
was observed in the levels of albumin and apoA-I protein or mRNA extracted from liver,
kidney or intestine of cubilin HT mice as compared to wildtype. Therefore, cubilin
deficiency leads to reduced albumin and apoA-I renal proximal tubule salvage back to
blood, which results in reduced albumin and apoA-I1HDL blood levels.

These findings are consistent with previous studies demonstrating renal proximal
tubule transcytosis of albumin and the necessity of this process in maintaining blood
albumin levels. In addition, clinical data indicate that proteinuria in patients with intact
glomerular function leads to reduced blood levels of HD L. Therefore, our study is
relevant to pathological proteinuria where patients might benefit from increased cubilin
expression to reduce proteinuria and raise albumin and HDL levels.

\
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Introduction
High density lipoproteins (HDL) and albumin are major blood components with
links to cardiovascular disease [82, 119, 194]. As such, understanding the metabolism
and homeostatic regulatory mechanisms of these constituents may hold keys to new
therapeutic approaches.

Cubilin is a multiligand receptor capable of mediating the endocytosis of albumin
and HDL, as well as its major apolipoprotein component, apoA-I [42,44, 102]. However,
the significance of cubilin to the homeostasis of HDL and albumin in the blood has not
been studied. Cubilin and its co-receptor megalin are expressed by absorptive cells
including proximal tubule cells (PTCs) [6].

Pr~sep,tly,

cubilin- and megalin-mediated

~.

"~I

?I

endocytic uptake represents the only established process by which PTCs reabsorb
proteins from the glomerular filtrate [42, 44, 195, 196]. Genetic mutations that impact

,

renal cubilin expression in humans, dogs and mice result in urinary wastage of an array of
macromolecules including albumin and apoA-I [30, 31].

While several studies demonstrate the role of cubilin in mediating renal uptake of
apoA-I and albumin [30, 31, 42], the precise fate of these proteins following PTC uptake
has been an open question. Although a general view is that ligand endocytosis by cubilin
and megalin leads to lysosomal degradation, several lines of evidence indicate that
cubilin-megalin-mediated uptake may also participate in a process by which certain
ligands are targeted for transcytosis and delivery back to the blood. For example, in
cultured renal PTCs, megalin mediates transcytosis of trans cob al amin-B 12 complex [112]
and retinol-binding protein in complex with retinol/vitamin A [111]. Megalin has also
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been shown to mediate transcytosis of thyroglobulin [197], Shh [198] and the megalincubilin binding protein, RAP [199]. Indirect evidence for cubilin playing a similar role in
ligand transcytosis comes from findings showing that albumin is transcytosed back to
circulation via the proximal tubule epithelium [109, 200, 201] as well as the fact that
cubilin-mediated uptake of1F-B 12 complex in the gut leads to its release into blood in the
form oftranscobalamin-B 12 [133].
Whether renal cubilin-mediated uptake of apoA-1 and albumin from the
glomerular filtrate might be part of a salvage process that impacts levels of these proteins
in the blood is not known. Here we sought to define the relationships between genetic
cubilin deficiency and renal uptake/urinary loss of apoA-I and albumin, and the extent to
which cubilin deficiency influences blood le\ler~f each constituent as well as HDL.

Materials and Methods

Animals

All studies involved the use of 2-12 month old male mice, cubilin heterozygous
with an EGFP cassette insertion in a site in which cubilin exons 1-6 were deleted

(Cubn +/del exon 1-6;EGFP) [136] or age/sex matched wild-type (WT) littermates on a mixed
129Sv/C57BL/6 genetic background. Mouse experimentation was conducted with
approval from the IACUC. Mice were housed in MUSC animal care facility with food
and water provided ad libitum. Genotypes of progeny were determined by PCR
performed with tail clip genomic DNA using a three primer set: cubilin sense strand
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primer, 5'-AGCCACGCTTATACTTACTGGTG-3' (residues 10413310-10413332 in
NT_039202.7); cubilin antisense strand primer, 5'TGACCCCTCACAAGTTGAACAG-3' (residues 10413656-10413635 in
NT_ 039202.7); and EGFP antisense strand primer, 5' - GGTCTTGT AGTTGCCGTCGT3' (residues 1281-1262 in GU045599.1). Cycling parameters for PCR amplification were:
98°C for 5 min and then 40 cycles of 98°C for 0.5 min, 55°C for 1 min and 72°C for 1
min. For WT animals, the expected size of the amplicon is "'350, whereas amplicons of
",350 and 520 bp are produced from Cubn +/del exon 1-6;EGFP mice.

Immunoblot analysis

Segments of small intestine, liver and kidney cortex were homogenized in 1%
Triton X-100, 0.5% Tween 20,0.5 M NaCI, 50 mM Hepes, pH 7.5 containing a protease
inhibitor cocktail (Complete-mini, EDTA-free, Roche, Germany), using a Polytronaggregate (Brinkmann Instruments, Switzerland). Extracts were clarified by
centrifugation at 14K x g for 30 min at 4°C. Protein concentration in extracts was
quantified using Pierce BCA Protein Assay Kit (Rockford, IL). Equal amounts of protein
from the extracts were loaded onto NuPAGE 4-12% polyacrylamide gradient, Bis-Tris
gels in the presence of SDS (no reducing agent). Following electrophoresis, the proteins
were transferred onto PVDF membranes, which were blocked with 5% non-fat milk in
TBS and probed with antibodies diluted in TBS containing 0.5% Tween 20, 5% non-fat
milk. Antibodies used in immunoblotting included goat anti-cubilin A20 (Santa Cruz),
rabbit anti-smooth muscle actin Abcam, Cambridge, MA), goat anti-apoA-I (ab7614,

77

Ab9am), and rabbit anti-ABCA 1 (NB400-105, Novus Biological, Littleton, CO).
Chemiluminescent detection of bound antibodies was achieved using the Pierce ECL
Western Blotting Substrate.

Immunohistochemistry

Mouse kidneys were fixed initially by perfusion fixation followed by immersion
of kidney segments in 4% paraformaldehyde PBS for 12 h. Kidney segments were then
embedded in paraffin and sectioned at 6 11m thickness. Tissue sections were incubated
with goat polyclonal anti-cubilin IgG (A20; Santa Cruz Biotechnology, Inc.; Santa Cruz,
CA), rabbit polyclonal anti-EGFP IgG (A~~, Cambridge, MA), goat polyclonal antialbumin (Bethyl Laboratories, Inc., Montgomery, TX) and/or goat anti-apoA-I (ab7614,
Abcam, Cambridge, MA). Tissue sections were incubated with donkey anti-goat and
donkey anti-rabbit Alexa fluor (488 or 568) conjugatds (Invitrogen; Carlsbad, CA).
Nuclei were stained using Draq5 (Cell Signaling Technology, Danvers, MA).
Immunolabeled sections were analyzed using a Leica SP5 confocal microscope (Leica
Microsystems Inc., Exton, PA).

Urine analysis

Urine was collected from 10-week-old male mice over a 5-day period. Mice were
individually placed in diuresis cages from 5PM to 8AM with 10% sucrose, but no food.
From 8AM to 5PM the mice were returned to regular cages and given food and water.
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This cycle was repeated for 5 days. Additionally, spot urine samples were collected by
placing mice on plastic wrap. Urine samples from 5 consecutive days were pooled.
Urinary creatinine levels were measured by ELISA using a Creatinine Companion kit
(Exocell Inc., Philadelphia, PA). Albumin levels in urine (diluted 1:500 in PBS) were
measured by ELISA using the Mouse Albumin ELISA Quantitation Set (Bethyl
Laboratories, Inc., Montgomery, TX). ApoA-I levels in urine (diluted 1:20 in PBS) were
measured by a two-antibody sandwich ELISA using goat anti-mouse apoA-I (ab7614)
and rabbit anti-mouse apoA-I (ab20453, Abeam, Cambridge, MA) and purified apoA-I as
a standard (Calbiochem, Darmstadt, Germany).

Blood apoA-I and albumin analysis

Blood from mice fasted for 6 h was drawn by retro-orbital bleeding using
heparinized micro-pipettes (Drummond Scientific Co), Broon:all, PA). Drawn blood was
kept on ice for

~1

h then subjected to centrifugatioI\ (2,000 x g) and the plasma

supernatant collected. ApoA-I levels in plasma (diluted 1:20,000 in PBS) were
determined by a two-antibody sandwich ELISA (Abeam). Albumin levels in plasma
(diluted 1:400,000 in PBS) were determined by a two-antibody sandwich ELISA (Bethyl
Laboratories).

Fast Protein Liquid Chromatography (FPLC)

FPLC separation of serum lipoproteins from pooled plasma samples (n = 6 WT
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and 6 heterozygotes) was achieved by gel filtration using two Superose 6HR 10/30
columns (Amersham Pharmacia Biotech, Piscataway, NJ) in series as previously
described [202]. Cholesterol, cholesterol ester, phospholipid and triglyceride levels in
each fraction were measured.

Analysis of blood lipoprotein levels by NMR

Quantitative analysis of serum lipoprotein levels from WT mice and
heterozygotes (from fasted males) was performed by LipoScience, Inc. (Raleigh, NC)
using nuclear magnetic resonance (NMR) spectroscopy as described in Hammad et al.
[203].

,-:../~~
,/1

qPCR

RNA from ileum, liver and kidney cortex was isolateli using RNA Stat-60 (Teltest, Inc, Friendswood, TX) and quality was assessed on an Agilent Bioanalyzer. cDNA
was prepared using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) according
to manufacturer instructions. qPCR was performed using iQ SYBR Green Supermix
(Quanta BioSciences, Inc., Gaithersburg, MD) reagents and a C 1000 Thermal Cycler
(Bio-Rad).

The

following

qPCR

pnmers

ATTTTCTCTGGGGTTTTGTTAC-3 '

and

TAAGTTTCCCTCCTCCGTAG-3'
AAGCCAGACCTGCGCTGGAG-3 '

were

used:

Cubilin

(NM_00I081084.2);
and
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ApoA-I

Cubilin

sense,

antisense,
ApoA-I

sense,

antisense,

5'5' 5' 5' -

AAAGCCAATGCGGGGGTGGG-3' ;

Abcal

CGTTTCCGGGAAGTGTCCTA-3'

and

Abcal

CTAGAGATGACAAGGAGGATGGA-3';

and

sense,

5' -

antisense,

5'-

sense,

Albumin

5'-

AGCCCAAGGCTACAGCGGAG-3' (NM_013454.3) [101] and Albumin antisense, 5'GGGTAGCCTGAGAAGGTTGTGGT-3' (NM_009654.2). Genes used for qPCR
standardization included: /3-actin sense, 5'-CGGGACCTGACAGACTACCTC-3' and /3actin anti-sense, 5'-AACCGCTCGTTGCCAATA-3' (NM_007393.3); Hprtl sense, 5'-

ATCATTATGCCGAGGATTTGGA-3'
CACACAGAGGGCCACAATGT-3'

and
(NM_013556);

CGCCGCTAGAGGTGAAATTCT-3'

and

anti -sense,

Hprtl

and

Rn18s

Rn18s

sense,

anti-sense

5' -

5'5' -

CGAACCTCCGACTTTCGTTCT-3' (NR 003278.2).
~,":", ~~,
,

( 1/

Preparation of human plasma HDL subfractions

Human plasma HDL2 (d

=

1.11 to 1.13 glml) and HQL3 (d

=

1.13 to 1.25 g/ml)

were isolated by density gradient ultracentrifugation as previously described [204]. Total
protein and apoA-I concentration was determined using Pierce BCA Protein Assay Kit
and apoA-I ELISA as described above. Equal amounts ofHDL subfraction were applied
to non-denaturing Novex 4-12% Tris-Glycine polyacrylamide gradient gels (Invitrogen,
Carlsbad, CA). Following 6 h of electrophoresis, the proteins were transferred to PVDF
membrane and immunoblotted for apoA-I as described above.
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Human HDL fractional clearance in mice

The clearance of HDL subfractions was measured in male mice following tail
vein injection with HDL2

(~15

Jlg/g of bodyweight) or HDL3 supplemented with 6%

purified apoA-1 (Calbiochem, Dannstadt, Gennany) (-AO Jlg/g) [205]. After the tail vein
injection, blood samples were collected at 10 mins by retro-orbital and subsequently by
tail vein bleeding at Ih, 3h, 6h, 12h, 24h, 48h and 72h. Human HDL subfraction
concentrations in mouse plasma were detennined by an ELISA using rabbit anti-apoA-1
(NBII0-55465, Novus Bio, Littleton, CO), sheep anti-apoA-1 (NB600-1538). The
antibodies used in this ELISA are specific to human apoA -I and display no cross
reactivity to mouse apoA-1. Standard curves for these assays were generated using
. '.

purified apoA-1 (Calbiochem) diluted in

~

5%;m~jtse

plasma. The concentration of human

HDL measured for each time point was nonnalized to the concentration measured at
10min for each mouse and average values plotted on a log scale.

Statistical analysis

Comparisons between WT and heterozygous mIce were perfonned with
GraphPad Prism (GraphPad Software, La Jolla, CA) using the Student's t test for
independent samples (two-tailed). Values are reported as mean ± STDev.
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Results

Cubilin heterozygous mice

Cubn deletion mutant mice were previously generated by Cubn exon 1-6 deletion
and an EGFP cassette insertion (Cubn +/del exon 1-6;EGFP) [136]. As previously shown [136],
cubilin null mice are embryonic lethal. However, Cubn heterozygous mice (Cubn +/del exon
1-6;EGFP)

develop without any obvious abnormalities and are physically comparable with

wild-type (WT) littermates. Blood urea nitrogen (BUN), urinary creatinine excretion and
total urine output levels were not significantly different between Cubn +/del exon 1-6;EGFP and
WT mice (data not shown). As shown in Figure 3-1, Cubn +/del exon 1-6;EGFP mice had
significantly reduced cubilin protein levels in !he,,~xtracts of ileum and kidney cortex as

. ,:., ~I
compared to WT mice. Cubilin co-receptor, megalin, levels in Cubn +/del exon 1-6;EGFP mice
kidneys were not significantly different compared to WT (Fig. 3-1A).

Effect of cubilin deficiency on blood HDL levels

To determine the effect of cubilin deficiency on the blood levels of HDL, multiple
approaches were applied to analyze plasma or serum from fasted mice. First, serum
lipoprotein levels were analyzed by NMR [203]. As shown in Figure 3-2, HDLassociated cholesterol was significantly reduced by ~27% in serum from Cubn +/del exon 16;EGFP mice

compared to WT. Similarly, HDL particle concentration was also

significantly reduced by "-'29% in serum from Cubn +/delexon 1-6;EGFP mice compared to WT.
By contrast, VLDL and LDL particle concentrations were not significantly different in
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serum from Cubn +/del exon 1-6;EGFP mice compared to WT. Next, pooled plasma samples
were separated by Fast Protein Liquid Chromatography (FPLC) and the lipid content of
each fraction analyzed. The fractions corresponding to HDL, contained cholesterol,
cholesterol ester and phospholipids that were significantly reduced by ----25% in the serum
from Cubn +/del exon 1-6;EGFP mice compared to WT (Fig. 3-3). In contrast, these lipids were
not significantly different in the non-HDL fractions in the serum from Cubn +/del exon 16;EGFP mice

compared to WT. Likewise, triglycerides, which are mostly associated with

non-HDL lipoproteins, were not significantly different in the serum from Cubn +/del exon 16;EGFP mice

compared to WT. Finally, plasma apoA-I concentration was analyzed by a

two-antibody sandwich ELISA using purified apoA-I as standard. Congruent with the
above approaches, a ",30% decrease in

apoA-lco~centration

..,:., -;~I

from Cubn +/del exon 1-6;EGFP mice compared to

was observed in plasma

wt (Fig. 3-4A).

Effect of cubilin deficiency on urinary apoA-I loss
To determine the effect of cubilin deficiency on the urine levels of apoA-I, spot
urine and 16 h urine samples were analyzed by the two-antibody sandwich ELISA using
purified apoA-I as standard. As shown in Figure 3-4B, apoA-I levels were significantly
increased by --4.5 fold in the urine of Cubn +/del exon 1-6,'EGFP mice compared to WT. This
urinary loss amounted to an average of 45.44 ng/day of apoA-I in the urine of Cubn +/del
exon 1-6;EGFP mice

compared to 9.04 ng/day in the WT (average excretion of 0.5 mg/day

creatinine in --1 ml urine). To determine if there were a correlation between urinary
apoA -I loss and decreased plasma apoA -I levels, urinary apoA -I concentrations were

84

plotted against plasma apoA-I levels (Fig. 4C). A significant inverse correlation was
observed between urinary apoA-I and plasma apoA-I concentration in both Cubn +/de/ exon
1-6;EGFP and

WT groups (R2 = 0.47 HT and 0.37 WT, p-value <0.05).

Effect of cubilin deficiency on blood albumin levels

To determine the effect of cubilin deficiency on the blood levels of albumin,
plasma samples from fasted mice were analyzed using a two-antibody sandwich ELISA.
Plasma albumin was significantly reduced by ~ 17% in Cubn +/del exon 1-6;EGFP mice
compared to WT (Fig. 3-5A). Since albumin constitutes a large portion of blood protein
content [46], total plasma protein was alsoq.Y~~9cfied using a BCA protein assay. As
shown in Figure 3-5B, total plasma protein was significantly reduced by --12% in

Cubn +/del exon 1-6;EGFP mice compared to WT.

\

Effect of cubilin deficiency on urinary albumin loss

To determine the effect of cubilin deficiency on the urine levels of albumin, spot
urine and 16 h urine samples were analyzed using the two-antibody sandwich ELISA.
Albumin levels were significantly increased by '"'-'2.4 fold in the urine of Cubn +/del exon 16;EGFP mice

compared to WT (Fig. 3-5C). This urinary loss amounted to an average of

232.83 Ilg/day of albumin in the urine of Cubn +/del exon 1-6;EGFP mice compared to 96.84
Ilg/day in the WT. Urine volumes and creatinine levels at 16 and 24 h were not
significantly different between Cubn +/delexon 1-6;EGFP and WT mice (data not shown).
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Effect of cubilin deficiency on apoA-I/HDL and albumin biosynthesis

To detennine if cubilin deficiency had an effect on apoA-I/HDL biosynthesis,
qPCR was used to measure tissue mRNA levels of apoA-I and Abca1, which catalyzes
the rate-limiting step in the lipidation of apoA-I into nascent HDL particles [98]. As
shown in Figure 3-6A and F, cubilin mRNA levels were significantly decreased by
--50% in the intestine and kidney of Cubn +/del exon 1-6;EGFP mice compared to WT.
However, there was no significant difference in apoA-I and Abca1 mRNA levels in
intestine, liver or kidney of Cubn +/deJ exon 1-6;EGFP mice compared to WT (Fig. 3-6).
Similarly, no significant difference was observed in albumin mRNA levels in intestine or
liver of Cubn +/del exon 1-6;EGFP mice compared to WT (data not shown) .

. . -~, ~/r
ApoA-I and Abca1 immunoblot analysis of extracts of these tissues was also
performed. Consistent with findings from the mRNA analyses, no significant differences
were observed in apoA-I and Abca1 protein levels in the extracts of intestine or liver
~
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Effect of cubilin deficiency on apoA-I/HDL fractional clearance
The clearance from blood of intravenously injected human HDL fractions was
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exon 1-6EGFP
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.
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measured In
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'
and WT mIce.
ectton,
human HDL3 were significantly higher (by --200%) in WT mice compared to Cubn +/del
exon 1-6;EGFP mice

(Fig. 3-7A). The area under the curve for apoA-I1HDL plasma clearance

in WT mice was significantly greater (by --140%) compared to Cubn +/del exon 1-6;EGFP mice
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(Fig. 3-7A). Similarly, the average half-life of these HDL particles was also reduced by
,...,28% in Cubn +/delexon 1-6,EGFP mice compared to WT (half-life in WT=15-18 h; half-life in
HT=9-15 h). These observations indicate that apoA-I1HDL fractional clearance is
significantly increased in Cubn +/del exon 1-6;EGFP mice compared to WT. As control, the
fractional clearance of the larger HDL2 fraction was also determined. Most ofHDL2
should not be filtered through the glomerulus due to its larger size [206]. As shown in

Figure 3-7B, the plasma concentration of human HDL2 in WT mice was not significantly
different compared to Cubn +/del exon 1-6;EGFP mice in all time points. Furthermore, the area
under the curve for HDL2 plasma clearance in WT mice was also not significantly
different compared to Cubn +/del exon 1-6;EGFP mice (Fig. 3-7B).

Effect of cubilin deficiency on apoA-I localization in the kidney cortex
To determine the effect of cubilin deficiency on apoA-I uptake by proximal
tubules, apoA-I localization was analyzed in the kidney corte~ by immunofluorescence
microscopy. Previously, we have shown that cubilin expression is monoallelic. Proximal
tubules in the Cubn +/del exon 1-6,EGFP mice stochastically express either the targeted EGFP
allele (cubilin deficient proximal tubules) or the WT cubilin allele. The EGFP expressing
cubilin deficient proximal tubule brush borders were also shown to localize albumin
significantly less compared to proximal tubules with WT cubilin expression (Fig. 2-1).
Similarly, apoA-I localization in the brush border ofEGFP expressing cubilin deficient
proximal tubules in the Cubn +/del exon 1-6;EGFP mouse kidney was greatly reduced (Fig. 3Be and D). ApoA-I localization in the proximal tubule brush borders were quantified by
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counting the number of proximal tubules with any observable apoA-1
immunofluorescence in 109 images from 4 WT and 5 HT mice. The number of apoA -1positive proximal tubules was significantly reduced by 36% in Cubn +/del exon 1-6;EGFP mice
compared to WT.

Discussion

Cubilin expressed by the proximal tubule cells (PTCs) mediates the endocytosis
of albumin and apoA -I that is filtered through the glomerulus [42, 44]. Mutations that
affect cubilin expression or function in humans and dogs lead to urinary loss of albumin
and apoA-I [42, 44]. Yet the consequences Qf.9~)jiiin deficiency and decreased salvage of
I,

albumin and apoA-1 by PTCs on the blood levels of albumin and apoA-I1HDL had not
been studied.

In this study, we used a cubilin deficient mouse model to establish a direct
\

association between renal cubilin-mediated endocytosis of filtered albumin and apoA-I
and their plasma levels. Consistent with previous studies [42, 44], cubilin
haploinsufficiency leads to decreased PTe uptake of albumin and apoA-1 and
significantly increased loss of albumin and apoA-I in the urine. Importantly, this
decreased PTe uptake of albumin and apoA-1 causes significant decreases in plasma
levels of albumin, apoA-I and HD L particle concentration. This was supported by an
inverse correlation between urinary loss of apoA-1 and plasma apoA-1 levels, and
analyses ofHDL half-life and clearance rate from blood. Indeed, cubilin HT mice had
significantly reduced blood half-life and increased clearance rate from blood of small
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HD L particles that can be filtered through the glomerulus. In contrast, there was not a
significant difference in the clearance rate from blood ofHDL2, larger particles that are
not filtered through the glomerulus [88]. Based on these data, we inferred that the
increased loss of apoA-I1HDL from blood would result in a continuous decline in blood
HDL levels until it is counter-balanced by either an increase in synthesis or decrease in
degradation of apoA-I1HDL resulting in a new homeostatic level of apoA-I/HDL that is
lower as compared to wildtype levels. We did not find a significant difference in apoA -I
biosynthesis at the mRN A or protein level in cubilin HT mouse tissues as compared to
WT. Thus, a decrease in apoA-I1HDL degradation is likely to provide the counter-balance
measure to allow blood apoA-I1HDL levels in cubilin HT to reach steady state.
Cubilin HT mice also had significantl~~uced HD L-associated lipid levels.
However, lipid rich HDL particles are not filtered through the glomerulus [88].
Therefore, it is unlikely that lipids are excreted in the urine to any appreciable amount. It
is more likely that the reduced HDL-associated lipid level~ in cubilin HT mice might be
as a result of reduced plasma apoA -I levels, and therefore, reduced total lipid carrying
capacity ofHDL.

Our findings are consistent with studies of renal cubilin knockdown using an anticubilin antisense RNA approach in a rat model of Adriamycin-induced kidney injury
[55]. Adriamycin treatment caused renal injury and increased albuminuria[55]. Antisense
RNA knockdown of renal cubilin reduced PTC uptake ofadriamycin and renal
injury[55]. However, cubilin knockdown also resulted in greater urinary wastage of
albumin and further reduction in serum albumin levels in this rodent model [55].
Furthermore, urinary wastage of cubilin ligands achieved by BSA overload in mice also
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resulted in reduced mouse serum albumin levels without any changes in glomerular
function or ultrastructure [36, 46]. Therefore, decreased cubilin expression or function
results in deficient albumin uptake from the glomerular filtrate by proximal tubule cells
resulting in reduced blood albumin levels.

Taken together, these lines of evidence suggest a salvage process involving PTC
cubilin-mediated uptake of apoA -I and albumin from the glomerular filtrate leading to
transcytosis of these ligands across the renal proximal tubule cells and deli very back into
circulation. Disruption of this process, as through genetic cubilin deficiency in our
studies, leads to reduced apoA-1 and albumin salvage and increased loss of these
molecules from the blood. Support for such a mechanism comes from live renal imaging
studies showing transcytosis of albumin in rat ~s and other studies demonstrating the

in vitro transcytosis of megalin ligands [ 109-112, 200, 201]. The underlying mechanisms
by which cubilin-mediated uptake would lead to ligand transcytosis remains to be
established. In a recent a study, a significant reduction in plasma albumin levels and
decreased half-life of albumin in the blood was observed in mice transplanted with
kidneys deficient in neonatal Fc receptor (FcRn) [201]. FcRn is expressed by renal
podocytes and PTCs, and binds albumin under acidic conditions [207-209]. However,
FcRn-deficient PTCs retained the capacity to bind albumin at their apical brush borders
[201]. This is consistent with other studies showing that FcRn is expressed within the
cytoplasm and not at the plasma membrane [36]. Together, these studies suggest that
following cubilin-mediated endocytosis, albumin might then bind to FcRn in acidic
vesicles and become routed for transcytosis [129, 201]. Therefore, at least in case of
albumin, the transcytosis pathway might involve cooperation of cubilin and FcRn.
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A role for renal cubilin-mediated salvage in maintaining HDL and albumin
homeostasis could have implications for cardiovascular diseases (CVD). Clinical
evidence indicates that HDL-C blood levels and serum albumin levels are inversely
correlated with risk of coronary heart disease (CHD) [80-83, 119]. Emerging evidence
indicate that this salvage pathway might be effected in human disease with consequential
effects on HDL and albumin homeostasis. For example, elevated urinary albumin
excretion was associated with a doubling of risk of CVD and all-case mortality in a study
of elderly subjects [210]. This study also showed an inverse correlation between urinary
levels of albumin and plasma levels of HDL-C. Similarly, patients with chronic renal
failure have decreased plasma HDL concentration [211]. Furthermore, a missense cubilin
variant is associated with albuminuria in both the"general population and in individuals
~~i
'-",'
,
Ir

with diabetes [212].

Decreased renal cubilin-mediated salvage may affect HDL homeostasis in
diabetes. In mouse models of diabetes, levels of renal cubhin are decreased [213]. While
renal cubilin levels have not been direct! y analyzed in diabetio patients, one study of
microalbuminuric type 1 diabetic patients reported aberrant shedding of cubilin in urine
along with cubilin ligands, albumin and apoA-I [63]. Other studies demonstrate that
diabetic subjects have lower blood HDL levels [114]. Furthermore, a study of
normoalbuminuric type 1 diabetic patients with normal glomerular function reported a
correlation between lower levels of total HDL-C and smaller sized HDL3-C with
albuminuria, but not larger HDL2-C [214]. Similarly, a shift ofHDL size distribution
toward large particles has been observed in patients with proteinuria [215]. However,
much work is required to analyze cubilin expression in these patient populations and

91

detennine whether a causal link exists between any changes in cubilin expression and
altered HD L levels. Demonstrating such a link would emphasize the need to upregulate
the renal cubilin-mediated salvage pathway to prevent CVD in these patient populations.

Future directions
Transcytosis of cubilin ligands by renal PTe
In this study, we demonstrate that cubilin is essential for maintaining blood levels
of both albumin and apoA-I1HDL. Cubilin deficiency leads to decreased uptake of these
ligands by the renal PTC and decreased half-life of these ligands in the blood. These
observations suggest that cubilin-mediated

upi;re of these ligands by PTC lead to their

transcytosis back to the blood, and in cubilin deficiency this mechanism is disrupted
resulting in increased loss of albumin and apoA-I1HDL from blood. Albumin transcytosis
~

in renal PTC has been demonstrated in whole animals by live imaging [192]. A similar
approach can be employed to demonstrated apoA-I PTC trans~ytosis by live imaging of
mouse kidneys. Since cubilin heterozygous mice express EGFP in cubilin deficient PTCs,
this approach would be expected to demonstrate that EGFP-expressing PTC are unable to
mediate the transcytosis of either apoA -I or albumin. Therefore, this approach is expected
to clearly elucidate the transcytosis of both apoA -I and albumin in the renal PTC and the
dependence of this process on cubilin function.

The mechanism of transcytosis of cubilin ligands in the renal PTC remains to be
established. One of the main limitations of studying transcytosis in the kidney is the
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inability to detect this process in fixed tissue by immunocytochemistry. This may be due
to the inability of antibodies to recognize cubilin ligands in acidic endosomes in which
the ligand confonnation might change. The availability of antibodies that recognize
albumin and apoA-I confonnation in acidic conditions would greatly facilitate designing
experiments to understand the mechanism of transcytosis of these ligands in the renal
PTC.

Study ofFcRn knockout mice have revealed that FcRn might be involved in the
transcytosis of albumin following its uptake by cubilin-mediated endocytosis[201]. Thus,
crossing the cubilin heterozygous mice with F cRn knockouts would be expected to lead
to no further reduction in albumin levels compared to either mouse model. Alternatively,
overexpression ofFcRn in renal PTC with cubi~/tdeficiency would not rescue albumin
I,

transcytosis. These experiments would lend support to the hypothesis that cubilin
mediates the initial uptake of albumin and FcRn is responsible for the subsequent
transcytosis.

The role of cubUin in maintaining albumin and apoA-I/HDL levels in kidney
diseases

Cubilin expression is decreased in diabetes, acute kidney injury, and possibly,
chronic kidney disease[ 10, 11]. Epidemiological data also indicate that in some of these
diseases total and small HDL particle levels are decreased[ 115]. In addition, this decrease
in HDL levels is associated with increased proteinuria[115, 116]. Since glomerular
function was intact in these subjects, it is likely that the proteinuria is as a result of
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proximal tubule dysfunction, specifically decreased cubilin expression[115]. Future
studies should utilize mouse models of these diseases, such as streptozocin-induced
diabetes, to demonstrate that reduced cubilin expression leads to proteinuria and reduced
levels of blood HDL. Furthermore, albumin levels should also be analyzed in these
mouse models with reduced cubilin expression. In addition to plasma levels, the
clearance rate from blood of both albumin and HDL is expected to be increased due to
reduced salvage in the kidney in diseases in which cubilin expression is reduced.

Treatment with PP AR agonists, HDAC inhibitors or DNA methylation inhibitors
could augment renal cubilin expression in these diseases. Increased cubilin expression
would be expected to lead to reduced loss in the urine, and consequently, increased blood
HD L and albumin levels. These studies would ~hlight the role of cubilin in kidney
diseases and might point to potential future therapies.
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Figure 3-6. Cubilin haploinsufficiency does not affect ApoA-I and Abcal
mRNA expression in the liver, kidney and intestine. qPCR analysis ofCubn (A
and F), apoA-I (B, D and G), and Abcal (C, E and H) transcript levels in mRNA
extracted from intestine, liver and kidney of age matche4 Cubn +/del exon 1-6,EGFP (RT)
and WT mice (n = 9 per group). Asterisks in A and F indicate a significant
difference from WT levels at p-values < 0.05.
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Figure 3-7. Cubn +/de/ exon 1-6;EGFP mice have increased fractional clearance of
small HDL particles. A, fractional clearance of human HDL3 (d> 1.13 g/mL)
supplemented with 6% purified apoA-I infused into Cubn +/del exon 1-6;EGFP (HT = 6)
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showed no statistically significant difference between the two data sets in B (i.e.,
area under the curves, p-value = 0.18).
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ABSTRACT
,I

S. OBAIDULLAH ASEEM. The Epigenetic Regulation of Cubilin and the Physiological
Role of this Receptor in Maintaining the Homeostasis of Serum Albumin and HDL

Cubilin is an endocytic receptor capable of mediating the endocytosis of multiple
ligands including High Density Lipoprotein apolipoprotein A-I (apoA-I) and albumin. It
is highly expressed on the epithelium of intestinal villi and renal proximal tubules. In the
kidney, endocytosis mediated by cubilin and its co-receptor megalin is the principal
mechanism for proximal tubule reabsorption of filtered proteins, such as albumin and
apoA-I. Yet, the consequences of cubilin deficiency on the blood levels of albumin and

apoA-I have not been studied. Furthennor~:~?~?'is downregulated in chronic diseases
I

such as diabetes. However, little is known about the regulation of cubilin expression.
In this study, we show that cubilin expression is under epigenetic regulation by at

least two processes. The first process involves inactivatioh of expression of one of the
cubilin alleles. This monoallelic expression state could not be\transformed to biallelic by
inhibiting DNA methylation or histone deacetylation. The second process involves
transcriptional regulation of cubilin by peroxisome proliferator-activated receptor
(PPAR) transcription factors that are themselves regulated by DNA methylation and
histone deacetylation. This is supported by findings that inhibitors of DNA methylation
and histone deacetylation, 5Aza and TSA, increase cubilin mRNA and protein in renal
and intestinal cell lines. Not only was the expression ofPPARa and y inducible by 5Aza
and TSA, but also the positive effects ofTSA and 5Aza on cubilin expression were
dependent on both increased PP AR transcription and activation. Additionally, 5Aza and
ix

TSA had similar effects on the expression of the cubilin co-receptor, megalin. Together,
~

these findings reveal that cubilin and megalin expression is under epigenetic control and
thus point to new avenues for overcoming pathological suppression of these genes
through targeting of epigenetic regulatory processes.
We also demonstrate that cubilin is necessary for maintaining the blood levels of
albumin and HDL. In a heterozygous mouse model of targeted cubilin gene deletion
(cubilin HT), cubilin haploinsufficiency led to a significant decrease in blood levels of
albumin and apoA-I as well as HDL and HDL-cholesterol. Cubilin HT mice displayed
reduced renal proximal tubule uptake of albumin and apoA-I, and significantly increased
urinary loss of albumin and apoA-I. Urinary levels of apoA-I inversely correlated with
plasma apoA-I levels. Furthermore, the frac~~iearance of smaller HDL particles
I

(d>1.13 glmL) from the blood was significantly increased in cubilin HT mice, indicating
a decreased half-life for HD L particles that are filtered through the glomerulus. In
contrast, there was no significant change in the fractional 'clearange of larger HD L2
particles, which are not filtered through the glomerulus.

Furt~nnore,

no significant

change was observed in the levels of albumin and apoA-I protein or mRNA extracted
from liver, kidney or intestine of cubilin HT mice as compared to wildtype. Therefore,
cubilin deficiency leads to reduced albumin and apoA-I renal proximal tubule salvage
back to blood, which results in reduced albumin and apoA-IIHDL blood levels. These
findings are consistent with previous studies demonstrating renal proximal tubule
transcytosis of albumin and the necessity of this process in maintaining blood albumin
levels. In addition, clinical data indicate that proteinuria in patients with intact glomerular
function leads to reduced blood levels ofHDL. Therefore, our study is relevant to

x

pathological proteinuria where patients might benefit from increased cubilin expression
.I

to reduce proteinuria and raise albumin and HDL levels.

xi

Chapter 1. An overview of cubilin expression, interactions and function

Introduction
Receptor-mediated endocytosis is a ubiquitous process by which cells in the body
internalize a variety of complex biological material [1]. Endocytosis is initiated with the
specific binding of the ligand to a receptor, followed by intracellular signaling that results
in the fonnation of an endocytic vesicle [2~:_£f'ri is a receptor that mediates the
!

endocytosis of a variety of protein ligands. It was first identified as a receptor for intrinsic
factor-cobalaminlvitamin-B I2 (IF-BI2) complex, and was initially named intrinsic factorcobalamin receptor [3]. Now the name cubilin is more colnmonly used and accepted.
Cubilin is co-expressed with two other membrane proteins, amnionless and
\

megalinlLRP2, and is dependent on these partners for its cell membrane localization and
endocytic function[ 4, 5]. Cubilin-mediated endocytosis is responsible for important
functions such as the absorption of nutrients in intestine and the reabsorption of proteins
in kidney[ 6, 7]. Loss of cubilin function, either by deletions of or mutations in the cubilin
gene (CVBN) or its partners, leads to vitamin BI2 deficiency due to its malabsorption in
the small intestine and proteinuria due to the inability of the renal proximal tubules to
absorb filtered proteins [8, 9]. Cubilin and megalin are downregulated in rodent models
of diseases such as diabetes and acute kidney injury [10, 11]. However, relatively little is

1

known about the regulation of cubilin expression in health and disease. Furthennore, key
.I

questions of cubilin function and its importance in maintaining homeostatic levels of its
ligands are unexplored. In this chapter, cubilin expression and regulation in health and
disease, interaction with its partner proteins and function will be reviewed. In addition,
the potential role of cubilin in regulating blood homeostasis of two of its ligands,
apolipoprotein A-I (apoA-I) and albumin, will be discussed, and gaps in the
understanding of processes involving cubilin will be identified.

Cubilin structure
Cubilin is an evolutionarily cons~~;rrtor protein that is expressed in many
organisms, including mammals and flies [6, 7, 12]. It is a 460-kDa peripheral membrane
glycoprotein that lacks a membrane-spanning region. The protein consists of 8 epidennal
growth factor (EGF)-like and 27 CUB (complement Clr/Cls, Ue~;f, and bone
morphogenic protein-I) domains (Fig. l-lA) [6, 7]. Since the,CUB domains constitute
88% of the protein mass, the name cubilin was proposed to replace intrinsic factorcobalamin receptor [13]. At the cubilin amino tenninus ( 113 residues) is an amphipathic
helix that can mediate its interaction with the plasma membrane[6, 7]. Perhaps more
important to cubilin plasma membrane anchorage is the integral membrane protein
amnionless (Amn), a transmembrane protein that interacts with the Ca+2-binding EGF
domains in the amino tenninal region of cubilin[4, 5]. The amino tenninal region is also
the site responsible for the fonnation of cubilin trimers [14]. Cubilin interacts with its
partner receptor, megalin, by the amino tenninus and CUB domains 12-17 and 22-27

2

[15]. Furthennore, the cubilin amino tenninus and CUB domains 5-8 bind IF-B12, and the
.1

amino terminus, possibly the EGF repeats and CUB domains 7-8 bind albumin [16, 17].
The endocytic receptor chaperone, receptor-associated protein (RAP), binds cubilin on
CUB domains 13-14 [16]. Cubilin is known to bind numerous other ligands, which are
listed in Table 1. However, the precise binding sites of these ligands have not been
worked out yet.

Cubilin expression

In adults, cubilin expression has been detected in various tissues including the
kidney [18], intestine [19], gallbladder [201~}ria [21], inner ear [22], male
reproductive tract [23], lung [24] and brain [25]. However, the highest level of cubilin
expression is likely at the absorptive epithelia of renal proximal tubules followed by the
small intestine. Rat and human renal podocytes have also'been s~own to express cubilin,
but mouse podocytes do not express cubilin [26]. Following its synthesis, cubilin is
transported to the apical membrane where it is expressed with amnionless and megalin
[4-7]. Amnionless is a 35-50 kDa protein, which is required for amnion and primitive
streak development in mice [27]. It is thought that cubilin and amnionless might interact
early in their synthesis fonning a complex, tenned Cubam [4,28]. Cubilin and
amnionless interaction is required for the apical trafficking and expression of either
protein in the kidney [4]. Mutations in the amnionless gene in dogs and genetic ablation
of amnionless in mice have both been shown to cause cubilin retention in cytoplasmic
compartments in renal proximal tubule cells [28, 29]. Likewise, cubilin deficiency in

3

humans and genetic knockdown of cubilin in mice both resulted in the cytoplasmic
.l

accumulation of amnionless in renal proximal tubule cells [30, 31]. Furthennore, all these
mutants also lack cubilin function in the proximal tubules [28-31]. Thus, the interaction
of cubilin and amnionless is indispensible for the apical expression of both proteins and
for cubilin function in the kidney. Whether this interaction has similar consequences on
the expression of cubilin and amnionless in the intestine has not been elucidated.

Cubilin interactions with amnionless and megalin
Since cubilin does not have a cytoplasmic domain, it must rely on its partners,
amnionless and megalin, for the cytoPlasmic,~ifling required for endocytosis. Initially,
it was proposed that megalin was solely responsible for the intracellular signaling of
cubilin-mediated endocytosis [13]. Indeed, cubilin directly interacts with megalin (see
above), and megalin deficiency, by genetic ablation in mibe and 4ue to mutation in
humans, leads to a failure of absorption of cubilin ligands in t~e kidney [1, 32]. Megalin
is a member of the low-density lipoprotein (LDL) receptor family that functions as an
endocytic receptor for numerous ligands [6, 7]. It has a cytoplasmic domain with binding
sites for various sorting and signaling proteins [6, 7]. Among these are two endocytic
(NPXY) motifs, believed to mediate the clustering of ligand bound megalin and cubilin
receptors into clathrin coated pits [6, 7]. Disabled-2 (Dab2) and autosomal recessive
hypercholesterolemia (ARH) are components of the clathrin coat that directly bind the
megalin endocytic motifs, and are involved in megalin-mediated endocytosis [2].
However, megalin deficient patients do not develop megaloblastic anemia[32]. This

4

observation prompted the hypothesis that cubilin-mediated endocytosis ofIF-B 12 in the
.I

intestine must be facilitated by amnionless. Indeed, amnionless also contains two
FXNPXF signals both of which are able to mediate the endocytosis of cubilin-amnionless
complex through interaction with Dab2 and ARH [33]. Therefore, cubilin-mediated
endocytosis can be facilitated by intracellular signaling from either megalin or
amnionless.

Once internalized, the endocytic vesicles fonn early endosomes where
acidification allows the dissociation of cubilin from its ligands (Fig. I-IB) [2]. At this
step, cubilin is either recycled back to the apical membrane or routed for lysosomal
degradation (Fig. I-IB)[34]. Likewise, cubilin ligands can be routed either into the
t .

/ Ii

.#.

~

transcytotic or lysosomal degradation pathw~Yrig. I-lB)[2]. Endosomal acidification
and fusion with lysosomes involves multiple proteins including Na+/H+ exchanger
isofonn 3 (NHE3), H+/Cr exchange transporter 5 (CIC5ICLCN5) and V-type H+ATPases, and Limp2/SCARB2 [35-37]. NHE3, CIC5 andV-type.H+-ATPases are
responsible for the acidification of endosomes, and Limp2/SGARB2 mediates endosome
fusion with lysosomes[35-37]. Mutations in these genes have also been shown to result in
proteinuria of cubilin and megalin ligands [35-37]. For example, mutations in SCARB2
and CLCN5 cause Action Myoclonus-Renal Failure Syndrome and Dent's disease
respectively [36, 37].

Cubilin function
Cubilin-mediated endocytosis allows for the absorption of numerous ligands in
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the intestine and renal proximal tubules (Table 1). Mutations in the CUBN or amnionless
.I

gene that result in deficient cubilin expression or function are described as the cause of
Imerslund-Grasbeck syndrome (IGS) [37]. Endocytosis mediated by the cubam complex
in the intestine is responsible for the absorption ofIF-BI2 [8]. Mutations in CUBN in
humans result in megaloblastic anemia-I, a component oflGS, which stems from
decreased intestinal IF-B12 endocytosis [38]. Similarly, mutations in AMN also result in
deficient vitamin B12 absorption in humans and dogs [28].

Intriguingly, cubilin has also been proposed to have a role in the absorption and
processing of lipids in the intestine [39]. Lipid absorption in the intestine is accompanied
by the localization of an intestinal alkaline phosphatase (IAP)-containing membrane
t .

,I,

'.'~

,

surrounding the lipid droplets in the cytosolf~'Cl,'.::A;o].
7f '" Cubilin has been shown to coI

localize with lAP around these lipid droplets [39]. This study, therefore, proposed a
possible role for cubilin in facilitating the intracellular trafficking of the lipid droplet and
binding to the basolateral membrane for exocytosis [39].l-Iowev~, this hypothesis has
not been confirmed in cubilin animal models yet. Since cubilin is a multi-ligand receptor
capable of binding diverse proteins, it is likely to be involved in the intestinal absorption
of nutrients in addition to vitamin B 12.

In the kidney, cubilin expressed by the proximal tubule mediates the endocytosis
of multiple proteins [6, 7]. The combined action of cubilin and megalin in the proximal
tubules is responsible for the absorption of the majority of proteins that are filtered across
the glomerulus [6, 7]. Presently, this is the only established mechanism by which filtered
proteins are reabsorbed by the proximal tubules. The list of protein ligands for cubilinmediated endocytosis by the proximal tubules includes vitamin carriers, such as vitamin
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D binding protein [41]; lipoproteins, such as apoA -I [42, 43]; albumin [44] and others
.I

(Table 1). Some of these ligands, such as albumin, are shared with megalin, whereas
others, such as apoA-I, bind solely to cubilin (Table 1) [42-44]. Defective cubilin
expression in the proximal tubule of dogs leads to urinary loss of large amounts of
albumin, apoA-I, vitamin D binding protein and transferrin [7, 41, 42, 44]. Likewise,
proteinuric lOS patients have been reported to have significant urinary loss of cubilin
ligands such as vitamin D binding protein [41], apoA-1 [42] and transferrin [7]. A mouse
model of full-length cubilin deletion by CUBN truncation is also reported to have
increased albuminuria but surprisingly no significant loss of other cubilin ligands in the
urine [31]. One possible explanation is that in this mouse model cubilin may not be fully
deleted, and a truncated fragment of cubilin capal;>le of binding some cubilin ligands
might still be expressed[31]. Additionally,

;~~~cmodels are known to have different

glomerular sieving coefficients depending on the rodent strain [45, 46]. Thus, proteinuria
and the amount and type of proteins filtered through the ~omerulus will probably vary
with rodent strain. Nevertheless, cubilin expression and function is certainly required for
\

the renal proximal tubule absorption of numerous ligands and its absence leads to urinary
loss of these ligands.
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Table 1. Cubilin ligands and partner proteins
Ligand name

Binding site

Carrier proteins
N-tenninus, CUB 5-8

Intrinsic-factor cobalamin/vitamin B 12 [47]
Vitamin D-binding protein# [41]
ApoA-I/HDL [42, 43]
ApoA-II [48]
Albumin# [44]

N-tenninus, CUB 7-8

Hemoglobin# [49]
Myoglobin# [50]
Transferrin [7]
Immune related proteins
Immunoglobulin light chains# [51]
Clara cell secretory protein [52]
Alphal-microglobulin# [30]

t '

: Ii

.~.

•
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Receptors
Megalin [13]

N-tenninus, CUB 12-17 and 22-27

Amnionless [5]

EOF-like modules

Cubilin [14]

N-tenninus
\

Others
Receptor-associated protein# [53]

CUB 13-14

Factor Vila (Recombinant activated)# [54]
Aminoglycosides# [22]
Doxorubicin (Adriamycin) [55]
Fibroblast growth factor 8 (FOF8) [56]
#Indicates ligands that are shared with megalin
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The regulation of cubilin expression in health and disease
Relatively little is known about the regulation of cubilin expression. Decreased
expression of cubilin in the intestine has been reported in aged mice, which might be in
part responsible for aging-induced vitamin B12 deficiency [57]. In the kidney, the fulllength cubilin expression does not change with age in rats even though megalin
expression is decreased [58]. However, aging results in lesser cubilin localization at the
apical brush border and more diffuse cytoplasmic localization in the proximal tubule cells
[58]. These observations warrant further investigation into the mechanisms of aginginduced changes in cubilin expression.
One possible mechanism for the decli~~ ~~tc:ubilin expression with aging might be
due to reduced retinoic acid signaling

[59].'·ctt~ has been shown to be robustly

upregulated by retinoic acid treatment in vitro [21]. However, the precise mechanism for
this effect remains to be established. Retinoic acid signaling is mediated by retinoic acid
~

receptors (RARs) and retinoid X receptors (RXRs), which form heterodimers upon
\

retinoic acid binding [60]. The heterodimers bind the retinoic acid response elements
(RAREs) or retinoid X response elements (RXREs) within the promoters of retinoic acidresponsive genes, and thereby, modifying transcriptional activity of these genes [60]. It is
not yet known whether the cubilin promoter region has any RAREs or RXREs or that the
effect of retinoic acid on cubilin expression is exerted via these receptors. Alternatively,
RXR, being a promiscuous receptor, can heterodimerize with other receptors such as
vitamin D3 receptor, liver X receptors, peroxisome proliferator-activated receptors
(PPARs) and others [61]. Intriguingly, cubilin co-receptor, megalin, has been recently
shown to be regulated by PPARa and'Y [62]. Since cubilin expression goes in conjunction
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with megalin expression, it is possible that PPARs also regulate cubilin expression in
,I

collaboration or independent of retinoic acid signaling.

Cubilin expression has been reported to be downregulated in several pathological
conditions, in which proteinuria is pathognomonic. Both cubilin and megalin are
downregulated in the kidney in streptozotocin-induced diabetes in mice[ 10]. This
downregulation is accompanied by cubilin and megalin loss of function, i.e. significant
albuminuria [10]. Although cubilin levels have not been directly analyzed in diabetic
patients yet, a study of type 1 diabetic patients reported urinary shedding of cubilin and
megalin accompanied by urinary loss of their ligands including albumin, apoA-I, vitamin
D-binding protein and others [63]. Diabetes also results in the downregulation of PP AR
levels in the kidney [64]. Thus, reduced PPAR l,tivity in diabetes might lead to
I.

decreased expression ofmegalin[62]. This association lends further support to the
hypothesis that PP ARs might also regulate cubilin expression and explain how it is
decreased in diabetes.
\

Cubilin and megalin expression in the kidney is also reduced in mouse models of
acute kidney injury (AKI), including lipopolysaccharide-induced endotoxemia and
ischemia-reperfusion kidney injury, which are accompanied by significant albuminuria
[11]. Furthermore, cubilin expression in both the intestine and kidney is downregulated in
a mouse model of cystic fibrosis [58, 65]. This decrease in the renal expression of cubilin
was accompanied by increased urinary loss of cubilin ligands [58]. The mechanism by
which cubilin and megalin are downregulated in these diseases is not known. AKI, cystic
fibrosis and diabetes each have a strong inflammatory component, which might reduce
PP AR levels [66, 67]. In contrast, PP AR stimulation attenuates the degree of renal
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dysfunction, injury, and inflammation caused by ischemia-reperfusion injury [68]. PP AR
,I

stimulation is also widely utilized in the treatment of diabetic patients [69]. Thus, reduced
PP AR activity in these conditions might lead to the decreased expression of both cubilin
and megalin. Further studies are required to delineate this link.

Another aspect of kidney disease is proximal tubule protein overload resulting
from damage to the glomerular filtration barrier. Although the effect of protein overload
on cubilin expression has not been studied, both in vivo and in vitro studies have
demonstrated that protein overload lead to decreased megalin expression [62, 70]. Protein
overload also activates the intrarenal renin-angiotensin system (RAS) [71], which has
been implicated in decreased cubilin expression in another pathological condition [72].
RAS is also implicated in inflammation

[73J{.~ch

in tum would affect PPAR activity.

Thus, it is likely that protein overload would also lead to decreased cubilin expression.

Cubilin has not been extensively studied in chronic kidney disease. Cubilin
l

dysfunction along with a paradoxical increase in cubilin expression has been reported in
\

the remnant kidney model of chronic kidney disease [74]. Furthermore, analysis of
genome-wide association studies revealed a correlation between a single-nucleotide
polymorphism (SNP) in the cubilin gene with levels of albuminuria in both the general
population and in diabetic patients [75]. Another study reported a different SNP in cubilin
gene associated with end-stage renal disease and graft failure in transplanted kidneys.
Although a causal link has not been established yet, these studies indicate a role for
cubilin in chronic kidney disease.
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Tubulointerstitial fibrosis is the principal process leading the progression from
chronic kidney disease to end-stage renal disease[76]. Renal fibrosis is brought on by
interplay of multiple factors, including the RAS, matrix metalloproteinases and tumor
growth factor (TGF)-beta [76]. TGF-beta is also demonstrated to downregulate cubilin
and megalin expression and function in vitro [77]. Since TGF -beta has been associated
with retinoic acid signaling in development, immunity and tissue repair [78], it is likely
that the effect ofTGF-beta on decreased cubilin expression is mediated by decreased
retinoic acid signaling. Therefore, cubilin dysregulation might be another component of
chronic kidney disease and progression to end-stage renal disease.

In summary, decreased cubilin expression and function has been observed in
multiple pathological conditions with strong . in~mmatory components. The regulation of
'"

cubilin expression in these diseases and in health probably involves the retinoic acid and
PPAR signaling pathways.

\

The potential role of cubilin in the homeostasis of serum apoA-I/HDL and albumin
In the intestine, cubilin mediates the absorption of vitamin B 12 bound to intrinsic
factor, IF-B12 [34]. Vitamin B12 then dissociates from both cubilin and intrinsic factor,
and is transferred to transcobalamin for secretion into blood [34]. Clearly, cubilin is
required to maintain homeostatic levels of vitamin B12 in the blood, and lack of cubilin
function leads to vitamin B12 deficiency [8]. In the kidney, however, the potential role of
cubilin in maintaining homeostatic levels of its ligands is not as clear. One view is that
cubilin and megalin-mediated endocytosis leads to the transcytosis of non-protein
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nutrients such as vitamin D, whereas the protein ligands undergo lysosomal degradation
[34]. However, there is evidence from multiple studies suggesting that cubilin protein
ligands may also undergo transcytosis. If this were indeed the case, then lack of cubilin
function would also result in decreased levels of these ligands in the blood. However, the
effect of renal cubilin deficiency on the plasma levels of its ligands has not been directly
studied. In this section, the metabolism of two cubilin ligands, apoA-I1HDL and albumin,
both of which are important components of this dissertation, will be reviewed. In
addition, a potential role for cubilin in maintaining blood levels of both ligands will be
postulated.

High Density Lipoprotein (HDL)

High density lipoprotein is a heterogeneous group of lipoproteins responsible for
the transport of cholesterol and lipids from the peripheraHtissue to the liver, termed
'reverse cholesterol transport' [79]. HDL also serves as an anti-inflammatory mediator
and a carrier for signaling lipids such as sphingosine-I-phosphate (S 1P) [79].

There is ample epidemiological evidence indicating that HDL-cholesterol (HDLC) blood levels are inversely correlated with risk of coronary heart disease (CHD)[8083]. In fact, data suggest that a 1% decrease in HDL-C is associated with a 2-3% increase
in CHD risk[84]. Furthermore, HDL-C levels are shown to be an independent risk and its
correlation with CHD is maintained when corrected for other risk variables, such as
triglyceride levels, obesity, and diabetes[80]. Recent studies suggest that signaling by
SIP carried on HD L might be a mechanistic basis of the cardiovascular effects of HD L
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[85-87]. Therefore, understanding HD L homeostasis is a critical component of future
,/

prevention and treatment ofCHD.

HDL biosynthesis

HDL biosynthesis can be separated into two phases: the synthesis and secretion of
HDL apolipoproteins, and the apolipoprotein lipidation [88]. The major HDL
apolipoproteins are apoA-I and apoA-II. ApoA-I constitutes approximately 70% ofHDL
protein and is virtually present in all HDL particles [89, 90]. Thus, it is not surprising that
apoA-I deficient mice have severely low levels ofHDL and develop significantly
increased atherosclerosis [89, 90]. Similarly, plasma apoA-I absence in humans leads to
significantly reduced HDL levels and early 0~set,90ronary artery disease [91].
,~ -~, ~/'

Overexpression of apoA-I, on the other hand~ has been shown to increase HD Lcholesterol (HDL-C) levels [92]. Therefore, apoA-I plasma levels correlate closely with
plasma HDL-C concentration. ApoA-I is synthesized both in the intestine and the liver,
l

and its expression has been shown to be increased by PP AR-a agonists in both humans
\

and mice [93]. In addition, the orphan nuclear receptor liver receptor homolog-1 (LRH -1)
has been reported to upregulate apoA-I transcription by directly binding the apoA-I
promoter [94]. However, studies ofHDL metabolism have that revealed apoA-I
fractional catabolic rate is a better determinant of human HDL-C levels than the rate of
apoA-I synthesis [95, 96].

ApoA-II constitutes about 20% ofHDL protein and is present in about two-thirds
ofHDL particles [88]. ApoA-II is synthesized only in the liver and its overexpression has
been shown to lead to increased HDL concentration in mice [97]. Unlike apoA-I, plasma
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apoA-11 concentration is determined primarily by the rate of its production [96].
.1

PPARa/y and alcohol have been shown to increase apoA-II production and plasma HDL
levels [88].

Newly synthesized apolipoproteins must acquire lipids in order to form HDL
particles. Evidence suggests that HD L apolipoprotein lipidation occurs primarily after
their secretion[88]. Newly secreted apoA-1 particles acquire lipids by the action of ATPbinding cassette, subfamily A, member 1 (ABCAl)[98]. ABCAI mediates the rate
limiting step in HDL particle formation, which is the cell surface assembly of apoA-1
particle with cholesterol and phospholipids[99]. This process leads to the formation of
nascent, discoidal HDL particles[99]. ABCAlioss of function mutations in the human
gene cause Tangiers disease, characterized,by, ~ low HDL levels and rapid HDL
degradation [100]. The liver X receptors a and

~ (LXRa/~)

are the major regulators of

ABCA 1 gene expression[96]. LXRs form heterodimers with their partner the retinoid X
receptor and are activated by oxysterols[96]. Although wIdely expressed, ABCA 1
expressed in the intestine and liver is responsible for the generation of virtually all of
plasma HDL [98, 101]. Liver-specific and intestine-specific Abcal knockout mice were
shown to have an approximately 80% and 30% decrease in plasma HDL respectively[98,
101]. Additionally, since scantily lipidated apoA-1 is rapidly degraded, it is thought that
this proportion may reflect the contribution of each organ to the plasma pool of apoA -I as
well [96]. Although, studies have shown that cubilin acts as a receptor for both apoA-1
and apoA-II, it is not clear whether cubilin plays a role in the biosynthesis of HDL[ 42,
44, 48, 102, 103].
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HDL maturation and remodeling
.1

Nascent HD L particles, fonned in the liver and intestine, undergo intravascular
maturation by acquiring more lipids[88]. Since extrahepatic tissues cannot metabolize
cholesterol and have to efflux cholesterol to HDL, most of the lipids on HDL particles
originate from extrahepatic sites[96]. This process is thought to happen by various
mechanisms, including aqueous diffusion and SR-BI and ABCG1-mediated transfer[96].
Lipids from these extrahepatic sites are delivered to the liver for excretion in bile or
metabolism by various pathways, a process tenned "reverse cholesterol transport". Free
cholesterol effluxed by peripheral tissue associates with HDL in plasma and is converted
to cholesterol esters by lecithin-cholesterol acyltransferase (LCAT) [88]. Cholesterol
esters are more hydrophobic and move to

the..C~pter

ofHDL particles, resulting in the

fonnation of mature, spherical HDL particles[88]. HDL particles also acquire
phospholipids fonn other lipoproteins such as VLD Land chylomicrons via the action of
phospholipid transfer protein (PLTP) and lipoprotein lipa~e (LPL), which results in the
fonnation of larger HDL2 particles[96]. HDL cholesterol esters (HDL-CE) are transferred
to apoB lipoproteins, such as chylomicrons, VLDL and LDL, in exchange for
triglycerides by the action of cholesteryl ester transfer protein (CETP) [96]. Cholesterol
esters carried by these particles can be transferred to liver via LDL-receptor. HDL-C can
be directly delivered to liver via the scavenger receptor class BI (SR-BI) [104]. HDL
phospholipids and triglycerides are also transferred to liver by hepatic lipase (HL) and to
other tissues and lipoprotein particles by endothelial lipase (EL) and secretory
phospholipase A2 (sPLA2) [96].

16

HDL catabolism
.1

Kinetic studies in humans have indicated that the rate of apoA -I turnover is a
more important determinant of plasma apoA-I and HDL-C concentration than its
production[95]. Animal studies using apoA-I labeled with covalently linked

[125 1]-labeled

tyramine cellobiose, which accumulates in the cells degrading the apolipoprotein, showed
that about a third of apoA -I is catabolized by the kidney and the rest is catabolized by the
liver[I05]. Relatively little is known about the hepatic uptake and degradation ofHDL.
ApoE-rich HDL is taken up by the liver via the LDLR and other apoE receptors[88].
However, the mechanism by which apoE-poor HDL is taken up by the liver is unknown.
Further research is required to elucidate the mechanisms of hepatic HDL catabolism.
>

'~I ~~l

In the kidney, apoA-I, presumably in lipId-poor form, is filtered at the glomerulus,
which then undergoes endocytosis via cubilin expressed on the proximal tubule epithelial
cells[ 42, 44]. One view is that ApoA-1 undergoes catabolism at the proximal tubules
1

following cubilin-mediated endocytosis [88]. Furthermore, the rate-limiting step is
\

thought to be glomerular filtration and that mature HD L is too large to be filtered and
escape renal catabolism[96]. In Tangier disease, in which ABCA 1 mutation leads to the
inability to lipidate newly synthesized apoA-I, apoA-1 is rapidly catabolized, primarily by
the kidneys[l 06]. This condition leads to drastically low plasma HDL levels. Therefore,
poor lipidation of apoA-1 prevents the formation of mature, larger HDL particles and
allows apoA -I filtration at the glomerulus and subsequent catabolism. This hypothesis is
supported by studies of LCAT deficiency, which results in accelerated apoA-1
catabolism[96]. The accelerated catabolism is presumed to happen because HDL particles
cannot acquire the cholesterol ester core to form larger, mature particles [96]. Mature
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HDL particles can be also remodeled into smaller particles that can be then subjected to
,I

glomerular filtration. The most important remodeling processes involve the HDL-CE
transfer to other lipoproteins via CETP, and HDL-CE and free cholesterol uptake by the
liver via SR-BI[88]. Both processes can affect the turnover of apoA-1. CETP deficiency
in humans is associated with reduced apoA-1 turnover, whereas overexpression ofCETP
and SR-BI in mice accelerates apoA-1 turnover[88, 107]. Another study investigating the
overexpression of endothelial lipase reported increased apoA -I catabolism[ 108].
However, apoA-I degradation was proportionally increased in both the liver and the
kidney[ 108]. In light of these observations, the lipidation status of HDL particles is
theorized to be an important factor in HDL/apoA-1 catabolism[88]. Yet critical gaps
remain in understanding the role of kidney in the ,catabolism ofHDL. Genetic and

,,:., t/"
functional cubilinlmegalin deficiency studies need to be undertaken to determine the
mechanism of renal HDL catabolism. Furthermore, whether renal catabolism of

,

HDL/apoA-1 has a regulatory effect on plasma HDL levels also remains unknown.

Based on more recent evidence, an alternative pathway of renal handling of apoAI, which avoids lysosomal degradation and delivers apoA-1 back into circulation, is also
plausible. Other cubilin and megalin ligands, such as albumin and retinol binding protein,
have been shown to undergo transcytosis across renal proximal tubule cells following
uptake [45, 109-113]. In fact, several studies have indicated that this process is critical for
maintaining homeostatic levels of albumin (see next section) [45, 113]. Additional
support for this concept comes from epidemiological studies of type 1 diabetic patients.
Diabetic patients generally suffer from dyslipidemia and lower levels of blood HDL
[114]. Furthermore, a study of normoalbuminuric type 1 diabetic patients with normal
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glomerular function reported a correlation between lower levels of total HDL-C and
I

smaller sized HDL3-C with albuminuria, but not larger HDL2-C [115]. Similarly, another
study reported a shift of HDL size distribution toward large particles in patients with
proteinuria [116]. Diabetes in a mouse model has been shown to lead to cubilin
downregulation, and in humans has been associated with increased shedding in the urine
along with its ligands apoA-I, albumin and others [10, 63]. Taken together, these lines of
evidence indicate that cubilin-mediated endocytosis might salvage renal filtered apoA-I
back to circulation, which is otherwise lost in the urine leading to decreased blood HDL
levels. Therefore, the kidney, in addition to catabolism, may also be involved in a
recycling pathway of apoA-I required for maintaining plasma homeostatic levels of
apoA-I/HDL.

Albumin

Albumin is the most abundant protein in plasma. It is also
a major constituent of
\
interstitial fluid, lymph and cerebrospinal fluid, and found in all bodily secretions [117].
Albumin has multiple functions in the plasma, including maintaining colloid oncotic
pressure of plasma, transport of hormones, fatty acids and metabolites, regulation of
microvascular permeability and others[118]. It is also associated with anti-oxidant, antithrombotic and anti-inflammatory properties[118]. Thus, albumin homeostasis in the
blood is critical and reduced levels of albumin in plasma, hypoalbuminemia, is observed
in numerous diseases. The most obvious symptom of hypoalbuminemia is edema caused
by reduced colloid osmotic pressure to counterbalance hydrostatic pressure [ 118].
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Hypoalbuminemia is most commonly caused by inflammatory responses, but is also
caused by other diseases including nephrotic syndrome, hepatic cirrhosis, heart failure,
and malnutrition [118]. Serum albumin levels are also associated with an independent
risk for cardiovascular disease [119]. Therefore, understanding the regulation of blood
albumin homeostasis might be important in treating and preventing many common
diseases. The processes responsible for maintaining homeostatic levels of albumin
include the absolute rate of albumin synthesis, degradation and exogenous loss, and
distribution between intravascular and extravascular compartments [118].

Albumin synthesis

The majority of serum albumin is

synt~es~~ed
.

--;:.

in the liver and secreted directly

" --, rl

',-

into hepatic plasma [11 7]. Although albumin expression has been reported in other
organs, including cubilin-expressing organs such as intestine and kidney, the contribution

,

of these organs to the serum pool of albumin is not clear [120]. Albumin synthesis in the
liver is regulated at the level of transcription and ---15g of albumin are produced to
\

maintain steady state levels (r--4g/dL) in humans [121]. The most important factors
regulating albumin synthesis are nutrition and inflammation [11 7]. Evidence suggests
that TNF -alpha in concert with other cytokines playa key role in inflammatory regulation
of albumin synthesis in cachexia of numerous chronic diseases, including cancers,
cirrhosis, AIDS and inflammatory disorders [11 7, 121]. Albumin synthesis is also
regulated by hormones including thyroid hormones and cortisone [117]. In addition,
albumin synthesis has been observed to change with osmotic pressure, for example
raising the colloidal content of plasma by exogenous administration of proteins resulted
in reduced albumin synthesis [117]. Albumin synthesis may also be decreased in
20

gastrointestinal diseases [117]. However, this is postulated to be due to poor hepatic
supply of amino acids [117].

Although cubilin is associated with intestinal absorption of nutrients, loss of
cubilin function dos not result in the severe malnutrition associated with reduced albumin
synthesis and hypoalbuminemia [8]. Therefore, cubilin is unlikely to playa direct role in
serum albumin synthesis.

Albumin catabolism
Serum albumin catabolism is not as well understood as its synthesis. No one
organ has been indicated as the major site of albumin degradation. According to early
kinetic studies in animals, albumin degradaJi,9~~§c'curs in the intravascular fluid
I"

compartment [122, 123]. Since blood cells alone are too few to account for albumin
degradation, the major degradation site is most likely the endothelium, and perhaps,
organs with fenestrated endothelium, all of which might take up

~lbumin

by pinocytosis

[123]. In addition, small fractions of albumin are degraded or Jost in stool, excreted or
degraded in the kidney, and metabolized by the liver [117]. The overall albumin
degradation equals the net hepatic albumin synthesis resulting in steady state levels [124].
Furthermore, albumin does not appear to undergo any specific processes that would label
it for degradation [117]. The endogenous half-life of albumin in humans and rodents is
approximately 19 and <1.5-2.5 days respectively [125].

More recently, it was demonstrated that the neonatal Fc receptor, also known as
the major histocompatibility complex-related Fc receptor (FcRn), plays a critical role in
protecting albumin from degradation [124]. FcRn is expressed in virtually all nucleated
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cells, and is located in acidic endosomes. It binds albumin only in acidic conditions
"I

following albumin endocytosis, and mediates the albumin recycling back into circulation,
thereby rescuing albumin from lysosomal degradation [123, 124]. In FcRn global
knockout mice, albumin degradation is twice as fast as in wildtype, indicating that FcRn
protects as much albumin from degradation as is produced [124]. Serum albumin
concentration in these mice was significantly reduced with a modest compensatory
increase in albumin synthesis to stabilize serum albumin steady state levels at about half
of normal [124].

In the kidney, where a small fraction of albumin is degraded, cubilin mediates the
reabsorption of albumin filtered through the glomerulus. One view is that cubilinmediated endocytosis of albumin results

in,t~ WSosomal

degradation of albumin[34].

However, evidence also suggests an alternative pathway of albumin recycling back to the
blood pool. In fact, FcRn is also expressed by the renal proximal tubules where it is
implicated in the transcytosis of albumin from the glomerblar filtrate, across the proximal
tubule epithelium and back into circulation [113, 126]. Mice with FcRn deficient kidneys
had reduced serum albumin levels, reduced albumin half-life in blood and increased
albuminuria [113]. These observations are consistent with another recent study
demonstrating albumin transcytosis in renal proximal tubules using fluorescent live
imaging [113]. However, FcRn deficient kidneys retain the capacity to bind albumin by
their brush borders [113]. This is consistent with numerous other studies demonstrating
that cubilin mediates the binding and endocytosis of albumin in the renal proximal tubule
cells, and that FcRn binds albumin in acidic endosomes after albumin endocytosis [126129]. Similarly, BSA overload of mice led to increased albuminuria due to overwhelming
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of the endosomal processing [36]. This albuminuria was accompanied with decreased
serum albumin levels [46]. Therefore, cubilin-mediated endocytosis of albumin might be
followed by albumin transcytosis across the renal proximal tubule epithelium and back
into circulation. If this were indeed the case, then cubilin deficiency in the renal proximal
tubules would lead to albuminuria and reduced serum albumin levels.

In summary, cubilin-mediated endocytosis of apoA-I and albumin filtered in the
kidney might lead to lysosomal catabolism or transcytosis and salvage back to the
circulating blood pool. In the latter case, cubilin deficiency would lead to reduced blood
levels of apoA-I1HDL and albumin.

\
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Figure 1-1. Schematic diagrams depicting the structdre of cubilin (A) and cubilinmediated endocytosis (B). (A) Cubilin is composed of27 CUB domains, 8 EGF-like
modules and a 113 residue amino tenninus. (B) Cubilin-mediated endocytosis is
clathrin-dependent and initiated by intracellular signaling from either megalin or
amnionless cytosolic domains. Once internalized the receptors are sorted in
endosomes either for lysosomal degradation or recycling back to the apical plasma
membrane. Similarly, cubilin ligands are either sorted for lysosomal degradation or
undergo transcytosis.
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Chapter 2. Cubilin expression is mono allelic and epigenetically augmented via
PPARs

Abstract
Cubilin is an endocytic receptor that is necessary for renal and intestinal
absorption of a range of ligands. Endocytosis mediated by cubilin and its co-receptor
megalin is the principal mechanism for proxim§:l.tubule reabsorption of proteins from the
,

.~ I

'~/"

glomerular filtrate. Cubilin is also required for intestinal endocytosis of intrinsic factorvitamin B12 complex. Despite its importance, little is known about the regulation of
cubilin expression.

Here we show that cubilin expression is under epigenetic regulation by at least
two processes. The first process involves inactivation of expression of one of the cubilin
alleles. This monoallelic expression state could not be transformed to biallelic by
inhibiting DNA methylation or histone deacetylation. The second process involves
transcriptional regulation of cubilin by peroxisome proliferator-activated receptor
(PP AR) transcription factors that are themselves regulated by DNA methylation and
histone deacetylation. This is supported by findings that inhibitors of DNA methylation
and histone deacetylation, 5Aza and TSA, increase cubilin mRNA and protein in renal
and intestinal cell lines. Not only was the expression of PP ARa and y inducible by 5Aza
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and TSA, but the positive effects ofTSA and 5Aza on cubilin expression were also
dependent on both increased PP AR transcription and activation. Additionally, 5Aza and
TSA had similar effects on the expression of the cubilin co-receptor, megalin. Together,
these findings reveal that cubilin and megalin mRNA expression is under epigenetic
control and thus point to new avenues for overcoming pathological suppression of these
genes through targeting of epigenetic regulatory processes.
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Introduction
I

Cubilin is a 460-kDa peripheral membrane glycoprotein, anchored to the plasma
membrane via an amino terminal amphipathic helix [6, 7] and through interactions with
the transmembrane protein, amnionless, forming the so-called cubam complex [4, 5].
Cubilin is expressed by the absorptive epithelia of tissues such as renal proximal
convoluted tubules [130], ileum [131], and yolk sac [132], where it mediates the
endocytosis of numerous ligands [6], in some cases acting in concert with another
endocytic receptor, LRP-2/megalin [102].

Cubilin was first described as the intrinsic factor-cobalamin/vitamin B12 receptor
important for intestinal absorption of vitamin ~121133]. Mutations of the cubilin gene are
,' .. ~,

~j

the cause of Imerslund-Grasbeck syndrome, also known as selective vitamin B12
malabsorption with proteinuria [134]. Proteinuria in these individuals results from the
inability of the cubilin-deficient kidney to reabsorb ligands that filter across the
l

glomerulus, including albumin and apolipoprotein A-I, the major apolipoprotein of HDL
\

[42, 44].

In vitro studies have shown that cubilin mRNA expression is stimulated by
retinoic acid and that it is not sterol-regulated [102]. Cubilin is co-expressed with megalin
in numerous tissues [20, 23, 102, 132], suggesting the possibility that the genes share
common transcriptional regulatory mechanisms. Peroxisome proliferator-activated
receptors (PPARs), transcription factors belonging to the nuclear receptor superfamily,
upregulate megalin expression [62], but it is not yet known whether these factors
influence cubilin expression. Furthermore, expression of megalin is regulated by histone
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acetylation and methylation and DNA methylation [135], but it is not yet known whether
.1

cubilin is regulated epigenetically in a similar manner.

The availability of a mouse carrying a knockin of an EGFP cassette into the
cubilin gene [136] has enabled precise histological analysis of cubilin expression. While
evaluating cubilin-EGFP expression in renal tissue of mice heterozygous for the knockin
allele, we observed a striking difference in the distribution of EGFP immunoreactivity
versus cubilin immunoreactivity. Although both were detected at sites that matched
cubilin distribution in wildtype animals, the cellular distributions in heterozygous mice
were largely exclusive such that cells appeared to express predominantly either EGFP or
cubilin. This led us to postulate that cubilin might undergo an allelic inactivation that
silenced or strongly diminished

expressiono£.e~er

the maternal or paternal allele. This

phenomenon, called monoallelic expression [137], can occur through chromosomal
inactivation (e.g., X inactivation), autosomal gene imprinting or random gene inactivation
[138]. Monoallelic expression of a variety of autosomal gbnes have been described [138,
139], including p120 catenin [140], certain cytokines [141], olfactory receptors and
antigen receptors [142, 143]. Here we explored the possibility that cubilin (Cubn), an
autosomal gene [144], is regulated through epigenetic mechanisms and whether such
processes might have consequences on cubilin function and on the expression of its
partners, amnionless and megalin.
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Materials and Methods

Animals

All studies involved the use of 1-6 month old male mice heterozygous for cubilin
exon 1-6 deletion with an EGFP cassette insertion (Cubn +/del exon 1-6;EGFP) [136] or age/sex
matched wildtype (WT) littermates. Mouse experimentation was conducted with approval
from the IACUC. Cubn +/del exon 1-6,EGFP (Cubilin HT) and WT mice were administered
Trichostatin A (TSA) (Sigma-Aldrich, St. Louis, MO) at 2 Jlg/g of mouse body weight or
equal volume of vehicle DMSO intraperitoneally for 7 consecutive days. TSA was
dissolved in DMSO to yield a solution of 6.048 mg/ml. This TSA solution or an equal
volume ofDMSO only was further diluted in

~alipe to

a final TSA concentration of --599

Jlg/ml, which was administered to mice.

Antibodies

Goat anti-cubilin IgG (A20) was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA), rabbit anti-EGFP IgG was from Abeam (Cambridge, MA), goat antialbumin was obtained from Bethyl Laboratories, Inc. (Montgomery, TX), mouse antihuman a-tubulin was purchased from Sigma-Aldrich (St. Louis, MO) and rabbit antiactin was from Abeam. Rabbit anti-human intrinsic factor serum was generously
provided by Dr. David H. Alpers (Washington University School of Medicine, St. Louis,
MO). Rabbit anti-porcine megalin (rb6286) was described previously [145]. Antiserum
to amnionless (rb4156/57) was prepared by immunizing rabbits with synthetic multiple
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antigenic peptide containing amino acid residues 165-178 (accession number
NM_001108061.1). The resulting antiserum reacted with a single ",45 kDa polypeptide in
mouse kidney extracts and ---35 kDa and 30 kDa bands in intestinal extracts and an ---30
kDa band in extracts ofE8.5 mouse embryo extracts and rat BN cells (Fig. 3D and data
not shown). Donkey anti-goat and donkey anti-rabbit-Alexa Fluor (488 or 568)
conjugates were purchased from Invitrogen (Carlsbad, CA).

Tissue procurement and immunofluorescence
Following euthanization, animals were perfused first with phosphate-buffered
saline (PBS) and then with 4% paraformald~h~~l,'PBS. Tissues were dissected and
further fixed by immersion in 4% paraformaldehyde PBS for 12 h. For kidney
immunohistochemical analysis, ---0.25 cm thick strips of cortex tissue were isolated. For

°

small intestine immunohistochemical analysis, '" 1 cm long se~ents of duodenum
(extending distally from the fundus of the stomach), jejunum (beginning ",5 cm from the
end of duodenum) and ileum (ending ",2 cm superior of the cecum) were isolated.
Isolated tissues were embedded in paraffin and sectioned at 6 flm thickness. Tissue
sections were incubated with primary antibodies diluted in PBS containing 3% BSA,
washed with PBS and incubated with Alexa Fluor conjugated secondary antibodies.
Nuclei were stained using Draq5 (Cell Signaling Technology, Danvers, MA). Labeled
sections were analyzed using a Leica SP5 confocal microscope (Leica Microsystems Inc.,
Exton, P A) using the 63x objective or a Zeiss Axio M2 microscope using the 40x
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objective. Whole mount images of unlabeled intestine EGFP-fluorescence were taken by
a Leica MZ FLIII microscope at ",5x magnification.
"1 VI·11·I fr om Cu
b +/de/
exon 1-6EGFP"1
"d"Issected under
Intesttna
n
'
mouse I eum were mlcroGFP light at lOx magnification using Leica MZ FLIII microscope. Villi that appeared
predominantly EGFP-positive or EGFP-negative as well as a random sampling of both
were separately isolated using dissection scissors in Hank's buffered salt solution (HBSS)
(Thermo Scientific) containing 4% FBS. Villi were then briefly span down, the
supernatant removed and RNA extracted from the samples using the RNeasy Plus Mini
Kit (QIAGEN, Valencia, CA). qPCR was performed as described below.

Immunoblot analysis

Unfixed segments of small intestine were homogenized in 1% Triton X-I00, 0.5%
l

Tween20, 0.5 M NaCl, 50 mM Hepes, pH 7.5 containing a protease inhibitor cocktail
(Complete-mini, EDTA-free, Roche, Germany) using a Polyt~on-aggregate (Brinkmann
Instruments, Switzerland). Extracts were subjected to centrifugation at lOOK x g for 30
min at 4aC. Protein concentration in extracts was quantified using Pierce BCA Protein
Assay Kit (Rockford, IL). Equal amounts of protein from the extracts were loaded onto
NuP AGE 4-12% polyacrylamide gradient, Bis-Tris gels in the presence of SDS (no
reducing agent). Following electrophoresis, the proteins were transferred onto PVDF
membranes, which were blocked with 5% non-fat milk in TBS and probed with primary
and secondary antibodies diluted in TBS containing 0.50/0 Tween 20 and 5% non-fat
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milk. Chemiluminescent detection of bound antibodies was achieved using the Pierce
EeL Western Blotting Substrate.

C ell culture

NRK-52E (NRK) (ATCC no. CRL-1571) and Caco-2 (ATCC no. HTB-37) cells
were cultured in DMEM (high glucose) with 10% fetal bovine serum, Glutamax (Life
Technologies, Grand Island, NY), non-essential amino acids, 100 units/ml penicillin, and
100 units/ml streptomycin (Thermo Scientific, Rockford, IL), and maintained at 37°C
and 5% CO2 • For trichostatin A (TSA) treatments, cells were plated at 1.0 x 104 cells/cm2
for 6 h, and subsequently treated for 24 h ~j1h ~9~-50 or 100 nM TSA (Sigma,

st. Louis,

MO) (281.6 pM final DMSO concentration in medium). For 5-Azacytidine (5Aza)
treatments, NRK cells were plated at 5 x 103 cells/cm2 for 6 h and subsequently treated
with 1, 5 or 10 J..lM 5Aza (Sigma) (281.6 pM final DMSO concentration in medium) for
60 h with three media changes at 0, 12 and 36 h. For Caco-2 cells, 5Aza treatments were
\

for 84 h with four media changes at 0, 12, 36 and 60 h. To evaluate the effects ofPPAR
transcription factor antagonists on TSA treated cells, TSA treated NRK cells were
incubated with PPARu antagonist (GW6471), PPARy antagonist, (GW9662) (Sigma), or

°

both, each at 1 JlM for 24 h. To evaluate the effects of PP AR transcription factor
antagonists on 5Aza treated cells, NRK cells were treated for 36 h with 5Aza and
incubated with 5Aza-free medium containing PPAR antagonists, each at 10 JlM for 24 h.
In studies evaluating the effects of transgenic PP ARu, NRK cells were transiently
transfected with pSG5 PP AR alpha plasmid [146] (plasmid 22751; Addgene, Cambridge,
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MA) using Lipofectamine LTX & PLUS Reagent (Invitrogen) according to
manufacturer's instructions. Nearly confluent NRK cells, grown in six-well plates, were
transfected with 1Jlg pSG5 PP AR alpha plasmid or a control plasmid using
Lipofectamine LTX at a 1:3 mass: volume ratio for'" 18 h. The cells were then allowed
to grow for 24 h in complete medium and treated with TSA or vehicle as described
above.

Primary renal tubule cells (PRTCs) were isolated and cultured as described
previously [147, 148]. Briefly, mouse renal cortices were dissected and minced in icecold dissection solution ofHBSS (Thermo Scientific) supplemented with 10mM glucose,
5mM glycine, ImM alanine and 15mM HEPES pH 7.4. The minced fragments were
transferred to a dissection solution containing ~. 0 glml soybean trypsin inhibitor, 1
mglml type 1 collagenase and 0.05% type 2 collagenase, and digested for 30 min at 37°C.
After digestion, the mixture was passed through a 250 Jlm pore size nylon sieve and the
flow-through material passed through an 80 Jlm pore

siz~ nylon sieve. Proximal tubules

(PT) retained on the 80 Jlm sieve were resuspended with 37°(,) HBSS solution containing
1% BSA and then subjected to centrifugation for 5 min at 170xg. The PT pellet was
resuspended in 1:1 mixture ofDMEM:FI2 culture medium containing 15mM HEPES
and 2mM L-glutamine (Thermo Scientific) supplemented with 9% FBS, 50nM
hydrocortisone, ITS (BD Biosciences, San Jose, CA), sodium pyruvate, non-essential
amino acids, 100 units/ml penicillin, and 100 units/ml streptomycin (Thermo Scientific),
and then plated and maintained at 37°C and 5% CO2 . PRTCs were cultured for 4 days
before treatment with a medium change every other day. PRTCs were then treated with
5Aza or TSA or DMSO (vehicle)-containing medium for additional 7 days. On day 7,

33

PRTCs were used for protein or RNA extraction using the RNeasy Plus Mini Kit
(QIAGEN, Valencia, CA) or fixed in 4% paraformaldehyde PBS with 1% Triton-XI 00
for 20 min for immunofluorescent microscopy.

For PPAR agonist and antagonist studies, semi-confluent PRTC cultures were
treated with PP AR alpha agonist, WyI4643 (Cayman Chemical Company, Ann Arbor,
MI), PPAR alpha antagonist, GW647I (Sigma) or vehicle DMSO only at the indicated
concentrations for 22hrs in complete media containing 3%FBS. Protein or RNA was
, extracted from independent experiments as already described.

qPCR

RNA from cells or tissue was isolated using the RNeasy Plus Mini Kit (QIAGEN,
Valencia, CA) and quality assessed on an Agilent Bioanalyzer. cDNA was prepared from
~

0.25-1 J,tg total RNA using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA)
according to manufacturer instructions. qPCR was perf~rmed using iQ SYBR Green
Supermix (Quanta BioSciences, Inc., Gaithersburg, MD) reagents and a CIOOO Thermal
Cycler (Bio-Rad). The relative values for each gene were determined using the cycle
thresholds and normalized to reference genes. The following qPCR primers were used:
rat Cubilin forward, 5'-TGGGAGCTGCGTCTATGATT-3' and rat Cubilin reverse, 5'AAGGAAGTTGCCGGAAGAGA-3' (NM_053332.2); rat MegalinlLrp2 forward, 5'ATCTGTGCTCCAGGTCCAAA-3' and rat MegalinlLrp2 reverse, 5'ATTGAGGCAGGTGAACTGGA-3' (NM_030827.l); rat PparD forward, 5'GGCCAAGAGAATCCACGAAG-3' and ratPPARD reverse, 5'-
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ACAAAAGGCGGATTGTTGCT-3' (NM_013196.1); ratPparD forward, 5'GGTGAAACTCTGGGAGATCCT-3' and ratPPARD reverse, 5'CATGGTAATTTCTTGTGAAGTGCT-3' (NM_013124.3); rat Gapdh forward, 5'GTGCCAGCCTCGTCTCATA-3' and rat Gapdh reverse, 5'AGGTCAATGAAGGGGTCGTT-3' (NM_017008.3); rat/mouse Rn18s forward, 5'CGCCGCTAGAGGTGAAATTCT-3' and rat/mouse Rn18s reverse, 5'CGAACCTCCGACTTTCGTTCT-3' (NR 046237.1); human Cubilin forward, 5'CCTGAACTGCGAATGGACTC-3' and human Cubilin reverse, 5'CATCACCCACTCGAAACTCG-3' (NM_OOI081.3); human Lrp2 forward, 5'GATTGGGCTGCTTCACGATT -3' and human Lrp2 reverse, 5'ATGGCAAGTCCAAACGGATG-3' (NM_004525.2); human Gapdh forward, 5'ATGTTCGTCATGGGTGTGAA-3' and human Gapdh reverse, 5'GGTGCTAAGCAGTTGGTGGT-3' (NM_002046.4); mouse Cubilin forward, 5'ATTTTCTCTGGGGTTTTGTTAC-3' and mouse

Cubili~

reverse, 5'-

TAAGTTTCCCTCCTCCGTAG-3' (NM_ 001081084.2); mouse MegalinlLrp2 forward,
\

5' -TGACTGCGGAGACA TGAGTG-3' and mouse MegalinlLrp2 reverse, 5'CACAGACCCAGTGTTGTGGA-3' (NM_OOI081088.1); mouse Gapdh forward, 5'CAGCCTCGTCCCGTAGACA-3' and mouse Gapdh reverse, 5'CAACAATCTCCACTTTGCCACT-3' (NM 008084.2); mousefJaetin forward, 5'AACCGCTCGTTGCCAATA -3' and mouse fJaetin reverse, 5'CGGGACCTGACAGACTACCTC-3' (NM 008084.2); and GFP forward, 5'CAACAGCCACAACGTCTATATCATG-3' and GFP reverse, 5'ATGTTGTGGCGGATCTTGAAG-3' (U50963.1) [149].
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Cubilin promoter luciferase transfection assays

BN cells for luciferase reporter assays were passaged in complete medium (MEM
with 10% fetal bovine serum, Glutamax (Life Technologies, Grand Island, NY), nonessential amino acids, 100 units/ml penicillin, and 100 units/ml streptomycin (Thermo
Scientific) as described previously [102]. Prior to transfection, BN cells were plated at
0.5 xl0 5 cells/cm2 in 24-well culture dishes in complete medium and grown overnight.
Control transfections were performed with PPARa (pSG5 PPAR alpha), PPARy (pcDNA
flag PPAR gamma; Plasmid 8895, Addgene) [150] or pcDNA3.1(+) (Life Technologies,
Grand Island, NY) expression plasmids in combination with a PP AR responsive
luciferase reporter plasmid (PPRE X3-TK-Iuc; Plasmid 1015, Addgene) [151].
Experimental transfections were conducted.wttl}lPARa, PPARy or pcDNA3.1(+)
I,.

expression plasmids in combination with a cubilin promoter luciferase plasmid (pCub 431 Luc) created by insertion of a mouse cubilin promoter fragment (-431 to -5, relative
to the translation start site) into the pGL3-Basic luciferasd report~r plasmid (Prom ega,
Madison, WI). Transfections were performed in triplicate with GenePORTER 2
(Genlantis, San Diego, CA) using 1.5 Jlg of each plasmid (3 Jlg total) and 15 JlI
GenePORTER 2 per transfection. Transfections proceeded for 24h after which cells were
lysed and extracts prepared for luciferase assay with the BD Monolight Enhanced
Luciferase Assay Kit (BD Biosciences, San Jose, CA) according to manufacturer
recommendations. Luciferase activity was measured using a Monolight 2012
Luminometer (BD Biosciences).
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Statistical analysis

Data are presented as mean ± SD of 3 replicates, representative of at least 3
independent experiments. Two-tailed Student's t-tests were used to compare control and
treatment groups.

Results

Monoallelic expression of cubilin in the renal proximal tubules

Kidney sections from wildtype mice and mice heterozygous for Cubn exon 1-6
deletion with an EGFP cassette insertion (Cubn~/del exon 1-6;EGFP) were immunolabeled with
~'.,I /i
C

•

antibodies to cubilin and EGFP. In kidneys from wildtype mice, all proximal tubules
displayed prominent and relatively uniform brush border immunolabeling with anticubilin IgG (Fig. 2-1A). By contrast, the kidneys of Cubnl/del exon 1-6;EGFP mice showed
strong immunolabeling in the brush border regions of only a subset of proximal tubules
\

(Fig. 2-1B). Evaluation ofEGFP immunolabeling in kidney sections from these mice

revealed a similar discontinuous distribution, with some cells showing high levels of antiEGFP immunofluorescence while adjacent cells had only weak fluorescence (Fig. 2-1q.
However, strikingly, the epithelial cells that had strong EGFP immunofluorescence,
displayed little or no cubilin immunolabeling (Fig. 2-1D). Conversely, the proximal
tubules that showed relatively low EGFP immunofluorescence displayed pronounced
cubilin immunolabeling. Similar observations were made in the kidneys of female

Cubn +/del exon 1-6;EGFP mice (data not shown). Thus, in the proximal tubule cells of
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Cubn +/del exon 1-6;EGFP mice, the level of EGFP immunofluorescence was inversely related
to the level of cubilin immunofluorescence. These observations suggest that one of the
two cubilin alleles in these heterozygous mice, either the targeted deletionlEGFP
insertion allele or the wild-type cubilin allele, is suppressed while the remaining allele is
active. Collectively, the findings suggest that cubilin gene is subject to monoallelic
inactivation in the kidney. The allelic inactivation appears to be stochastic in that adjacent
proximal tubule cells could be found in which one cell was expressing high levels of
EGFP and the other not. The fact that most proximal tubule cells in Cubn +/del exon 1-6;EGFP
kidneys were not completely devoid ofEGFP immunofluorescence suggests that the
inactivation process is not absolute.

EGFP expressing, cubilin deficient proximal tubule cells display reduced albumin
localization in Cubn +/de/ exon 1-6;EGFP mice

Cubilin located on the brush border of renal proximal ~ubule cells mediates
binding and endocytosis of albumin from the glomerular filtrate [44]. In kidneys of
wildtype mice, albumin is localized on the apicallbrush border regions of renal proximal
tubules (Fig. 2-1E and F). In Cubn +/del exon 1-6;EGFP mice, pronounced albumin
immunolabeling was apparent in the apicallbrush border regions of a subset of renal
proximal tubules that showed relatively low EGFP immunofluorescence (Fig. 2-1G and
H). By contrast, proximal tubules with strong anti-EGFP immunofluorescence showed

little or no albumin immunolabeling in the brush border region. These findings suggest
that the cubilin-deficient proximal tubules (i.e., those cells with strong anti-EGFP
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immunofluorescence) are unable to efficiently bind and endocytose albumin, which is
consistent with other studies showing that cubilin deficiency leads to albuminuria [44,
152].

Expression of megalin and amnionless in the kidney of Cubn+/de/ exon 1-6;EGFP mice

We next evaluated the expression of two cubilin-binding membrane proteins,
megalin and amnionless, in proximal tubules of Cubn +/de/ exon 1-6;EGFP mice. As shown in

Figure 2-2A, anti-megalin immunolabeling was relatively uniform in the brush border
regions of all proximal tubules. Furthermore, the relative levels of megalin
immunolabeling were uniform among all pro?\!~j1- tubules, irrespective of the varied
levels of anti -cubilin immunolabeling (Fig. 2-2A and B boxed areas). Based on these
findings, cubilin deficiency resulting from monoallelic inactivation in Cubn +/de/ exon 16;EGFP

mice apparently has no effect on the expression of megalin ~n the renal proximal

tubule brush border. By contrast, immunofluorescence analysi~ of amnionless showed
that in proximal tubules having little or no anti -cubilin labeling, amnionless accumulated
within the proximal tubule cells as compared to proximal tubule cells having high levels
of anti-cubilin labeling (Fig. 2-2D-F). These findings are consistent with previous studies
showing that cubilin prevents intracellular accumulation of amnionless [31].

Expression of cubUin in the intestine

EGFP-fluorescence (hereafter referred to as cubilin-EGFP fluorescence) was
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EGFP fluorescence was detected in all segments of the small intestine, i"e., duodenum,
jejunum and ileum (Fig. 2-3).

Cubilin expression in the duodenum had not been previously reported. To
substantiate this, anti-cubilin immunoblot analysis of intestinal extracts from wild-type
mice was performed (Fig. 2-3D). Similar to what has been observed in rat and canine
ileal extracts [131, 153], mouse ileum and jejunum extracts contained ",460 kDa
monomer, multimer and ",200 kDa forms of cubilin. Cubilin was also detected in extracts
of the duodenum, however the stoichiometry of the various immunoreactive forms in the
duodenum was different from that of ileum and jejunum (i.e., levels of cubilin multimer >
monomer> ---200 kDa forms). The cubilin metn~ane anchor, amnionless, was detected in
all three segments of the small intestine, as was the cubilin ligand intrinsic factor (Fig. 2SD). Megalin expression in the small intestine was also examined and highest levels were

detected in the ileum and jejunum and lowest levels in thelduodenum (Fig. 2-3D).
\

In all three segments of the small intestine, cubilin-EGFP fluorescence was found
in patches of intestinal villi, with regions of relatively strong fluorescence interspersed in
areas of little or no fluorescence. Closer examination revealed that cubilin-EGFP
fluorescence was in discrete segments of each villus (Fig. 2-3E-H).

To test the hypothesis that cubilin is monoallelically expressed in the small
intestine, we performed qPCR analysis on microdissected villi from the ileum of
Cubn +/del exon 1-6;EGFP mice that were predominantly either EGFP positive, EGFP negative
or both. If cubilin expression were biallelic, then the expectation would be that both
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cubilin and EGFP mRNA would only be detected in EGFP-positive cells and no cubilin
or EGFP mRNA would be detected in EGFP-negative enterocytes. However, as shown in

Figure 2-31, cubilin mRNA was not only detected in EGFP-negative enterocytes, it was
also significantly higher as compared to EGFP-positive cells. Conversely, EGFP-negative
enterocytes expressed significantly lower EGFP mRNA levels as compared to EGFPpositive cells (Fig. 2-31). Based on these findings the cubilin gene appears to be largely
expressed from one allele in intestinal cells (i.e., monoallelic expression).
We next examined sections of small intestine from Cubn +/del exon 1-6;EGFP mice after
immunolabeling with antibodies to cubilin and EGFP. Anti -cubilin IgG-reactive material
was apparent as a discrete layer on the apical surfaces of anti-EGFP-positive enterocytes
as well as anti-EGFP-negative enterocytes

(Fig:~)-4A,

arrowheads). In addition, anti-

cubilin immunolabel was also detected within the cytoplasm of ileal enterocytes as
punctate foci located on the apical side of the nuclei (Fig. 2-4A, arrows). This
cytoplasmic staining was present in both anti-EGFP-posidve and anti-EGFP-negative
enterocytes. Thus, despite EGFP-positive enterocytes having significantly lower
expression of cubilin mRNA (Fig. 2-31), they appear to have similar cubilin protein
levels compared to EGFP-negative enterocytes, which have higher expression of cubilin
mRNA. These findings are consistent with the fact that cubilin is known to be secreted
and taken up by enterocytes [39, 154]. As such, enterocytes with the active wild-type
cubilin allele might express and secrete cubilin, which could then bind to EGFP-positive
enterocytes and result in similar levels of cubilin protein in all enterocytes.
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Amnionless in the intestine of Cubn+/de/ exon 1-6,'EGFP mice

We also perfonned anti -amnionless labeling of sections of small intestine from
Cubn +/del exon 1-6,·EGFP mice. Amnionless immunolabeling was present on the cell surface

and in the cytoplasm of EGFP-positive and EGFP-negative enterocytes (Fig. 2-4C and
D). There were no apparent differences in the relative levels or in the subcellular

localization of amnionless between EGFP-positive and EGFP-negative enterocytes. This
is in contrast to what was seen in the kidney, in which amnionless accumulated within
EGFP-positive proximal tubule cells as compared to EGFP-negative proximal tubule
cells (Fig. 2-2F).

Intrinsic factor in the intestine of Cubn+/de/ exon 1-6;EGFP mice

Cubilin expressed by intestinal enterocytes mediates binding and endocytosis of
l

intrinsic factor-cobalamin complex from the intestinal lumen [15S]. Ileal segments from
Cubn +/del exon 1-6;EGFP mice were examined for immunolocalization of intrinsic factor in

cubilin-EGFP-positive and cubilin-EGFP-negative enterocytes. As shown in Figure 2-4E
and F, intrinsic factor immunolabeling was observed on the apical surfaces (Fig. 2-4E,
arrowheads) and within the cytoplasm of both EGFP-positive and EGFP-negative

enterocytes. There was no apparent difference in the relative level of anti-intrinsic factor
immunolabel in EGFP-positive and EGFP-negative enterocytes (Fig. 2-4F). This was
similar to the pattern of intrinsic factor immunolabeling observed in the wildtype
intestine (Fig. 2-4G and H). Based on these observations, the pattern of intrinsic factor

uptake corresponds to anti-cubilin immunolabel found on all enterocytes (Fig. 2-4A),
regardless of the mosaic pattern of cubilin-EGFP or cubilin mRNA expression.

Epigenetic regulation of cubUin

Several lines of evidence suggest that one of the two cubilin alleles may be
inactivated epigenetically in the kidney and intestine: 1) EGFP expressed from the
targeted cubilin allele displays a distinct mosaic pattern in the kidney and intestine, 2)
proximal tubule cells expressing the targeted cubilin allele expressed little or no cubilin
and displayed reduced binding of albumin, suggesting that the wild-type cubilin allele in
these cells was inactive, and 3) EGFP-negatiy~~pterocytes express significantly higher
,

I,

levels of cubilin mRNA as compared to EGFP-positive cells in Cubn +/del exon 1-6;EGFP mice.
Inactivation of the cubilin allele might occur through epigenetic modifications that
control the transition of chromatin from transcriptionally active t~ inactive state. Histone
deacetylation and DNA methylation at CpG sequences are tWQ types of epigenetic
modifications that mediate transcriptional inactivation.

CubUin promoter lacks conserved CpG islands

To determine whether DNA methylation regulates cubilin transcription, we first
analyzed the regions flanking the transcription start site of the mouse cubilin gene for
CpO islands using the CpG island analysis feature of the UCSC Genome Browser and the
EMBOSS CpGPlot algorithm [156,157]. Analysis of5' flanking sequences extending
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from approximately -20,000 to + 3,SOO relative to the transcription start site of the mouse
cubilin gene did not detect any CpG islands (data not shown). A similar analysis of the
human and rat cubilin genes using the CpG island analysis feature of the UCSC Genome
Browser did not detect any CpG islands. These findings did not preclude the possibility
that cubilin expression in these species might be regulated by non-CpG DNA methylation
[IS8]. It is also possible that DNA methylation indirectly regulates cubilin transcriptional

activation.

Effects of 5Aza on cubilin in NRK and Caco-2 cells
We therefore evaluated the effects o.{!?~PNA methylation inhibitor, S.'/

azacytidine (SAza), on cubilin expression in renal NRK cells and intestinal Caco-2 cells.
In NRK cells, SAza treatments augmented cubilin mRNA expression as measured by
qPCR (Fig. 2-5A). In Caco-2 cells, 1 and 5 JlM 5Aza treatments augmented cubilin
expression, but 10 JlM 5Aza decreased cubilin expression (Fi~. 2-5C) as compared to the
vehicle control. These findings suggested that DNA methylation was directly or
indirectly regulating cubilin expression in cultured renal and intestinal epithelial cells.
The effect of SAza treatment on the expression of megalin was also evaluated in these
cells. SAza treatment stimulated megalin expression in NRK cells (Fig. 2-5B), but
inhibited megalin expression in Caco-2 cells (Fig. 2-5D).
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Effects of TSA on cubilin in NRK and Caco-2 cells
We next evaluated the effects of the histone deacetylase (HDAC) inhibitor,
trichostatin A (TSA), on cubilin mRNA expression in NRK and Caco-2 cells. TSA
treatment elicited a concentration dependent increase in cubilin mRNA expression in
both cell lines (Fig. 2-SE and 6). The magnitude of the effect ofTSA on cubilin
expression was generally greater than that achieved using 5Aza. TSA treatment also
augmented megalin expression in both NRK and Caco-2 cells (Fig. 2-SF and H).

Effects of 5Aza and TSA on cubilin monoallelic expression in PRTCs and in vivo
To determine whether allelic inacti\'~tlJlof the cubilin gene might be released by
5Aza or TSA treatment, we employed primary renal tubule cells (PRTCs) isolated from

Cubn +/del exon 1-6;EGFP kidneys. Following isolation of these cells, we consistently observed
l

that <10% of the cultured PRTCs were EGFP-positive which is in contrast to the
\

approximately 1: 1 ratio of EFGP-positive to EGFP-negative cells in proximal tubules as
assessed by immunofluorescence microscopy. The basis for this observation remains to
be defined but it may be an indication that cubilin deficiency in PRTCs might reduce
their migration out of tubules onto the culture plate, inhibit adhesion to the culture plate,
or reduce cell proliferation in vitro.

The mixed population ofPRTCs (i.e., EFGP-positive and EGFP-negative PRTCs)
isolated from Cubn +/del exon 1-6;EGFP kidneys were treated with TSA. TSA treatment
(10nM) resulted in a --2-fold increase in cubilin mRNA levels (Fig. 2-6A), but the effect
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was reduced at higher concentration. TSA treatment also increased megalin mRNA levels

(Fig. 2-6B). Immunoblot analysis of extracts from TSA-treated PRTCs was also
performed and the results showed that both cubilin and megalin protein expression was
augmented by the treatment (Fig. 2-6C). Furthermore, immunoblot analysis of extracts
from 5Aza treated PRTCs was performed and the results showed that both cubilin and
megalin protein expression was augmented by the treatment (Fig. 2-6C).

We next reasoned that if 5Aza or TSA treatment were able to transform cubilin
monoallelic expression to biallelic, then we should observe an increase in the number of
anti-EGFP positive cells. We therefore determined the percent ofEGF-positive cells in
21 imaged fields ofDMSO treated PRTCs and in 34 imaged fields ofTSA treated (10
nM) PRTCs. As shown in Figure 2-6D, TSAilJ!}ltment ofPRTCs did not elicit a
,

I,

significant change in the percentage of anti-EGFP positive PRTCs as compared to vehicle
treated cells (also see Supplementary figure 1). Similarly, PRTCs treated with 5Aza did
not lead to an increase in the number of anti-EGFP positi{re cells ~s compared to vehicle
treated cells (data not shown). In these 5Aza experiments, PRJC proliferation was
inhibited by 5Aza treatment to a much greater extent than was observed for NRK cells.
Since TSA or 5Aza treatment did not increase the number ofEGFP expressing cells, we
concluded that cubilin monoallelic expression was not effected by either treatment.
Evaluating the effects of combined TSA and 5Aza was not possible due to the
detrimental effects that the combined drugs had on PRTC growth. For this reason, we
evaluated the effects of combined TSA and 5Aza treatment using NRK cells. The results
showed that the stimulation of cubilin mRNA expression achieved by combined TSA and
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5Aza treatment was not greater than that observed with TSA, which consistently elicited
the greatest magnitude increase (data not shown).

To determine ifTSA treatment changes cubilin expression in vivo, age-matched
male Cubn +/del exon 1-6;EGFP and WT mice were treated with TSA at 2 Jlgig of mouse body
weight. TSA treatment resulted in significantly increased cubilin mRNA expression in
the ileum of Cubn +/del exon 1-6;EGFP mice (Fig. 2-7A). TSA treatment also increased megalin
mRNA levels in both WT and Cubn +/delexon 1-6;EGFP mice (Fig. 2-7B). We reasoned that if
TSA treatment transforms cubilin monoallelic expression to biallelic, we should observe
significantly increased number of Cubn-EGFP expressing villi. However, TSA treatment
did not appear to increase the number of Cubn-EGFP expressing villi in the intestine of

Cubn +/del exon 1-6;EGFP mice (Fig. 2-7C and D)~~ematively, the Cubn-EGFP fluorescence
intensity appears to be increased with TSA treatment, indicating increased cubilin-EGFP
expression from the active allele. These observations indicate that although intestinal
cubilin expression is increased by TSA treatment, cubilin'monoallelic expression is not
transformed to biallelic.

Epigenetic regulation of cubilin via PPARs
The above findings suggested that TSA and 5Aza treatment increased cubilin
expression by increasing the transcription of the active cubilin allele. HDACs, which are
inhibited by TSA, are known co-repressors of the transcription factors, Peroxisome
Proliferator-Activated Receptor (PP AR) [159-162]. Conversely, PP AR co-activators
increase histone acetylation, resulting in PPAR -mediated transcription [159, 161-163].
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Recent studies show that the expression ofPPAR-y is also regulated by DNA methylation
[164] and histone deacetylation [162]. Furthennore, renal megalin expression is known to
be regulated by PP ARs [62]. We therefore tested whether epigenetic regulation of PP ARs
mediated the effects of 5Aza and TSA on cubilin and megalin expression. Computerized
transcription factor binding site analysis identified three PPAR response elements
conserved in human and mouse cubilin promoters (Fig. 2-8). Analysis of cubilin
promoter activity in cells transfected with a cubilin promoter-Iuciferase reporter found
that cubilin transcription was increased by transfection of cells with PP ARa and y
expression constructs (Fig. 2-8B-D). Furthennore, endogenous cubilin (and megalin)
mRNA expression in NRK cells was blocked by the PPARa and y antagonists, GW6471
and GW9662 (Fig. 2-8E and F). To further evaluate the role of PP ARs in regulating
-~I /1
,"

cubilin expression, we utilized PRTCs. PPARa agonist, Wy14643, treatment ofPRTCs
resulted in a significant increase in cubilin protein levels over a range of agonist
concentrations (Fig. 2-9A). Cubilin mRNA levels were

al~o

significantly increased by

PPARa agonist treatment at 100JlM concentration (Fig. 2-9C). By contrast, PPARa
antagonist, GW6471, significantly decreased endogenous cubilin mRNA expression and
also inhibited the increased cubilin expression achieved by agonist treatment (Fig. 2-9D).
PPARa agonist and antagonist treatments resulted in similar reciprocal changes in the
mRNA levels of A cadI, a known PP ARa-responsive gene [165, 166] (Supplementary

figure 2). Treatment of PRTCs with the PP ARy agonist (Rosiglitazone) also resulted in a
significant increase in cubilin protein levels (Fig. 2-9E). Rosiglitazone at 50nM
concentration also elicited a modest, but significant increase in cubilin mRNA expression
(Fig. 2-9G). Furthennore, the PP ARy antagonist, GW9662, inhibited the increased
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cubilin expression achieved by Rosiglitazone treatment (Fig. 2-9H). Together, these
findings indicate that, similar to megalin [62], cubilin is a gene regulated by both PP ARa
andy.

We next evaluated the effects of 5Aza and TSA on the expression ofPPARa and
yin NRK cells. As shown in Figure 2-l0A, 5Aza treatment elicited a dose dependent
increase in PP ARa mRNA expression. 5Aza also augmented PP ARy expression (Fig. 2lOB) at low concentrations but not at the highest concentration tested (10 JlM). Similarly,

TSA treatment ofNRK cells also produced a concentration dependent increase in PPARa
mRNA levels (Fig. 2-l0C). TSA also increased PPARy expression at the highest
concentration tested (100 nM) (Fig. 2-l0D).

f

'~:'I
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The observations that TSA and 5Aza increased PPARa and y mRNA levels
suggested the possibility that cubilin upregulation by TSA and 5Aza resulted from
increased expression ofPPAR. We therefore evaluated th~ effects ofPPARa and y
antagonists on TSA and 5Aza induction of cubilin expression> As shown in Figure 2lOE, the upregulation of cubilin by 5Aza was inhibited by PPARy antagonist as well as

combined PP ARa and y antagonist treatments. Acadl, a known PP ARa responsive gene
[165, 166], was also increased by 5Aza treatment and the increase was inhibited by
PP ARa antagonist treatment (Supplementary figure 2B). These findings suggested that
the 5Aza-induced expression of cubilin is dependent on 5Aza-induced expression of
PP ARy. Parallel studies showed that 5Aza-mediated induction of megalin expression was
also dependent on 5Aza-induced expression of both PPARa and y (Fig. 2-l0F).
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The effects ofPPARa and y antagonists on TSA-induced cubilin expression were
also evaluated. Results showed that cubilin upregulation by TSA was inhibited by
PP ARa antagonist as well as combined PP ARa and y antagonist treatments (Fig. 2-

lOG). The fact that combined PP ARa and y antagonist treatment produced a greater
magnitude decrease than either antagonist alone suggested that TSA-induced expression
of cubilin is dependent on TSA-induced expression of both PP ARa and y. Parallel studies
showed that TSA-induced expression of megalin was also dependent on TSA-induced
expression of both PPARa and y (Fig. 2-10H). A cadi levels were also increased in
response to TSA treatment and the increase inhibited by PP AR antagonist treatment

(Supplementary figure 2C).
We next tested whether the increase((tr~~scription of PPARs was sufficient to
induce cubilin expression or whether the epigenetic modifiers also influenced the
activation state of PP AR. NRK cells were transfected with a PP ARa expression
l

construct, which greatly increased levels ofPPARa mRNA (Fig. 2-11A). However, the
\

increased PPARa levels alone did not increase cubilin mRNA levels (Fig. 2-11B).
Similarly, the addition of PP ARa agonist alone did not alter cubilin expression (Fig. 2-

lIB). Yet the combination ofPPARa overexpression and PPARa agonist treatment
caused a significant increase in cubilin mRN A expression. These findings indicate that
under normal conditions PP ARs are fully active in NRK cells and the addition of an
agonist alone does not increase cubilin expression. Thus, both PP ARa upregulation and a
PP ARa agonist are required to augment cubilin expression. When control transfected
cells were treated with TSA there was a 4-fold increase in cubilin expression (Fig. 2-
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lIB). The addition of agonist to these cells did not elicit any further increase (Fig. 2lIB). By contrast, PPARa overexpression combined with TSA treatment caused an 8fold increase in cubilin expression. As with controls, the addition of agonist to these cells
did not significantly increase the level of cubilin expression (Fig. 2-IIB). These findings
indicate that the TSA mediated increase in cubilin expression not only involves an
increase in PP AR transcription but also PP AR activation.

Discussion

Here we present evidence that the cubilin gene undergoes allelic inactivation. The
t

evidence includes findings showing that

,j,"

cubilip:~xpression

in the kidneys of mice

I,

heterozygous for targeted cubilin deletionlEGFP insertion is mosaic such that some
proximal tubule cells display active expression of EGFP (i.e., the targeted allele) as well
as suppressed expression of the wild-type cubilin allele, while oth.er proximal tubule cells
display the inverse pattern. Mosaic expression of cubilin was also observed in all three
segments of the small intestine, with cubilin-EGFP fluorescence found in discrete
segments of each villus. Additional support for enterocytes displaying allelic inactivation
of the cubilin gene came from qPCR studies of Cubn +/del exon 1-6;EGFP mice showing that
cubilin mRNA levels were significantly reduced in isolated regions of the small intestine
expressing EGFP as compared to non-EGFP expressing regions. At the protein level,
unlike what was seen in the kidney, enterocytes displayed both expression of the cubilin
allele bearing the targeted deletionlEGFP insertion and contained immunologically
detectable cubilin. Since enterocytes have been shown to release cubilin in association
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with extracellular surfactant-like particles [39], which bind to the apical portion of the
cell [154], it is reasonable to expect that cubilin expressed in some enterocytes from the
wild-type cubilin allele is being released and taken up via cubilin binding receptors (e.g.,
megalin and/or amnionless) expressed by enterocytes in which the wild-type cubilin
allele is suppressed. Furthermore, this form of cubilin appears to be capable of
endocytosis of its ligand, intrinsic-factor cobalamin complex, since intrinsic factor uptake
was similar in enterocytes with suppressed wild-type cubilin allele and those with an
active wild-type cubilin allele.

Unlike what was observed in the kidney where amnionless accumulates
intracellularly in cubilin-deficient cells, the consequences of cubilin deficiency on
amnionless trafficking in intestinal cells was;RO~~lear. Based on our intestinal data, we
speculated that a secreted form of intestinal cubilin might act in a non-cell autonomous
manner to prevent the accumulation of amnionless in enterocytes having lower
endogenous cubilin expression. It is also important to poirlt out that the intestine appears
to express multiple cubilin and amnionless isoforms, which have different stoichiometries
in the kidney (Fig. 2-3D). Therefore, it is possible that in the intestine, cubilin and
amnionless trafficking to the apical cell membrane are not interdependent.

The finding that 5Aza and TSA treatments were unable to release the suppression
of the silenced cubilin allele suggests that DNA methylation and histone deacetylation
may not be the only mechanisms of regulation of cubilin mono allelic expression. Indeed,
diverse mechanisms exist to mediate allelic inactivation including interplay of DNA
modifications by DNA methylation and modifications of the histone proteins by
acetylation, methylation, SUMOylation or phosphorylation [167, 168]. Additionally,
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imprinted monoallelic expression of certain gene clusters is in part mediated by
noncoding RNAs under the control of methylation of imprint control elements [167].
Intriguingly, the cubilin gene is located in the mouse chromosome 2 proximal region,
which is one of several chromosomal regions known to contain genes that undergo
parental imprinting during development [169, 170]. Our observation that groups of
adjacent proximal tubule cells shared the same inactive cubilin allele suggests that the
allelic inactivation is inherited clonally from a progenitor that underwent imprinting
during development. Further research will be required to define the precise mechanisms
regulating cubilin monoallelic expression.

Since cubilin monoallelic expression was unaltered by 5Aza and TSA treatments,
,

we concluded that the increased cubilin mRNA11"els were due to effects of these agents
,

(,

on the transcriptionally active cubilin allele. Both histone deacetylation and DNA
methylation are associated with PP AR repression [162, 164]. In fact, HDAC 1 and 3 are
known PPARy co-repressors [171-173]. Conversely, PPAR co-activators, such as

CBP/p300 and SRC-1, possess histone acetylase activity required for chromatin
remodeling to allow PPAR-mediated transcription [162, 163, 174, 175]. Furthermore,
recent findings show that the cubilin coreceptor, megalin, is a PP AR -responsive gene and
its expression is augmented through inhibition of histone deacetylation [62, 135]. In light
of these studies, we recognized the possibility that the observed effects of TSA and 5Aza
on cubilin might also involve PP AR induction. This led us to discover that the observed
effects of 5Aza and TSA on cubilin expression were dependent on PP ARa and y
induction. Specifically, we showed that cubilin was a PP ARa and y responsive gene, that
the expression ofPPARa and y was inducible by 5Aza and TSA alone, and that the
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effects ofTSA and 5Aza on cubilin expression were dependent on increased expression
of PP ARa and y. Similarly, we showed that TSA and 5Aza-induced megalin expression
was dependent on increased expression ofPPARa and y.

While TSA and 5Aza treatments augmented PP AR and cubilin mRNA levels, no
significant increase in cubilin levels was achieved by overexpressing PP ARa in the
absence ofPPARu agonist. Therefore, the effects ofTSA and 5Aza on cubilin mRNA
levels cannot be attributed to increased PP AR mRNA levels alone. We inferred that, in
addition to increasing PP AR expression, 5Aza and TSA treatments must also lead to
PP AR activation. The underlying mechanism for the apparent agonist-independent effects
of TSA on induction of PP AR-dependent transcription of cubilin remains to be
.',

established. TSA and/or 5Aza might

..t

augmenfl~('els of endogenous PP AR agonists, cause

demethylation of sites on the cubilin gene, or reduce histone occupancy of the cubilin
promoter. Any of these effects might be sufficient for promoting PP AR action in an
l

agonist-independent manner. Since HDACs are known co-repressors and HATs are coactivators ofPPARs [162], it is reasonable to expect that inhiBiting HDAC activity will
shift PP ARs towards a more active state. In fact, HDAC inhibitors have been reported to
act as atypical PP AR agonists [161] and studies have shown that inhibition of HDACs
stimulates transcription ofPPAR responsive genes [171, 176]. Therefore, it is likely that
increased acetylation of histones associated with the cubilin promoter in response to
HDAC inhibitor treatment is sufficient to promote PPAR-driven cubilin expression.

Our findings that cubilin and megalin expression is regulated by DNA
methylation and histone deacetylation raise questions as to whether these genes might be
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predisposed to inactivation by disease-associated increases in DNA methylation and
histone deacetylation. DNA methylation is a major contributing factor to various diseaserelated processes, such as tumorigenesis, atherogenesis and diabetic nephropathy [177179] (including glomerular and interstitial fibrosis [180]). Global DNA
hypennethylation is associated with inflammation and increased mortality in chronic
kidney disease [181] and chronic inflammation has even been implicated as a driving
factor associated with increased DNA methylation in diseases such as chronic gastritis
and gastric cancer [182, 183]. Furthennore, the inflammatory cytokine, IL-6, exerts an
impact on epigenetic changes in cells via regulation of DNA methyltransferase [184].
Histone deacetylation catalyzed by HDACs also contributes to the pathogenesis of
various diseases including gastric and colorectal cancer [185, 186], renal disease such as

. ~~, t,·

polycystic kidney disease [187] and macrophage infiltration and fibrotic changes
associated with tubulointerstitial injury [188].
HDAC inhibitors appear to have significant therap~utic potential in kidney
disease [189]. For example, a number of studies have demonstrated efficacy ofTSA in
ameliorating renal injury in mice following unilateral ureteral obstruction [188],
nephrotoxic serum nephritis [190] and in lupus pathogenesis [191]. In light of findings
presented herein, it is possible that drugs that inhibit HDACs might ameliorate renal
disease by releasing epigenetic suppression of PP ARs, cubilin and megalin. Intriguing
new findings from rodent studies highlight the potential reno-protective benefits of
increased megalin expression on early phase renal injury in responses to protein overload
[62]. Specifically, the studies showed that megalin expression in rats is decreased by
BSA overload and that augmenting megalin expression in rats by PP ARy agonist
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treatment correlated with a reduction in BSA-induced proteinuria. Effects of PP AR
agonist treatments on renal expression of the albumin receptor, cubilin, were not
evaluated in those studies. Thus, it was not clear whether the mechanistic basis for the
observed effects involved PPAR agonist induced changes in cubilin expression. Our
studies demonstrate that cubilin, like megalin, is under PP AR transcriptional regulation
and suggest that the amelioration of protein overload-induced albuminuria by PP AR
agonists observed in other studies is mediated by augmented levels of cubilin.

Future directions

Cubilin mono allelic expression

In this study, we demonstrated that cubilin expression in the kidney and intestine
is predominantly from one allele, i.e. monoallelic expression. This monoallelic
l

expression could not be transformed to biallelic by treating RPTC from adult mice with
TSA or 5Aza, which inhibit HDACs and DNA methylation re~pectively. We postulated
that DNA methylation and histone deacetylation might not be the only mechanisms of
regulation of cubilin monoallelic expression. Cubilin monoallelic expression might be
regulated by interplay of diverse epigenetic processes, including DNA methylation;
modifications of the histone proteins by acetylation, methylation, SUMOylation or
phosphorylation; and noncoding RNAs under the control of methylation of imprint
control elements [ 167, 168]. Alternatively, cubilin monoallelic expression might be
determined in embryonic development. Indeed, the cubilin gene is located in the mouse
chromosome 2 proximal region, which is one of several chromosomal regions known to
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contain genes that undergo parental imprinting during development[ 169, 170].
Furthermore, our observation that groups of adjacent proximal tubules or intestinal villi
shared the same inactive cubilin allele suggests that the allelic inactivation is inherited
clonally from a progenitor that underwent imprinting during development. It is
conceivable that epigenetic mechanisms such as DNA methylation or histone
deacetylation have different roles during development and in adult cells, e.g. determining
allelic inactivation in development and regulating the expression of the active allele in
adults. Therefore, future studies should test the effect of inhibiting DNA methylation or
histone deacetylation during embryonic development on adult cubilin expression.
Preliminary experiments showed that dams treated with 2J.!M 5Aza 14.5 and 16.5 days
post coitus were able to carry pregnancy to teon .. Strikingly, cubilin expression appeared
r~1 };'i
to be decreased in the intestine of 16-day-old pups from one of these pregnancies
.

compared to vehicle treatment. The fact that the effect of 5Aza treatment during
development was passed on to juvenile pups lends furtherlsupport to the hypothesis that
cubilin allelic expression might be determined during development. Further such
\

experiments with different concentrations of 5Aza and other epigenetic modifiers are
required to elucidate the regulation of cubilin expression during development.

Cubilin expression, function and interaction with amnionless in the intestine
Our observation that enterocytes with deficient endogenous cubilin mRNA
expression contained immunologically detectable cubilin is consistent with previous
studies showing that cubilin fragments are secreted and taken up by enterocytes [39,
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154]. This form of cubilin appears to be capable of endocytosis of its ligand, IF-B12, since
intrinsic factor uptake was detected in enterocytes with deficient endogenous cubilin
expression. Future work is required to demonstrate that exogenous administration of
cubilin protein in vitro would result in cubilin-mediated endocytosis of cubilin ligands.

Unlike the renal proximal tubule cells where amnionless accumulates
intracellularly in cubilin-deficient cells, enterocytes lacking endogenous cubilin
expression did not have amnionless intracellular accumulation. It is not clear whether the
secreted form of cubilin prevents amnionless intracellular accumulation or whether the
intestinal cubilin and amnionless isoforms are not interdependent in their trafficking to
the apical membrane. Future work can resolve this by in vitro knock down of cubilin,
,

amnionless or both in intestinal cells, and

anaL~}ng

cubilin and amnionless expression at

the apical membrane. Furthermore, cubilin and amnionless protein within and at the
surface of enterocytes as well as in intestinal lumen content should be isolated and
sequenced. This might identify the secreted form of cubilih and also reveal which
intestinal cubilin isoforms have the amnionless binding site. \

The role of cubilin in the intestinal absorption of nutrients is very important, yet
poorly understood. Presently, IF-B12 complex is the only identified ligand for cubilinmediated endocytosis in the intestine[ 4 7]. Since cubilin is a multi -ligand receptor known
to bind many ligands, it is highly likely that cubilin mediates the absorption of other
nutrients in addition to vitamin-B 12 . Future work should explore the possibility that
cubilin might mediate the absorption of other vitamins in the intestine. One approach that
might be a good starting point would be to purify cubilin and cubilin-bound material from
the intestine, and perform protein sequencing and mass spectrometry analysis to identify

58

proteins and other material bound to cubilin. This might reveal numerous candidates for
intestinal cubilin-mediated absorption of nutrients.

PPAR regulation of cubilin expression in kidney diseases
Our studies demonstrated that cubilin expression is upregulated by PP ARs, which
are themselves regulated by epigenetic modifications, i.e. DNA methylation and histone
deacetylation. Evidence suggests that decreased renal cubilin expression in diseases such
as diabetes and acute kidney injury might involve decreased PP AR expression or activity
[10, 11, 64, 66-68]. This link has to be directly established in future studies. Furthermore,
the effect of increased cubilin expression by l~~foent with PP AR agonists on disease
,

I,

outcomes such as proteinuria and overall renal function should be studied.

Epigenetic modifiers, such as treatment with HDAC inhibitors, have been shown
l

to lead to better disease outcomes in models of acute kidney injury in rodents [188-190].
\

There is also evidence that diabetic nephropathy might be ameliorated by treatment with
epigenetic modifying inhibitors [192, 193]. It is not clear whether these effects of
epigenetic modifiers are dependent on increased cubilin or PPAR expression and activity.
Cubilin and PP AR expression and function should be tested in these disease models with
and without treatment with epigenetic modifiers. To tease out the dependence of the
beneficial effects of epigenetic modifiers on PP AR activity, treatment with epigenetic
modifiers could be compared with PP AR agonists alone in these diseases.
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reduced albumin binding to brush borders of cubilin-deficient renal proximal
tubules cells.
A shows a confocal micrograph ofa section of wild type mouse kidney labeled with
anti-cubilin IgG (red) and the nuclear stain, DraqS. B shows a confocal image from a
section ofa Cub"+/d,/,x.,, / -6;£GFP mouse kidney labeled with anti-cubilin and DraqS.
Asterisks indicate proximal tubules displaying relatively low levels of anti-cubilin
immunolabeling. C and D are merged images of anti-cubi lin immunolabeling (red)
and anti-EGFP immunolabeling (green) and nuclear staining,(blue}. D is a digitally
zoomed in view of the boxed area in C. E and G show confocal imajles of antialbumin labeled sections from wildtype (E) and Cub,,+ld,/,x., /-6;£GF (F) mouse
kidneys. F and H show images of the sections shown in £ and G merged with antiEGFP labeling_ G, glomerulus.
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Figure 2-2. Megalin expression is uniform whereas amnionless accumulates in
.
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un +/d,1 ~,"n 1-6 ''EGFP nuce.
A-C show confocal images of a section of C ubn +ldel ,xon Ir 6:EGFP mouse kidney labeled
with anti-megalin IgG (A), anti-cubilin (8). C is a merged image of anti-megalin and
anti-cubilin immunolabeling together with DraqS nuclear sta,ining (blue). Boxed areas
in A and 8 highlight an example of a proximal tubule displaying strong anti-megalin
immunolabeling and relatively weak anti-cubilin labeling. D shows a confocal image
from a section of a C ubn +/d,1,xon 1-6:EGFP mouse kidne~ labeled with anti-amnionless
(Amn). E is a merged image of the section ofCubn +d,I,xon 1-6:EGFP mouse kidney
shown in D labeled with anti-amnionless, anti-cubilin and the nuclear stain, DraqS
(blue). F is a digitally zoomed in view of the boxed areas in D and E showing a
proximal tubule displaying strong anti-cubilin immunolabeling adjacent to two
proximal tubules with little or no anti-cubilin labeling. Arrowheads indicate
intracellular accumulations of Amn immunolabeling. G, glomerulus.
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Figure 2-3. Cubilin expression in the intestine of Cubn+/de/ exon 1-6;EGFP mice.
A-C show images ofEGFP fluorescence in the luminal surface of whole mount
segments of the duodenum (A), jejunum (B) and ileum (9) from a Cubn +!del exon 1-6;EGFP
mouse. D shows an immunoblot analysis of detergent e~tracts of segments of the
intestine and kidney using antibodies to cubilin, megalin, amnionless (Amn), intrinsic
factor (IF) and tubulin. E is a DIC image of the luminal face,of the small intestine
(ileum) from a Cubn +!del exon 1-6;EGFP mouse. F is an epifluorescence image showing
EGFP fluorescence in the epithelial cells of the intestinal villi shown in E. Note the
mosaic pattern of cubilin-EGFP fluorescence. G is a cross section of the small
intestine from a Cubn +!del exon 1-6;EGFP mouse showing cubilin-EGFP expression in
patches of villi. H is a high magnification view of a cluster of villi showing segmental
cubilin-EGFP expression in epithelial cells within individual villi. I is a qPCR analysis
of cubilin and EGFP mRNA levels in microdissected intestinal villi segments (n=4
mice) that were either predominantly EGFP-positive, negative or both. Asterisks
indicate that mRNA levels measured in EGFP-positive or EGFP-negative villi were
significantly different (p<O.05) from the levels in RNA prepared from villi containing
both EGFP-positive and EGFP-negative cells. Pound signs indicate that mRNA levels
measured in EGFP-positive villi were significantly different (p<O.05) from levels in
EGFP-negative villi.
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Figure 2-4. Subcellular localization of cubilin, amnion less and intrinsic factor in
ileal enterocytes.
A shows a confocal image from a section of a Cub" +/d, /,-,"" /·6:£GFP mouse ileum
labeled with anti ·cubilin. B is a merged imi}!ie-?fthe section of Cub" +/de/exo" /·6:£GFP
mouse intestine shown in A labeled with anti.6ubilin and anti-EGFP together with
DraqS nuclear staining (blue). Arrowheads in A and B point to anti-cubilin label on the
apical surfaces of enterocytes. Arrows in A and B point to anti·cubilin label in the
cytoplasm of anti-EGFP·positive enterocytes. Asterisks in B indicate goblet cells
devoid of anti-EGFP labeling and lacking apical anti-cubilin labeling. C shows a
confocal image from a section of a Cub" +/d, / exon /·6: £GFP !nouse ileum labeled with anti·
amnionless. D is a merged image of the section of Cub" +/de/ exon /·6:£GFP mouse intestine
in C showing cubilin-EGFP expression together with DraqS puclear labeling.
Arrowheads in C and D point to anti-amnionless label on the apical surfaces of
enterocytes. Arrows in C and D point to anti-amnionless label in the cytoplasm of
EGFP-positive enterocytes. E shows a confocal image from a section of a Cub" +/de/ exo"
/ ·6:EGFP mouse ileum labeled with anti-intrinsic factor (IF). F is a merged image of the
section of Cub" +/d, / « 0" /·6:£GFP mouse intestine in £ together with cubilin-EGFP
expression. Arrowheads in £ point to anti-intrinsic factor IgG-reactive material present
on the surfaces of both anti·EGFP·positive and anti-EGFP·negative enterocytes. G
shows a confocal image from a section of a wildtype mouse ileum labeled with anti·
intrinsic factor. H is a merged image of the section of the wildtype mouse intestine
shown in G together with the image from the EGFP channel.
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Figure 2-5. 5Aza and TSA elicit increases in cubilin expression in NRK and Caco2 cells.
A-D, qPCR analysis of cubilin and megalin mRNA expression in RNA isolated from
NRK and Caco-2 cells cultured for 60 h with three medium changes and 84 h with
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Figure 2-6. TSA or 5Aza treatment does not have an effect on cubilin mono allelic
expression in PRTCs.
A, upstream flanking sequence of the mouse cubilin gene (Cubn). Putative
PP ARlRXR heterodimer binding sites, identified by Genomatix DiAlign, are
indicated. Sequence elements are numbered relative to t\le translation start site (+ 1). B ,
representation of the pCub -431 Luc mouse Cubn promoter construct containing
mouse Cubn proximal flanking sequence (-431 to -5), including the -97 putative
PPARlRXR binding element (shaded box), linked to a luciferase cassette. C, an
established PP AR reporter construct is transactivated by PP ARu and PP ARy in
transfected BN cells. Reporter plasmid (pPPRE X3-TK-Iuc) was cotransfected with
either a PP ARu expression plasmid (pSG5 PP AR alpha), a PP ARy expression plasmid
(pcDNA flag PP AR gamma) or a negative control plasmid (Con). Relative luciferase
activity in lysates from transfected cells is shown. D , PPARu and PP ARy transactivate
the mouse cubilin proximal promoter. Cotransfections were done with the pCub-431
Luc promoter plasmid and either PPARu, PPARy, or a negative control plasmid (Con)
as described for C. Relative luciferase activity in lysates from transfected cells is
shown. E and F, qPCR analysis of cubilin (Cubn) and megalin mRNA in NRK cells
cultured in the presence or absence ofPPARu or PPARy antagonists, GW6471 and
GW9662 (each at 10 J.!M) for 24 h. Asterisks indicate p<0.05.
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Figure 2-8. PPAR regulation of cubUin expression.
A and B , qPCR analysis of cubilin and megalin mRNA expression in RNA isolated
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drug treatment groups were significant at p<O.OS.
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Figure 2-9. PPARa and '1 regulate cubilin expression in PRTCs.
A anti-cubilin and actin immunoblot analysis of extracts ofPRTCs treated with the PPARa agonist,
Wy14643, at the indicated concentrations for 22 h. B densitometric analysis of anti-cubilin
immunoblot experiments represented in A (n=3). C qPCR analysis of cubilin mRNA in PRTCs
treated with the PP ARa agonist, Wy14643, at the indicated concentrations for 22 h. D qPCR
analysis of cubilin mRNA in PRTCs treated with either PPARa agonist (1 OOJ-lM), PPARa
antagonist, GW6471 (1 oJ-lM) , or both for 22 h. E shows anti-cubilin and actin immunoblot analysis
of extracts ofPRTCs treated daily with the PPARy agonist, Rosiglitazone, at the indicated
concentrations for 3 days. F densitometric analysis of anti-cubilin immunoblot experiments
represented in E (n=3). G qPCR analysis of cubilin mRNA in PRTCs treated daily with the PPARy
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immunoblot analysis of extracts ofPRTCs treated twice with PPARy antagonist, GW9662 (10J-lM)
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differences between agonist treatment alone and combined agonist with antagonist treatment groups
were significant at p<O.OS.
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Figure 2-10. 5Aza and TSA elicit increases in PPARa/y expression, and PPAR
antagonists block 5Aza and TSA-mediated increase in cubilin expression.
A-B, qPCR analysis ofPPARu and y mRNA expression in RNA isolated from NRK
cells cultured for 60 h with 3 medium changes each containing the indicated doses of
SAza. C and D , qPCR analysis of PP ARa and y mRNA expression in RNA isolated
from NRK cells cultured for 24 h with the indicated doses of TSA. E and F , qPCR
analysis of cubilin and megalin was performeg 9D. RNA from NRK cells treated for 36
h with 2 medium changes each containing 5~ ', of SAza and then a 24 h treatment
with SAza-free medium containing PPAR antagonists (each at 10JlM). G and H , qPCR
analysis of cubilin and megalin mRNA in RNA isolated from NRK cells cultured for
24 h with TSA alone (100 nM) or TSA (100 nM) plus PPAR antagonists (each at
10JlM). Cubilin, megalin and PP ARa and y mRNA levels were normalized to
GAPDH. Asterisks indicate that differences between mRtNA levels in vehicle control
and drug treatment groups were significant at p<O.OS. Pound sighS indicate that
differences between mRNA levels in drug treatment groups alone and drug treatment
with PPAR antagonists were significant at p<O.OS.
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Supplementary figure 2-1. A-C, show confocal images ofanti- EGFP and anti-cubilin
labeled renal proximal tubules cell s isolated from the cortex of Cubn +/de/ exon / -6;EGFP
mouse kidneys and treated for 24 h with DMSO vehicle. D-F, show confocal images
of anti-EGFP and anti-cubi lin labeled cells isolated from the renal cortex of Cub" +/de/
exon /-6;EGFP mouse kidneys and treated for 24 h with TSA (10 nM). Nuclei (blue) were
stained using DraqS.
,
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Supplementary figure 2-2. A, qPCR analysis of A cadi mRNA expression in PRTCs
treated with PPARu antagonist, GW6471 (1 OJlM) , PPARu agonist (100JlM), or both
for 22 h. B, qPCR analysis of Acadl was performed on RNA from NRK cells treated
for 36 h with 2 medium changes each containing 5JlM of 5Aza and then a 24 h
treatment with 5Aza-free medium containing PPAR antagonists (each at 10JlM). C,
qPCR analysis of A cadi mRNA in RNA isolated from NRK cells cultured for 24 h
with TSA alone (100 nM) or TSA (100 nM) plus PPAR antagonists (each at 10JlM).
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Chapter 3. Cubilin is essential for maintaining blood levels of high density
lipoprotein and albumin

Abstract
Cubilin is an endocytic receptor capable of mediating the endocytosis of multiple
ligands. It is highly expressed by the renal proximal tubule cells where cubilin and its coreceptor megalin mediate the absorption of filt~r~~~proteins, including albumin and High
" .... , "I
,

'/

Density Lipoprotein apolipoprotein A-I (apoA-I). Cubilin deficiency or mutant cubilin
expression in humans and other animals lead to urinary loss of albumin and apoA-I.
However, the consequences of this urinary loss on the bloop homeostasis of albumin and
apoA-I/HDL had not been studied.

Using a heterozygous mouse model of targeted cubilin gene deletion (Cubilin
HT), we show that cubilin haploinsufficiency led to a significant decrease in blood levels
of albumin and apoA-1 as well as HDL and HDL-cholesterol. Cubilin HT mice displayed
reduced renal proximal tubule uptake of albumin and apoA-I, and significantly increased
urinary loss of albumin and apoA-I. Urinary levels of apoA-1 inversely correlated with
plasma apoA-1 levels. Furthermore, the clearance rate of smaller HDL particles (d>1.13
glmL) from the blood was significantly increased in cubilin HT mice, indicating a
decreased half-life for HDL particles that are filtered through the glomerulus. In contrast,
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there was not a significant change in the clearance rate from blood of HDL2 , larger
particles that are not filtered through the glomerulus. Furthennore, no significant change
was observed in the levels of albumin and apoA-I protein or mRNA extracted from liver,
kidney or intestine of cubilin HT mice as compared to wildtype. Therefore, cubilin
deficiency leads to reduced albumin and apoA-I renal proximal tubule salvage back to
blood, which results in reduced albumin and apoA-I1HDL blood levels.

These findings are consistent with previous studies demonstrating renal proximal
tubule transcytosis of albumin and the necessity of this process in maintaining blood
albumin levels. In addition, clinical data indicate that proteinuria in patients with intact
glomerular function leads to reduced blood levels of HD L. Therefore, our study is
relevant to pathological proteinuria where patients might benefit from increased cubilin
expression to reduce proteinuria and raise albumin and HDL levels.
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Introduction
High density lipoproteins (HDL) and albumin are major blood components with
links to cardiovascular disease [82, 119, 194]. As such, understanding the metabolism
and homeostatic regulatory mechanisms of these constituents may hold keys to new
therapeutic approaches.

Cubilin is a multiligand receptor capable of mediating the endocytosis of albumin
and HDL, as well as its major apolipoprotein component, apoA-I [42,44, 102]. However,
the significance of cubilin to the homeostasis of HDL and albumin in the blood has not
been studied. Cubilin and its co-receptor megalin are expressed by absorptive cells
including proximal tubule cells (PTCs) [6].

Pr~sep,tly,

cubilin- and megalin-mediated

~.

"~I

?I

endocytic uptake represents the only established process by which PTCs reabsorb
proteins from the glomerular filtrate [42, 44, 195, 196]. Genetic mutations that impact

,

renal cubilin expression in humans, dogs and mice result in urinary wastage of an array of
macromolecules including albumin and apoA-I [30, 31].

While several studies demonstrate the role of cubilin in mediating renal uptake of
apoA-I and albumin [30, 31, 42], the precise fate of these proteins following PTC uptake
has been an open question. Although a general view is that ligand endocytosis by cubilin
and megalin leads to lysosomal degradation, several lines of evidence indicate that
cubilin-megalin-mediated uptake may also participate in a process by which certain
ligands are targeted for transcytosis and delivery back to the blood. For example, in
cultured renal PTCs, megalin mediates transcytosis of trans cob al amin-B 12 complex [112]
and retinol-binding protein in complex with retinol/vitamin A [111]. Megalin has also
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been shown to mediate transcytosis of thyroglobulin [197], Shh [198] and the megalincubilin binding protein, RAP [199]. Indirect evidence for cubilin playing a similar role in
ligand transcytosis comes from findings showing that albumin is transcytosed back to
circulation via the proximal tubule epithelium [109, 200, 201] as well as the fact that
cubilin-mediated uptake of1F-B 12 complex in the gut leads to its release into blood in the
form oftranscobalamin-B 12 [133].
Whether renal cubilin-mediated uptake of apoA-1 and albumin from the
glomerular filtrate might be part of a salvage process that impacts levels of these proteins
in the blood is not known. Here we sought to define the relationships between genetic
cubilin deficiency and renal uptake/urinary loss of apoA-I and albumin, and the extent to
which cubilin deficiency influences blood le\ler~f each constituent as well as HDL.

Materials and Methods

Animals

All studies involved the use of 2-12 month old male mice, cubilin heterozygous
with an EGFP cassette insertion in a site in which cubilin exons 1-6 were deleted

(Cubn +/del exon 1-6;EGFP) [136] or age/sex matched wild-type (WT) littermates on a mixed
129Sv/C57BL/6 genetic background. Mouse experimentation was conducted with
approval from the IACUC. Mice were housed in MUSC animal care facility with food
and water provided ad libitum. Genotypes of progeny were determined by PCR
performed with tail clip genomic DNA using a three primer set: cubilin sense strand
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primer, 5'-AGCCACGCTTATACTTACTGGTG-3' (residues 10413310-10413332 in
NT_039202.7); cubilin antisense strand primer, 5'TGACCCCTCACAAGTTGAACAG-3' (residues 10413656-10413635 in
NT_ 039202.7); and EGFP antisense strand primer, 5' - GGTCTTGT AGTTGCCGTCGT3' (residues 1281-1262 in GU045599.1). Cycling parameters for PCR amplification were:
98°C for 5 min and then 40 cycles of 98°C for 0.5 min, 55°C for 1 min and 72°C for 1
min. For WT animals, the expected size of the amplicon is "'350, whereas amplicons of
",350 and 520 bp are produced from Cubn +/del exon 1-6;EGFP mice.

Immunoblot analysis

Segments of small intestine, liver and kidney cortex were homogenized in 1%
Triton X-100, 0.5% Tween 20,0.5 M NaCI, 50 mM Hepes, pH 7.5 containing a protease
inhibitor cocktail (Complete-mini, EDTA-free, Roche, Germany), using a Polytronaggregate (Brinkmann Instruments, Switzerland). Extracts were clarified by
centrifugation at 14K x g for 30 min at 4°C. Protein concentration in extracts was
quantified using Pierce BCA Protein Assay Kit (Rockford, IL). Equal amounts of protein
from the extracts were loaded onto NuPAGE 4-12% polyacrylamide gradient, Bis-Tris
gels in the presence of SDS (no reducing agent). Following electrophoresis, the proteins
were transferred onto PVDF membranes, which were blocked with 5% non-fat milk in
TBS and probed with antibodies diluted in TBS containing 0.5% Tween 20, 5% non-fat
milk. Antibodies used in immunoblotting included goat anti-cubilin A20 (Santa Cruz),
rabbit anti-smooth muscle actin Abcam, Cambridge, MA), goat anti-apoA-I (ab7614,
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Ab9am), and rabbit anti-ABCA 1 (NB400-105, Novus Biological, Littleton, CO).
Chemiluminescent detection of bound antibodies was achieved using the Pierce ECL
Western Blotting Substrate.

Immunohistochemistry

Mouse kidneys were fixed initially by perfusion fixation followed by immersion
of kidney segments in 4% paraformaldehyde PBS for 12 h. Kidney segments were then
embedded in paraffin and sectioned at 6 11m thickness. Tissue sections were incubated
with goat polyclonal anti-cubilin IgG (A20; Santa Cruz Biotechnology, Inc.; Santa Cruz,
CA), rabbit polyclonal anti-EGFP IgG (A~~, Cambridge, MA), goat polyclonal antialbumin (Bethyl Laboratories, Inc., Montgomery, TX) and/or goat anti-apoA-I (ab7614,
Abcam, Cambridge, MA). Tissue sections were incubated with donkey anti-goat and
donkey anti-rabbit Alexa fluor (488 or 568) conjugatds (Invitrogen; Carlsbad, CA).
Nuclei were stained using Draq5 (Cell Signaling Technology, Danvers, MA).
Immunolabeled sections were analyzed using a Leica SP5 confocal microscope (Leica
Microsystems Inc., Exton, PA).

Urine analysis

Urine was collected from 10-week-old male mice over a 5-day period. Mice were
individually placed in diuresis cages from 5PM to 8AM with 10% sucrose, but no food.
From 8AM to 5PM the mice were returned to regular cages and given food and water.
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This cycle was repeated for 5 days. Additionally, spot urine samples were collected by
placing mice on plastic wrap. Urine samples from 5 consecutive days were pooled.
Urinary creatinine levels were measured by ELISA using a Creatinine Companion kit
(Exocell Inc., Philadelphia, PA). Albumin levels in urine (diluted 1:500 in PBS) were
measured by ELISA using the Mouse Albumin ELISA Quantitation Set (Bethyl
Laboratories, Inc., Montgomery, TX). ApoA-I levels in urine (diluted 1:20 in PBS) were
measured by a two-antibody sandwich ELISA using goat anti-mouse apoA-I (ab7614)
and rabbit anti-mouse apoA-I (ab20453, Abeam, Cambridge, MA) and purified apoA-I as
a standard (Calbiochem, Darmstadt, Germany).

Blood apoA-I and albumin analysis

Blood from mice fasted for 6 h was drawn by retro-orbital bleeding using
heparinized micro-pipettes (Drummond Scientific Co), Broon:all, PA). Drawn blood was
kept on ice for

~1

h then subjected to centrifugatioI\ (2,000 x g) and the plasma

supernatant collected. ApoA-I levels in plasma (diluted 1:20,000 in PBS) were
determined by a two-antibody sandwich ELISA (Abeam). Albumin levels in plasma
(diluted 1:400,000 in PBS) were determined by a two-antibody sandwich ELISA (Bethyl
Laboratories).

Fast Protein Liquid Chromatography (FPLC)

FPLC separation of serum lipoproteins from pooled plasma samples (n = 6 WT
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and 6 heterozygotes) was achieved by gel filtration using two Superose 6HR 10/30
columns (Amersham Pharmacia Biotech, Piscataway, NJ) in series as previously
described [202]. Cholesterol, cholesterol ester, phospholipid and triglyceride levels in
each fraction were measured.

Analysis of blood lipoprotein levels by NMR

Quantitative analysis of serum lipoprotein levels from WT mice and
heterozygotes (from fasted males) was performed by LipoScience, Inc. (Raleigh, NC)
using nuclear magnetic resonance (NMR) spectroscopy as described in Hammad et al.
[203].

,-:../~~
,/1

qPCR

RNA from ileum, liver and kidney cortex was isolateli using RNA Stat-60 (Teltest, Inc, Friendswood, TX) and quality was assessed on an Agilent Bioanalyzer. cDNA
was prepared using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) according
to manufacturer instructions. qPCR was performed using iQ SYBR Green Supermix
(Quanta BioSciences, Inc., Gaithersburg, MD) reagents and a C 1000 Thermal Cycler
(Bio-Rad).

The

following

qPCR

pnmers

ATTTTCTCTGGGGTTTTGTTAC-3 '

and

TAAGTTTCCCTCCTCCGTAG-3'
AAGCCAGACCTGCGCTGGAG-3 '

were

used:

Cubilin

(NM_00I081084.2);
and
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ApoA-I

Cubilin

sense,

antisense,
ApoA-I

sense,

antisense,

5'5' 5' 5' -

AAAGCCAATGCGGGGGTGGG-3' ;

Abcal

CGTTTCCGGGAAGTGTCCTA-3'

and

Abcal

CTAGAGATGACAAGGAGGATGGA-3';

and

sense,

5' -

antisense,

5'-

sense,

Albumin

5'-

AGCCCAAGGCTACAGCGGAG-3' (NM_013454.3) [101] and Albumin antisense, 5'GGGTAGCCTGAGAAGGTTGTGGT-3' (NM_009654.2). Genes used for qPCR
standardization included: /3-actin sense, 5'-CGGGACCTGACAGACTACCTC-3' and /3actin anti-sense, 5'-AACCGCTCGTTGCCAATA-3' (NM_007393.3); Hprtl sense, 5'-

ATCATTATGCCGAGGATTTGGA-3'
CACACAGAGGGCCACAATGT-3'

and
(NM_013556);

CGCCGCTAGAGGTGAAATTCT-3'

and

anti -sense,

Hprtl

and

Rn18s

Rn18s

sense,

anti-sense

5' -

5'5' -

CGAACCTCCGACTTTCGTTCT-3' (NR 003278.2).
~,":", ~~,
,

( 1/

Preparation of human plasma HDL subfractions

Human plasma HDL2 (d

=

1.11 to 1.13 glml) and HQL3 (d

=

1.13 to 1.25 g/ml)

were isolated by density gradient ultracentrifugation as previously described [204]. Total
protein and apoA-I concentration was determined using Pierce BCA Protein Assay Kit
and apoA-I ELISA as described above. Equal amounts ofHDL subfraction were applied
to non-denaturing Novex 4-12% Tris-Glycine polyacrylamide gradient gels (Invitrogen,
Carlsbad, CA). Following 6 h of electrophoresis, the proteins were transferred to PVDF
membrane and immunoblotted for apoA-I as described above.
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Human HDL fractional clearance in mice

The clearance of HDL subfractions was measured in male mice following tail
vein injection with HDL2

(~15

Jlg/g of bodyweight) or HDL3 supplemented with 6%

purified apoA-1 (Calbiochem, Dannstadt, Gennany) (-AO Jlg/g) [205]. After the tail vein
injection, blood samples were collected at 10 mins by retro-orbital and subsequently by
tail vein bleeding at Ih, 3h, 6h, 12h, 24h, 48h and 72h. Human HDL subfraction
concentrations in mouse plasma were detennined by an ELISA using rabbit anti-apoA-1
(NBII0-55465, Novus Bio, Littleton, CO), sheep anti-apoA-1 (NB600-1538). The
antibodies used in this ELISA are specific to human apoA -I and display no cross
reactivity to mouse apoA-1. Standard curves for these assays were generated using
. '.

purified apoA-1 (Calbiochem) diluted in

~

5%;m~jtse

plasma. The concentration of human

HDL measured for each time point was nonnalized to the concentration measured at
10min for each mouse and average values plotted on a log scale.

Statistical analysis

Comparisons between WT and heterozygous mIce were perfonned with
GraphPad Prism (GraphPad Software, La Jolla, CA) using the Student's t test for
independent samples (two-tailed). Values are reported as mean ± STDev.
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Results

Cubilin heterozygous mice

Cubn deletion mutant mice were previously generated by Cubn exon 1-6 deletion
and an EGFP cassette insertion (Cubn +/del exon 1-6;EGFP) [136]. As previously shown [136],
cubilin null mice are embryonic lethal. However, Cubn heterozygous mice (Cubn +/del exon
1-6;EGFP)

develop without any obvious abnormalities and are physically comparable with

wild-type (WT) littermates. Blood urea nitrogen (BUN), urinary creatinine excretion and
total urine output levels were not significantly different between Cubn +/del exon 1-6;EGFP and
WT mice (data not shown). As shown in Figure 3-1, Cubn +/del exon 1-6;EGFP mice had
significantly reduced cubilin protein levels in !he,,~xtracts of ileum and kidney cortex as

. ,:., ~I
compared to WT mice. Cubilin co-receptor, megalin, levels in Cubn +/del exon 1-6;EGFP mice
kidneys were not significantly different compared to WT (Fig. 3-1A).

Effect of cubilin deficiency on blood HDL levels

To determine the effect of cubilin deficiency on the blood levels of HDL, multiple
approaches were applied to analyze plasma or serum from fasted mice. First, serum
lipoprotein levels were analyzed by NMR [203]. As shown in Figure 3-2, HDLassociated cholesterol was significantly reduced by ~27% in serum from Cubn +/del exon 16;EGFP mice

compared to WT. Similarly, HDL particle concentration was also

significantly reduced by "-'29% in serum from Cubn +/delexon 1-6;EGFP mice compared to WT.
By contrast, VLDL and LDL particle concentrations were not significantly different in
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serum from Cubn +/del exon 1-6;EGFP mice compared to WT. Next, pooled plasma samples
were separated by Fast Protein Liquid Chromatography (FPLC) and the lipid content of
each fraction analyzed. The fractions corresponding to HDL, contained cholesterol,
cholesterol ester and phospholipids that were significantly reduced by ----25% in the serum
from Cubn +/del exon 1-6;EGFP mice compared to WT (Fig. 3-3). In contrast, these lipids were
not significantly different in the non-HDL fractions in the serum from Cubn +/del exon 16;EGFP mice

compared to WT. Likewise, triglycerides, which are mostly associated with

non-HDL lipoproteins, were not significantly different in the serum from Cubn +/del exon 16;EGFP mice

compared to WT. Finally, plasma apoA-I concentration was analyzed by a

two-antibody sandwich ELISA using purified apoA-I as standard. Congruent with the
above approaches, a ",30% decrease in

apoA-lco~centration

..,:., -;~I

from Cubn +/del exon 1-6;EGFP mice compared to

was observed in plasma

wt (Fig. 3-4A).

Effect of cubilin deficiency on urinary apoA-I loss
To determine the effect of cubilin deficiency on the urine levels of apoA-I, spot
urine and 16 h urine samples were analyzed by the two-antibody sandwich ELISA using
purified apoA-I as standard. As shown in Figure 3-4B, apoA-I levels were significantly
increased by --4.5 fold in the urine of Cubn +/del exon 1-6,'EGFP mice compared to WT. This
urinary loss amounted to an average of 45.44 ng/day of apoA-I in the urine of Cubn +/del
exon 1-6;EGFP mice

compared to 9.04 ng/day in the WT (average excretion of 0.5 mg/day

creatinine in --1 ml urine). To determine if there were a correlation between urinary
apoA -I loss and decreased plasma apoA -I levels, urinary apoA -I concentrations were
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plotted against plasma apoA-I levels (Fig. 4C). A significant inverse correlation was
observed between urinary apoA-I and plasma apoA-I concentration in both Cubn +/de/ exon
1-6;EGFP and

WT groups (R2 = 0.47 HT and 0.37 WT, p-value <0.05).

Effect of cubilin deficiency on blood albumin levels

To determine the effect of cubilin deficiency on the blood levels of albumin,
plasma samples from fasted mice were analyzed using a two-antibody sandwich ELISA.
Plasma albumin was significantly reduced by ~ 17% in Cubn +/del exon 1-6;EGFP mice
compared to WT (Fig. 3-5A). Since albumin constitutes a large portion of blood protein
content [46], total plasma protein was alsoq.Y~~9cfied using a BCA protein assay. As
shown in Figure 3-5B, total plasma protein was significantly reduced by --12% in

Cubn +/del exon 1-6;EGFP mice compared to WT.

\

Effect of cubilin deficiency on urinary albumin loss

To determine the effect of cubilin deficiency on the urine levels of albumin, spot
urine and 16 h urine samples were analyzed using the two-antibody sandwich ELISA.
Albumin levels were significantly increased by '"'-'2.4 fold in the urine of Cubn +/del exon 16;EGFP mice

compared to WT (Fig. 3-5C). This urinary loss amounted to an average of

232.83 Ilg/day of albumin in the urine of Cubn +/del exon 1-6;EGFP mice compared to 96.84
Ilg/day in the WT. Urine volumes and creatinine levels at 16 and 24 h were not
significantly different between Cubn +/delexon 1-6;EGFP and WT mice (data not shown).
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Effect of cubilin deficiency on apoA-I/HDL and albumin biosynthesis

To detennine if cubilin deficiency had an effect on apoA-I/HDL biosynthesis,
qPCR was used to measure tissue mRNA levels of apoA-I and Abca1, which catalyzes
the rate-limiting step in the lipidation of apoA-I into nascent HDL particles [98]. As
shown in Figure 3-6A and F, cubilin mRNA levels were significantly decreased by
--50% in the intestine and kidney of Cubn +/del exon 1-6;EGFP mice compared to WT.
However, there was no significant difference in apoA-I and Abca1 mRNA levels in
intestine, liver or kidney of Cubn +/deJ exon 1-6;EGFP mice compared to WT (Fig. 3-6).
Similarly, no significant difference was observed in albumin mRNA levels in intestine or
liver of Cubn +/del exon 1-6;EGFP mice compared to WT (data not shown) .

. . -~, ~/r
ApoA-I and Abca1 immunoblot analysis of extracts of these tissues was also
performed. Consistent with findings from the mRNA analyses, no significant differences
were observed in apoA-I and Abca1 protein levels in the extracts of intestine or liver
~

exon 1-6"EGFP
.
r. 3-1).
fr om Cu
b +/del
n
'
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compared to WT (S upplem en tary -Jig.
\

Effect of cubilin deficiency on apoA-I/HDL fractional clearance
The clearance from blood of intravenously injected human HDL fractions was
· Cu
b +/deJ
exon 1-6EGFP
. A t 48 and 72 hr post tn]
..
.
IeveIs 0 f
measured In
n
'
and WT mIce.
ectton,
human HDL3 were significantly higher (by --200%) in WT mice compared to Cubn +/del
exon 1-6;EGFP mice

(Fig. 3-7A). The area under the curve for apoA-I1HDL plasma clearance

in WT mice was significantly greater (by --140%) compared to Cubn +/del exon 1-6;EGFP mice
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(Fig. 3-7A). Similarly, the average half-life of these HDL particles was also reduced by
,...,28% in Cubn +/delexon 1-6,EGFP mice compared to WT (half-life in WT=15-18 h; half-life in
HT=9-15 h). These observations indicate that apoA-I1HDL fractional clearance is
significantly increased in Cubn +/del exon 1-6;EGFP mice compared to WT. As control, the
fractional clearance of the larger HDL2 fraction was also determined. Most ofHDL2
should not be filtered through the glomerulus due to its larger size [206]. As shown in

Figure 3-7B, the plasma concentration of human HDL2 in WT mice was not significantly
different compared to Cubn +/del exon 1-6;EGFP mice in all time points. Furthermore, the area
under the curve for HDL2 plasma clearance in WT mice was also not significantly
different compared to Cubn +/del exon 1-6;EGFP mice (Fig. 3-7B).

Effect of cubilin deficiency on apoA-I localization in the kidney cortex
To determine the effect of cubilin deficiency on apoA-I uptake by proximal
tubules, apoA-I localization was analyzed in the kidney corte~ by immunofluorescence
microscopy. Previously, we have shown that cubilin expression is monoallelic. Proximal
tubules in the Cubn +/del exon 1-6,EGFP mice stochastically express either the targeted EGFP
allele (cubilin deficient proximal tubules) or the WT cubilin allele. The EGFP expressing
cubilin deficient proximal tubule brush borders were also shown to localize albumin
significantly less compared to proximal tubules with WT cubilin expression (Fig. 2-1).
Similarly, apoA-I localization in the brush border ofEGFP expressing cubilin deficient
proximal tubules in the Cubn +/del exon 1-6;EGFP mouse kidney was greatly reduced (Fig. 3Be and D). ApoA-I localization in the proximal tubule brush borders were quantified by
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counting the number of proximal tubules with any observable apoA-1
immunofluorescence in 109 images from 4 WT and 5 HT mice. The number of apoA -1positive proximal tubules was significantly reduced by 36% in Cubn +/del exon 1-6;EGFP mice
compared to WT.

Discussion

Cubilin expressed by the proximal tubule cells (PTCs) mediates the endocytosis
of albumin and apoA -I that is filtered through the glomerulus [42, 44]. Mutations that
affect cubilin expression or function in humans and dogs lead to urinary loss of albumin
and apoA-I [42, 44]. Yet the consequences Qf.9~)jiiin deficiency and decreased salvage of
I,

albumin and apoA-1 by PTCs on the blood levels of albumin and apoA-I1HDL had not
been studied.

In this study, we used a cubilin deficient mouse model to establish a direct
\

association between renal cubilin-mediated endocytosis of filtered albumin and apoA-I
and their plasma levels. Consistent with previous studies [42, 44], cubilin
haploinsufficiency leads to decreased PTe uptake of albumin and apoA-1 and
significantly increased loss of albumin and apoA-I in the urine. Importantly, this
decreased PTe uptake of albumin and apoA-1 causes significant decreases in plasma
levels of albumin, apoA-I and HD L particle concentration. This was supported by an
inverse correlation between urinary loss of apoA-1 and plasma apoA-1 levels, and
analyses ofHDL half-life and clearance rate from blood. Indeed, cubilin HT mice had
significantly reduced blood half-life and increased clearance rate from blood of small
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HD L particles that can be filtered through the glomerulus. In contrast, there was not a
significant difference in the clearance rate from blood ofHDL2, larger particles that are
not filtered through the glomerulus [88]. Based on these data, we inferred that the
increased loss of apoA-I1HDL from blood would result in a continuous decline in blood
HDL levels until it is counter-balanced by either an increase in synthesis or decrease in
degradation of apoA-I1HDL resulting in a new homeostatic level of apoA-I/HDL that is
lower as compared to wildtype levels. We did not find a significant difference in apoA -I
biosynthesis at the mRN A or protein level in cubilin HT mouse tissues as compared to
WT. Thus, a decrease in apoA-I1HDL degradation is likely to provide the counter-balance
measure to allow blood apoA-I1HDL levels in cubilin HT to reach steady state.
Cubilin HT mice also had significantl~~uced HD L-associated lipid levels.
However, lipid rich HDL particles are not filtered through the glomerulus [88].
Therefore, it is unlikely that lipids are excreted in the urine to any appreciable amount. It
is more likely that the reduced HDL-associated lipid level~ in cubilin HT mice might be
as a result of reduced plasma apoA -I levels, and therefore, reduced total lipid carrying
capacity ofHDL.

Our findings are consistent with studies of renal cubilin knockdown using an anticubilin antisense RNA approach in a rat model of Adriamycin-induced kidney injury
[55]. Adriamycin treatment caused renal injury and increased albuminuria[55]. Antisense
RNA knockdown of renal cubilin reduced PTC uptake ofadriamycin and renal
injury[55]. However, cubilin knockdown also resulted in greater urinary wastage of
albumin and further reduction in serum albumin levels in this rodent model [55].
Furthermore, urinary wastage of cubilin ligands achieved by BSA overload in mice also
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resulted in reduced mouse serum albumin levels without any changes in glomerular
function or ultrastructure [36, 46]. Therefore, decreased cubilin expression or function
results in deficient albumin uptake from the glomerular filtrate by proximal tubule cells
resulting in reduced blood albumin levels.

Taken together, these lines of evidence suggest a salvage process involving PTC
cubilin-mediated uptake of apoA -I and albumin from the glomerular filtrate leading to
transcytosis of these ligands across the renal proximal tubule cells and deli very back into
circulation. Disruption of this process, as through genetic cubilin deficiency in our
studies, leads to reduced apoA-1 and albumin salvage and increased loss of these
molecules from the blood. Support for such a mechanism comes from live renal imaging
studies showing transcytosis of albumin in rat ~s and other studies demonstrating the

in vitro transcytosis of megalin ligands [ 109-112, 200, 201]. The underlying mechanisms
by which cubilin-mediated uptake would lead to ligand transcytosis remains to be
established. In a recent a study, a significant reduction in plasma albumin levels and
decreased half-life of albumin in the blood was observed in mice transplanted with
kidneys deficient in neonatal Fc receptor (FcRn) [201]. FcRn is expressed by renal
podocytes and PTCs, and binds albumin under acidic conditions [207-209]. However,
FcRn-deficient PTCs retained the capacity to bind albumin at their apical brush borders
[201]. This is consistent with other studies showing that FcRn is expressed within the
cytoplasm and not at the plasma membrane [36]. Together, these studies suggest that
following cubilin-mediated endocytosis, albumin might then bind to FcRn in acidic
vesicles and become routed for transcytosis [129, 201]. Therefore, at least in case of
albumin, the transcytosis pathway might involve cooperation of cubilin and FcRn.
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A role for renal cubilin-mediated salvage in maintaining HDL and albumin
homeostasis could have implications for cardiovascular diseases (CVD). Clinical
evidence indicates that HDL-C blood levels and serum albumin levels are inversely
correlated with risk of coronary heart disease (CHD) [80-83, 119]. Emerging evidence
indicate that this salvage pathway might be effected in human disease with consequential
effects on HDL and albumin homeostasis. For example, elevated urinary albumin
excretion was associated with a doubling of risk of CVD and all-case mortality in a study
of elderly subjects [210]. This study also showed an inverse correlation between urinary
levels of albumin and plasma levels of HDL-C. Similarly, patients with chronic renal
failure have decreased plasma HDL concentration [211]. Furthermore, a missense cubilin
variant is associated with albuminuria in both the"general population and in individuals
~~i
'-",'
,
Ir

with diabetes [212].

Decreased renal cubilin-mediated salvage may affect HDL homeostasis in
diabetes. In mouse models of diabetes, levels of renal cubhin are decreased [213]. While
renal cubilin levels have not been direct! y analyzed in diabetio patients, one study of
microalbuminuric type 1 diabetic patients reported aberrant shedding of cubilin in urine
along with cubilin ligands, albumin and apoA-I [63]. Other studies demonstrate that
diabetic subjects have lower blood HDL levels [114]. Furthermore, a study of
normoalbuminuric type 1 diabetic patients with normal glomerular function reported a
correlation between lower levels of total HDL-C and smaller sized HDL3-C with
albuminuria, but not larger HDL2-C [214]. Similarly, a shift ofHDL size distribution
toward large particles has been observed in patients with proteinuria [215]. However,
much work is required to analyze cubilin expression in these patient populations and

91

detennine whether a causal link exists between any changes in cubilin expression and
altered HD L levels. Demonstrating such a link would emphasize the need to upregulate
the renal cubilin-mediated salvage pathway to prevent CVD in these patient populations.

Future directions
Transcytosis of cubilin ligands by renal PTe
In this study, we demonstrate that cubilin is essential for maintaining blood levels
of both albumin and apoA-I1HDL. Cubilin deficiency leads to decreased uptake of these
ligands by the renal PTC and decreased half-life of these ligands in the blood. These
observations suggest that cubilin-mediated

upi;re of these ligands by PTC lead to their

transcytosis back to the blood, and in cubilin deficiency this mechanism is disrupted
resulting in increased loss of albumin and apoA-I1HDL from blood. Albumin transcytosis
~

in renal PTC has been demonstrated in whole animals by live imaging [192]. A similar
approach can be employed to demonstrated apoA-I PTC trans~ytosis by live imaging of
mouse kidneys. Since cubilin heterozygous mice express EGFP in cubilin deficient PTCs,
this approach would be expected to demonstrate that EGFP-expressing PTC are unable to
mediate the transcytosis of either apoA -I or albumin. Therefore, this approach is expected
to clearly elucidate the transcytosis of both apoA -I and albumin in the renal PTC and the
dependence of this process on cubilin function.

The mechanism of transcytosis of cubilin ligands in the renal PTC remains to be
established. One of the main limitations of studying transcytosis in the kidney is the
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inability to detect this process in fixed tissue by immunocytochemistry. This may be due
to the inability of antibodies to recognize cubilin ligands in acidic endosomes in which
the ligand confonnation might change. The availability of antibodies that recognize
albumin and apoA-I confonnation in acidic conditions would greatly facilitate designing
experiments to understand the mechanism of transcytosis of these ligands in the renal
PTC.

Study ofFcRn knockout mice have revealed that FcRn might be involved in the
transcytosis of albumin following its uptake by cubilin-mediated endocytosis[201]. Thus,
crossing the cubilin heterozygous mice with F cRn knockouts would be expected to lead
to no further reduction in albumin levels compared to either mouse model. Alternatively,
overexpression ofFcRn in renal PTC with cubi~/tdeficiency would not rescue albumin
I,

transcytosis. These experiments would lend support to the hypothesis that cubilin
mediates the initial uptake of albumin and FcRn is responsible for the subsequent
transcytosis.

The role of cubUin in maintaining albumin and apoA-I/HDL levels in kidney
diseases

Cubilin expression is decreased in diabetes, acute kidney injury, and possibly,
chronic kidney disease[ 10, 11]. Epidemiological data also indicate that in some of these
diseases total and small HDL particle levels are decreased[ 115]. In addition, this decrease
in HDL levels is associated with increased proteinuria[115, 116]. Since glomerular
function was intact in these subjects, it is likely that the proteinuria is as a result of
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proximal tubule dysfunction, specifically decreased cubilin expression[115]. Future
studies should utilize mouse models of these diseases, such as streptozocin-induced
diabetes, to demonstrate that reduced cubilin expression leads to proteinuria and reduced
levels of blood HDL. Furthermore, albumin levels should also be analyzed in these
mouse models with reduced cubilin expression. In addition to plasma levels, the
clearance rate from blood of both albumin and HDL is expected to be increased due to
reduced salvage in the kidney in diseases in which cubilin expression is reduced.

Treatment with PP AR agonists, HDAC inhibitors or DNA methylation inhibitors
could augment renal cubilin expression in these diseases. Increased cubilin expression
would be expected to lead to reduced loss in the urine, and consequently, increased blood
HD L and albumin levels. These studies would ~hlight the role of cubilin in kidney
diseases and might point to potential future therapies.
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Figure 3-2. NMR analysis of serum lipoproteins shows reduced serum HDL
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Figure 3-3. FPLC gel fIltration analysis of serum shows reduced serum HDL
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Figure 3-6. Cubilin haploinsufficiency does not affect ApoA-I and Abcal
mRNA expression in the liver, kidney and intestine. qPCR analysis ofCubn (A
and F), apoA-I (B, D and G), and Abcal (C, E and H) transcript levels in mRNA
extracted from intestine, liver and kidney of age matche4 Cubn +/del exon 1-6,EGFP (RT)
and WT mice (n = 9 per group). Asterisks in A and F indicate a significant
difference from WT levels at p-values < 0.05.
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Figure 3-7. Cubn +/de/ exon 1-6;EGFP mice have increased fractional clearance of
small HDL particles. A, fractional clearance of human HDL3 (d> 1.13 g/mL)
supplemented with 6% purified apoA-I infused into Cubn +/del exon 1-6;EGFP (HT = 6)
and WT (n = 3) mice. Asterisks indicate p-value· <0.05. Areas under the curves in A
were statistically different (p-value < 0.05):"'B~;fractional clearance of human HDL2
(d = 1.11 to 1.13 g/ml) infused into WT and HT mice (n = 5HT, 3WT). Analysis
showed no statistically significant difference between the two data sets in B (i.e.,
area under the curves, p-value = 0.18).
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